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Abstract  
Diabetic macular oedema, which can cause rapid visual deterioration, may not have 
early warning signs at times. Assessment of diabetic retinal complications is made 
chiefly by clinical examination combined with optical coherence tomography (OCT) 
and fundus fluoroscein angiography (FFA). However, assessment usually does not 
occur until the late stages of diabetic retinopathy (DR), and, as retinal neurologic 
changes precede clinical changes, as tested in this thesis, by the time clinical assessment 
is performed, much of the functional visual loss has already occurred. More robust 
diagnostic modalities are required to detect progression of retinopathy in the early 
stages, before irreversible damage has already happened, and advances in the treatment 
of diabetic macular oedema is imperative as the current standard treatment in the form 
of laser photocoagulation is ineffective in improving the vision as authenticated in the 
following chapters. 
In this thesis, both treatment and diagnostic strategies of diabetic macular oedema 
(DMO) are investigated. Although laser photocoagulation is effective in short term in 
treating diabetic macular oedema, its mechanism of action is unknown; is associated 
with considerable collateral damage; and long term visual prognosis is meagre at a 
mean change in visual acuity at 5 years of -5.23. The 3-year outcome was also inferior 
to the clinical trial results with more people gaining vision (≥ 15 letter gain) in the 
diabetic retinopathy clinical research network (DRCRN) group compared to this cohort 
(26% versus 9%). Furthermore, three times more patients lost vision (> 15 letter loss) in 
the real-life setting of this cohort compared to the clinical trial results of the DRCRN 
group (27% versus 8%, respectively). Therefore, improved preventative and treatment 
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modalities are essential to prevent progression in the early stages and to improve 
functional vision in late stages.  
In an attempt to look for new treatment strategies, we hypothesized that retinal 
oxygenation by inhibition of dark adaptation in the rod photoreceptor, could possibly 
inhibit progression of diabetic maculopathy. Illuminated-mask treatment of individuals 
with early diabetic maculopathy revealed encouraging results that point to an 
inexpensive and non-invasive therapy. Whilst 19 out of 34 study eyes with cysts at the 
beginning of the trial improved, 11 out of 30 fellow eyes with no demonstrable cysts at 
the onset developed cystic macular changes towards the end of 6 month trial. 
In the final chapters the correlation of visual functions with anatomic appearance were 
examined. The results of functional assessments, including visual acuity, colour contrast 
sensitivity, and microperimetry, had variable relation to structural changes at the macula 
with OCT. Therefore, an urgent need remains for the development of reliable diagnostic 
and preventative tools for the early assessment and treatment of visual function defects 
related to diabetic macular oedema. 
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1:  INTRODUCTION 
1.1 Epidemiology of diabetes mellitus & related ocular complications 
Globally, the prevalence of diabetes mellitus (DM) in adults aged ≥20 years was 4.0% 
in 1995, 4.5% in 2010 and the number is expected to reach 5.4% by 2030 (Amos AF, 
1997; King H, 1998; Wild S, 2004). A more recent study has estimated the prevalence 
of DM was 6.4% in 2010 and will increase to 7.7% by 2030 (Shaw JE, 2010). These 
percentages correspond to an increase to 522 million patients with diabetes from the 
current 366 million (Whiting DR, 2011). Cases of diabetes-related complications are 
expected to increase rapidly to 20-30% above present levels between 2035 and 2045 
(Bagust A, 2002). For the UK, Amos et al. (1997) projected the growth of diabetes at 
4.1%. Currently, the UK has more than 2.6 million people with diabetes and estimated 
to increase up to 4 million by 2025, of which approximately 90% have Type 2 and 10% 
have Type 1 diabetes (Forouhi NG, 2006; Diabetes UK, 2010). 
DM over time can lead to various complications and among which the macro vascular 
complications include cardio-vascular disease, stroke and peripheral vascular disease 
and the micro vascular complications of diabetes include neuropathy, nephropathy and 
diabetic retinopathy (DR). Diabetic retinopathy with its clinical manifestations of 
Proliferative Diabetic Retinopathy (PDR), Vitreous Haemorrhage (VH), Diabetic 
Macular Oedema (DMO) and Clinically Significant Macular Oedema (CSMO) is one of 
the leading causes of blindness in developed countries (Klein BE, 2007; Taylor HR, 
2001; Ockrim Z, 2010). Diabetic macular oedema is the leading cause of visual 
impairment in patients with DR (Resnikoff S, 2004). A recent meta-analysis has put the 
age standardised global prevalence rates of diabetic eye disease at 35.4% (35.2–35.6) 
for any DR, 7.24% (7.15–7.33) for PDR, 7.48% (7.39–7.57) for DME, and 11.7% 
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(11.6–11.8) for VTDR. Extrapolating these percentages to the contemporary world 
diabetic population at the time of the study there were 92.6 million (91.2– 94.0) adults 
who had any DR, 17.2 million (16.6–17.7) had PDR, 20.6 million (19.6– 21.6) had 
DME, and 28.4 million (27.6– 29.2) had VTDR.   Some of the other prominent 
epidemiologic studies quoted the prevalence of DR at the time of diagnosis of Type I 
diabetes is in between 0 and 3% (Klein R, 1997) and in Type II there is higher evidence 
of presence of retinopathy at 6.7-30.2% (Kohner EM, 1998). Nearly all patients have 
some degree of retinopathy after 15-20 years of Type 1 DM and the figure is 60% in 
Type II diabetics (Aiello LP, 1998). The prevalence of macular oedema (DMO) is found 
to be proportional to the duration of diabetes. The Wisconsin Epidemiologic Study of 
Diabetic Retinopathy (WESDR) stated that 0% of Type I diabetics showed evidence of 
DMO with less than 5 years of disease duration compared with 29% after 20 years 
duration. Similarly in Type II diabetics, DMO was found in 3% of patients with less 
than 5 years disease duration and 28% after 20 years duration (Klein R, 1984). The 10-
year incidence of any DR, DMO, or CSMO in WESDR study was 89.3, 20.1, and 9.2% 
in Type I diabetics, 79.2, 25.4, and 32.8% in insulin-treated Type II diabetes, and 66.9, 
13.9, and 21.4% in noninsulin-treated Type II diabetes (Klein R, 1996). In a subsequent 
study by the same group, 25-year cumulative rate of progression of DR has been 
calculated as 83% in Type 1 DM and the 25-year cumulative incidence of diabetic 
macular oedema (DMO) and clinically significant macular oedema (CSMO) found to be 
29% and 17% respectively (Klein R, 2008, 2009). A UK-based study estimated DR 
prevalence among patients with DM at 40% and sight-threatening retinopathy (STR) at 
14% (Raymond NT, 2009) and prevalence of CSMO at 6.4-6.8%. It was estimated in 
the UK in 2008 that 218,000 people had severe sight loss (blindness), and the numbers 
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predicted to double by 2050 (Access economics, 2009). Of this number, 8.7% are 
reported to be owing to diabetic eye disease. Our understanding of the pathophysiologic 
mechanisms underlying DR and the development of complications is constantly 
evolving, due to ongoing research (van Dijk HW, 2012; Curtis TM, 2012; Antonetti 
DA, 2006; Curtis TM, 2009; Ciulla TA, 2003), and various hypotheses have been put 
forward which will be discussed further in the following sections.   
It is well known from the DCCT (Diabetes Control and Complications Trial) that DR 
and its complications can progress despite strict glycaemic and blood pressure control, 
and at a certain threshold, its effects become irreversible. This phenomenon is known as 
―retinopathic momentum‖ and at this stage any form of intervention will not affect 
progression (Bailey CC, 1999). This may occur with no visual symptoms, so early 
screening and prevention of visual loss is imperative (DCCT, 1993) 
 
1.2 Normal Retina 
The retina, which literally means ‗net‘, is formed from two parts of the embryonic optic 
cup: a) Neurosensory retina from the inner wall, b) Retinal pigment epithelium from the 
outer wall. The inner neuroblastic cells of the neurosensory retina differentiate into 
ganglion cells, Muller cells and amacrine cells, whilst the outer cells differentiate into 
rods and cones, bipolar cells and the horizontal cells. The macula is a comparatively 
dark area of 5.5 mm in diameter, situated at the posterior pole of the eyeball, temporal 
to optic disc and contributes to the central 10-15° of the visual field (Figure 1.1). The 
fovea is the central depressed part of the macula and is 1.85 mm in diameter and 
corresponds to the central 5° of the visual field. The foveola forms the central floor of 
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the fovea. The Fovela avascular zone (FAZ) is located inside the fovea but outside the 
foveola. 
 
Figure 1.1: Colour photograph of fundus showing macula (outer circle) 
 
The main function of the retina is to catch light via its photoreceptor and pigment 
epithelial cells. The photoreceptor cells‘ photopigment molecules absorb the light, 
causing a change in the photoreceptor‘s membrane potential. This initiates a series of 
signals that travel through the neurons of the retina, and into the optic nerve leading to 
the brain. The neural cells involved in this process are remarkably similar to those of the 
brain (Litzinger TC, 2002). The microscopic structure of the retina includes three types 
of cells and their synapses arranged in 10 layers (Figure 1.2). 
 
1.2.1 Layers of retina: 
Retina is laid out in 10 layers, each with a specific role in the processing the light 
stimulus and maintaining the integrity of the tissue. The layers from out to in are as 
given in Table 1.1 and Figure 1.2. 
The RPE (retinal pigment epithelium) forms the outer most layer of retina. It is firmly 
adherent to the underlying Bruch‘s membrane (basal lamina of choroid) and is loosely 
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adherent to the layer of photoreceptors. The potential space between the RPE and 
sensory retina is called the subretinal space. Layer of rods and cones are considered as 
neuroepithelium and the end organ for vision. Rods are absent in an area of 300 m at 
the centre of fovea; but are present in a large number around the fovea in a 5-6mm ring 
shaped zone. 
 
Table 1.1: Retinal layers  
1) Retinal pigment epithelium (RPE) 
2) Photoreceptor layer (Rods and Cones) 
3) External limiting membrane 
4) Outer nuclear layer 
5) Outer plexiform layer 
6) Inner nuclear layer 
7) Inner plexiform layer 
8) Ganglion layer 
9) Nerve fibre layer 
10) Internal limiting membrane 
 
 
 
Figure 1.2: Retinal layers and cells (adopted from www.vetmed.vt.edu), May 2013 
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The external limiting membrane, which appears to pass through the processes of 
photoreceptors, is formed by junctions (zonulae adherens) between the cell membrane 
of photoreceptors and Muller cells. The outer nuclear layer is formed by the nuclei of 
rods and cones. The outer plexiform layer is the synapses between rod and cone 
pedicles with the dendrites of bipolar cells and processes of horizontal cells. This layer 
marks the transition between the outer and inner layers. The inner nuclear layer contains 
the nuclei of bipolar cells, horizontal cells, and the majority of the amacrine cells. The 
inner nuclear layer is followed by the inner plexiform layer, which essentially consists 
of synapses between axons of bipolar cells and dendrites of ganglion cells and the 
processes of amacrine cells. The ganglion cell layer consists of cell bodies and nuclei of 
ganglion cells. This layer is absent in the region of the foveola. The axons of ganglion 
cells extend in the opposite direction towards the nerve fibre layer. These cells are 
responsible for initiating the cascade of events that takes an image projected onto the 
retina, and converting it from photons to an electrochemical signal capable of being read 
by the brain. 
 
1.2.2 Cells involved: 
Three types of cells comprise the retinal structure (Khurana AK, 2008).  
 
1.2.2.1 Vascular cells: 
Pericytes are modified smooth muscle cells (SMCs) that regulate vascular flow by 
dilating and contracting. Endothelial cells line the inner capillary wall, regulate 
haemostatic function, and constitute the inner blood retinal barrier (BRB) (Figure 1.3). 
  19 
 
Figure 1.3: Organisation of the capillary neurovascular unit. (A) Rings of smooth 
muscle encircle arterioles, while pericytes send processes along and around capillaries, 
without fully covering the vessel. (B) Pericytes are located outside the endothelial cells 
and are separated from them and the parenchyma by a layer of basal lamina. In the 
parenchyma, astrocyte end-feet and neuronal terminals are closely associated with the 
capillary. (Hamilton NB, 2010) 
 
1.2.2.2 Neural cells: 
Neural cells of the retina include photoreceptors as well as retinal pigment epithelial 
(RPE), amacrine, bipolar, and ganglion cells. These cells mediate phototransduction; 
they convey nerve impulses from the photoreceptor across the synapse to the bipolar 
and retinal ganglion cells, and to the lateral geniculate nucleus of the brain (Masland 
RH, 2001).  
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1.2.2.2a RPE cells: 
These form the outer most layer of the neural retina and provide supportive functions to 
the photoreceptors. (Strauss O, 2005). 
 
 
Figure 1.4: The Retinal Pigment Epithelium in Visual Function. PEDF (pigment 
epithelium derived growth factor), VEGF (vascular endothelial growth factor) (Strauss 
O, 2005) 
 
The RPE functions in brief are: 
a) Important role in photoreceptor renewal and recycling of vitamin A 
b) Form the outer blood-retinal barrier and actively pumps water and ions from sub 
retinal space.  
c) Supply inter photoreceptor matrix and help with retinal cell adhesion 
d)Transports nutrients and metabolites through blood-retinal barrier and elaborates 
extra cellular matrix. 
e) Regulate and transports ions, water, growth factors and nutrients to the outer 
segments of the photoreceptors. 
f)  Phagocytose outer tips of photoreceptors and recycle them 
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g) Provides mechanical support to the layer of photoreceptors  
h) Help in manufacturing photopigment 
i)  Reduce scatter of light to the photoreceptors and shield them from excessive light 
exposure by using the Melanin pigment. 
 
1.2.2.2b Photoreceptors (Figure 1.5): 
 
Figure 1.5: Retinal photoreceptors. Shown are inner segments with synaptic endings, 
body with most mitochondria, and outer segment disks where photo transduction 
occurs. (Picture adapted from ―www.thebrain.mcgill.ca‖, Aug 2011) 
 
The adult human retina has approximately 130 million photoreceptors of which 
approximately 120 million are rods and rest is cones (Khurana AK, 2008). Rods are 
long cylindrical structures and are highly sensitive to light and send signals of grey 
shades to the brain. Cones are thicker and shorter compared to rods, and send signals of 
fine details and colour to the brain. The photoreceptors capture light and convert it into 
electrical signals by a process called phototransduction and is transmitted to brain, 
  22 
which is perceived as light images. The critical element in this process of 
phototransduction is the photopigment within the photoreceptors. Opsin is the light 
sensitive protein within the photoreceptors, which binds with vitamin A, and the 
complex is called rhodopsin in rods. When light photons strike, this bonding is broken 
and disrupts the electrical field within the photoreceptor, which initiates the electrical 
impulse. Where as the cones possess three different types of opsins, which individually 
bind to vitamin A and are responsible for perception of three primary colours: red, blue 
or yellow. Cones are not as sensitive as rods for low intense light and therefore need 
very specific wavelength of light to initiate the electrical impulse. Cones possess 
complex network of postsynaptic connections in contrary to rods. The bipolar cells, 
which have synaptic connections with photoreceptors respond differently to excited 
cones and there by create ―ON‖ and ―OFF‖ signals (Nawy S, 1991). Phototransduction 
(Figure 1.6) in the photoreceptors involves absorption of photon energy by the 11-cis-
retinal molecule of opsin molecules, which are G-protein coupled receptors in the 
photoreceptor cell membrane. Absorption of photon by 11-cis-retinal leads to formation 
of all-trans-retinal, which stimulates the attached opsin, transducin, to bond with 
guanine-triphosphate (GTP). The GTP binding causes the alpha-subunit of the 
transducin to translocate to an enzyme called phosphodiesterase (PDE) located on the 
membrane, where it binds to the inhibitory gamma subunit of PDE. This binding event 
decreases the inhibitory effect of the gamma PDE subunit, causing PDE to start actively 
hydrolysing cyclic guanine-monophosphate (cGMP). Channels in the photoreceptor 
membrane bind cGMP and open, releasing sodium (Na
+
) and calcium ions (Ca
2+
) into 
the cell. Loss of cGMP by PDE activity causes closure of these channels, which in turn 
causes the whole cell to hyperpolarise and induce a signal (Yau KW, 1994). 
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Figure 1.6: Molecular steps in photoactivation.  Depicted is an outer membrane disk in 
a rod. Step 1: Incident photon (hv) is absorbed and activates a rhodopsin by 
conformational change in the disk membrane to R*. Step 2: R* makes repeated contacts 
with transducin molecules, catalyzing activation of R* to G* by release of bound GDP 
in exchange for cytoplasmic GTP. Step 3: G* binds the inhibitory γ subunits of PDE, 
thereby activating its α and β subunits. Step 4: Activated PDE hydrolyzes cGMP. Step 
5: Guanylyl cyclase (GC) synthesizes cGMP, the second messenger in the 
phototransduction cascade. Reduced levels of cytosolic cGMP cause cyclic nucleotide 
gated channels to close; this closure prevents further influx of Na+ and Ca2+. Figure 
adapted from Leskov IB, 2000. 
 
1.2.2.2c Bipolar cells: 
Bipolar cells (Figure 1.7) are neuronal cells in the inner nuclear layer connecting outer 
plexiform layer to inner retinal layers. They have a central body, dendrites and axons 
(Masland RH, 2001). Dendrites receive information from photoreceptors and horizontal 
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cells and pass it on to ganglion and amacrine cells through axons in the inner plexiform 
layer. The bipolar cells could be designated either as rod or cone bipolar cells based on 
their respective connections, and as ―ON‖ or ―OFF‖ cells based on their response to 
glutamate released by photoreceptors (Nawy S, 1991). 
 
Figure 1.7: Bipolar cells. Picture adapted from (http://www.retinalmicroscopy.com)                                                                                             
 
1.2.2.2d Horizontal cells (Figure 1.8): 
Horizontal cells form part of lateral neurons along with amacrine cells. They are 
laterally interconnecting neurons present in the outer plexiform layer and help with 
integrating the information received from multiple photoreceptor cells (Masland RH, 
2001). They help in adjusting the eyes to see well under bright and dim conditions and 
increase contrast. They help in increased visual acuity by enhancing lateral inhibition.  
 
1.2.2.2e Amacrine cells (Figure 1.9) 
Amacrine cells are interneurons in the inner nuclear layer and synapses in the inner 
plexiform layer with bipolar and ganglion cells, and influence retinal signal processing 
(Masland RH, 2001). They are responsible for complex processing of the retinal image 
brightness, contrast and detecting motion.  
  25 
 
Figure 1.8: Horizontal cells. Picture adapted from (http://www.retinalmicroscopy.com) 
 
Figure 1.9: Amacrine cells. Picture adapted from (http://www.retinalmicroscopy.com)                                                                                    
 
Figure 1.10: Ganglion cells. Picture adapted from www.ucl.ac.uk 
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1.2.2.2f Ganglion cells (Figure 1.10) 
Ganglion cells are a type of neuronal cells, which collect the visual information from 
bipolar and amacrine cells through their dendrites and the final output reaches the brain 
through their axons. Ganglion cells vary significantly depending on their projections, 
functions, based on which different types of gangion cells may be defined: ―W‖ cells 
are excited by rods and function to perceive directional movement. The ―X‖ cells are 
responsible for colour vision. The axons of the ganglion cells of the retina converge, 
forming the optic nerve. The ―Y‖ cells are largest of all and assist with perception of 
changes in light intensity and rapid movements of the image. Ganglion cells have action 
potentials unlike other integrator neurons and changes in light intensity and shifting of 
images over the field of vision cause a change in the firing rate in ganglion cells 
(Masland RH, 2001). These ―ON‖ and ―OFF‖ responses, which take the form of 
changes of frequency of firing, are interpreted by brain as final output signals. 
 
1.2.2.3 Glial cells (Figure 1.11): 
Three types of glial cells are found in the retina: Muller cells, microglia, and astrocytes 
of which Muller cells are the major component. The interaction of these cell types is 
crucial for the functional integrity of retinal metabolism. 
Macroglia are support cells that regulate the retinal metabolism and modulate the 
function of neurons and blood vessels (Abbott NJ, 1992). Muller cells form the 
architectural support; provide metabolic support and homeostatic regulation. They are 
located in the inner nuclear layer and project their processes from internal limiting 
membrane to the outer limiting membrane where junctional complexes with bases of 
photoreceptors are formed. 
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Figure 1.11: Glial cells. Picture adapted from www.retinalmicroscopy.com  
 
Muller cells are also thought to have neural progenitor activity. Retinal tissue 
autoregulates its blood flow in response to various local and systemic factors through 
various chemical and cellular interactions (Harris A, 1998). Muller cells regulate the 
glutamate metabolism, extracellular ionic balance, and neuronal function. Impairment of 
this autoregulation in diabetes (Sinclair SH, 1982) could lead to derangement of the 
neural metabolism. Localization of astrocytes is limited to the nerve fibre layer. Their 
processes wrap around the blood vessels and ganglion cells and play a supportive role in 
the BRB framework. The interaction of astrocytes is important to induce expression of 
tight junction proteins and to maintain BRB (Gardner TW, 1997; Abbott NJ, 1992). 
Together, the macroglial cells integrate the vascular and neuronal activities of the retina. 
Microglia cells are related to tissue macrophages. They lie quiescent and are activated 
by homeostatic changes in the retina, which causes them to become phagocytic and help 
with the immune defence. (Broderick C, 2000; Zeng XX, 2000). 
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1.2.3 Growth factors: 
Various growth factors are involved in regulating the retinal metabolism, including 
insulin growth factor (IGF-1), vascular endothelial growth factor (VEGF), platelet-
derived growth factor (PDGF), tissue necrosis factor (TNF), endothelin-1 and hypoxia-
induced factor (HIF-1) (Whitmire W, 2011; Ciulla TA, 2003). Excessive additional 
metabolic stress on the retina, such as occurs in DR, could lead to derangement of the 
function of these factors and disruption of the BRB system leading to maculopathy and 
macular oedema. 
 
1.2.4 Retinal circulation: 
Retinal circulation differs from cerebral circulation in several important ways. The 
retinal circulation is sparse, to minimise optical interference. There is large 
arterioveinous oxygen tension difference. There are no vascular autonomic innervations, 
and auto regulation is mainly by metabolic feedback. Finally, there are no lymphatics. 
Fluid balance in the retinal layers completely depends on the equilibrium of hydrostatic 
and osmotic pressure gradients within the retinal vasculature. The blood-retinal barrier 
(BRB) selectively permits components into the extracellular fluid; thus, the 
composition, particularly of the ions, is self-regulated by the retina.  In normal retina, 
there is a capillary-free space around the arteries, but not around the veins, because the 
partial pressure of oxygen around the arteries is more than that around the veins. Thus, 
there is no stimulus for capillary growth (Antonetti DA, 1999).  
The outer four layers of the retina get their nutrition from choriocapillaries, and the rest 
of inner layers are supplied by central retinal artery. The outer plexiform layer is partly 
supplied by choriocapillaries by diffusion, and partly by central retinal artery. The fovea 
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is an avascular area mainly supplied by choriocapillaries by diffusion. The retinal 
vessels are end arteries, which do not anastomose with each other. The macula receives 
its blood supply mainly from the superior and inferior temporal branches of the central 
retinal artery. In the parafoveal zone the capillary network is well developed and is 
three-layered. The foveal avascular zone (FAZ) is a capillary free zone of about 500 m 
in diameter. Enlargement of FAZ, and the perifoveal intercapillary area, as a measure of 
capillary density are related to visual acuity and contrast sensitivity (Arend O, 1995; 
1997) 
 
1.2.5 Blood-retina barrier (BRB): 
The BRB maintains the integrity of the neurosensory retina by compartmentalising and 
separating the vascular from the neural component. The BRB has two major 
components. The tight junctions between RPE cells form the outer retinal barrier 
(Cunha-Vaz JG, 1966). The tight junctional complexes between retinal vascular 
endothelium and glial cells form the inner BRB (Nishikiori N, 2007). The RPE cells 
may secrete paracrine vascular cytokines that are important for the survival of adjacent 
endothelia and maintenance of BRB (Witmer AN, 2003). 
 
1.2.6 Visual function: 
Photoreceptors and RPE form the receptor complex, which allows light energy to be 
transformed into visual stimuli. The outer complex of the photoreceptor faces the long 
apical microvillus of the RPE and forms a complex junction of interaction. The RPE is 
responsible for supplying photoreceptors with nutrients such as glucose, retinol, and 
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fatty acids. Photoreceptors are involved in photoexcitation and phototransduction, 
through which they convert light energy into neural signals (Strauss O, 2005). 
 
1.3 DMO aetiopathogenesis 
Diabetes can be broadly classified into four categories: Type I and II diabetes; 
Gestational diabetes; Diabetes secondary to genetic defects of beta-cell function or 
pancreatic diseases; and Diabetes induced by drugs or chemicals (Alberti KG, 1998).  
Type I diabetes, which accounts for 5-10% of the diabetic population, is the result of 
autoimmune destruction of beta cells in the pancreas and lack of insulin production. 
Type-I diabetes has an immunogenic aetiopathogenesis, and it may be genetically or 
nongenetically mediated (Atkinson MA, 1994). Environmental factors such as viruses 
and nutrition may play a role as early as in utero (Leslie RD, 1994), and high birth 
weight is associated with an increased risk of Type I diabetes (Dahlquist G, 1996).  
In contrast to Type I, Type II DM has a multifactorial aetiopathogenesis. It is caused by 
defects in insulin secretion and insulin sensitivity (resistance). This form of DM 
accounts for 90-95% of all subjects with diabetes. Changes in nutritional habits, with 
increased uptake of saturated fats, refined sugars, and alcohol combined with reduced 
intake of fibres, as well as smoking, family history, ethnicity, and sedentary lifestyle all 
contribute to Type II diabetes risk (Stumvoll M, 2005). 
Gestational diabetes results from glucose intolerance during pregnancy, owing to the 
excess demand for insulin by the pregnant body.  
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1.3.1 Abnormalities in insulin secretion: 
β-cell dysfunction includes abnormalities in pulsatility and in kinetics of insulin 
secretion, quantitative and qualitative abnormalities of insulin, β-cell loss and its 
progression. Both initial peak secretion and later oscillatory release of insulin are 
affected in Type II DM (Polonsky KS, 1988; O'Rahilly S, 1988). It has been shown that 
insulin secretary abnormalities start as early as 10 years before the diagnosis of diabetes 
is made clinically (Whitmire W, 2011; Harris MI, 1992).  
 
1.3.2 Insulin resistance: 
Insulin resistance is influenced by both genetic and environmental factors. It is usually 
associated with visceral obesity, dyslipidemia, hypertension, hyperinsulinemia, 
impaired fibrinolysis, endothelial dysfunction, vascular inflammation and premature 
atherosclerosis (Stern M, 1999).  
 
1.3.3 Increased glucagon secretion: 
Increased insulin resistance leads to enhanced gluconeogenesis by liver, stimulated by 
glucagon, and decreased utilisation of glucose by muscle tissue. Glucagon secretion is 
also stimulated by excessive release of free fatty acids and adipocytokines. Glucagon 
and vasoactive intestinal peptide (VIP) receptors were found in retinal neuronal 
amacrine cells in chicks and regulate the proliferation of neural progenitors (Ekman R, 
1985; Fischer AJ, 2005). 
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1.3.4 Pathogenesis of micro vascular retinal complications: 
Diabetes mellitus is associated with both macro vascular and micro vascular co-
morbidities. Macro vascular complications include cerebro vascular disease, coronary 
heart disease, and peripheral vascular disease. Micro vascular complications include 
diabetic retinopathy (DR), diabetic neuropathy, and diabetic nephropathy. Diabetic 
retinopathy is complicated by diabetic macular oedema (DMO) and proliferative 
diabetic retinopathy (PDR). 
Retinopathy in Type 1 DM is indistinguishable from that in Type 2 DM. The clinical 
hallmarks of diabetic maculopathy include microaneurysms, haemorrhages, exudates, 
retinal oedema, which are caused by increased vascular permeability and new vessel 
proliferation. Fluoroscein angiographic studies have shown that the reduced capillary 
density (capillary drop) along with an increased foveal avascular zone is correlated with 
decreased visual ability (Arend O, 1995, 1997) in diabetic retinopathy. There is also 
capillary dilatation and increased blood flow in early stages of diabetic retina (Grunwald 
JE, 1994; 1995), which leads to damage of BRB and increased vascular permeability 
(Cunha-Vaz JG, 1966) and formation of diabetic macular oedema. Other signs of DR 
progression also follow these changes (Aiello LP, 1998).  
Until recently, DMO had been mainly considered a vascular pathology (Curtis TM, 
2009; Cunha-Vaz JG, 1975). However, while many studies have emphasized early 
vascular changes as the cause of DMO, evidence shows that functional and neuronal 
changes can be identified before development of vascular pathology (Barber AJ, 2003, 
2012; Antonetti DA, 2006; van Dijk HW, 2012). These changes are considered to be the 
direct effect of diabetes on the neural retina, rather than the effects of BRB breakdown. 
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In the following sections, the micro vascular, neural, and functional changes that lead to 
macular oedema in a diabetic retina are discussed. 
 
1.3.4.1 Neuronal changes: 
Diabetes affects all cell types in the retina (Table 1.2) as well as the metabolism of 
retinal neural tissue. A combination of insulin deficiency, increased apoptosis, glial cell 
reactivity, microglial activation, and altered glutamate metabolism leads to irreversible 
neurodegenerative changes, which underlie the functional visual deficits that occur prior 
to onset of visible retinal changes (Barber AJ, 2003, 2012). Lack of insulin and IGF-1 
results in diminished trophic stimuli and activates caspases, resulting in enhanced 
apoptosis (Whitmire W, 2011). Neuronal death triggers the release of VEGF and other 
vasoactive cytokines and leads to disruption of the BRB, which is pathognomonic of 
DMO. Structural modifications of the dendrites occur, including increased length, 
density, and total number of terminals. These changes exclusively happen in the ―ON‖ 
ganglion cells (Gastinger MJ, 2008). Loss of retinal ganglion cell bodies is reflected by 
a reduction in the number of axons in the optic nerve (Scott TM, 1986). Lack of insulin 
reduces glutamate metabolism in the Muller cells and increases glial fibrillary acidic 
protein (GFAP) expression (Li Q, 2002). In addition, loss of glial cell efficiency to 
dispose glutamate causes neurotoxic levels of glutamate to accumulate in the 
extracellular fluid. Increased glutamate toxicity causes phosphorylation of 
neurofilaments by inhibiting axonal transport and causing ganglion cell death 
(Gastinger MJ, 2001). Thus, insulin acts as a survival factor for retinal neurons, and its 
deficiency directly leads to apoptosis (Barber AJ, 2001; Whitmire W, 2011). 
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Table 1.2: Retinal cells affected by diabetes  
Cell Type Characteristics 
Vascular Altered tight junctions; endothelial cell and pericyte death 
Glial Altered contacts with vessels; release inflammatory mediators; impaired 
glutamate metabolism 
Microglial Increased number; release inflammatory mediators 
Neurons Death of ganglion cells, inner nuclear layer; axonal atrophy 
Adapted from Gardner TW, 2002 
 
Retinal astrocytes are very sensitive to ischaemia and degeneration. New blood vessels 
growing at the margin of the perfused and ischaemic retina do not grow in a normal 
pattern, because of the lack of support from astrocytes. These structural and functional 
changes are noted in the glia long before changes in the retinal vasculature. Two studies 
found decreased axonal nerve fibres in the optic nerve and increased glial cell 
proliferation in experimental rats (Barber AJ, 2003; Scott TM, 1986). Increased glial 
activity is manifested as the increased expression of GFAP immunoreactivity and 
content in Muller cells and astrocytes. Glia has a supportive role for neural and vascular 
elements in the retina (Newman E, 1996); alterations of its function affect the retinal 
metabolism. VEGF has neuroprotective properties (Jin KL, 2000; Sondell M, 1999), but 
other, stronger vascular effects have detrimental effects on the diabetic retina. 
Current assessment of DMO is based on clinical retinal examination for microvascular 
changes, which are thought to cause secondary neuronal changes (Table 1.3). However, 
recent evidence (Table 1.3) indicates that: 1) neuronal changes predispose to vascular 
changes, 2) early functional changes are due to the effects of insulin on retinal neuronal 
tissue, and 3) manifested clinical vascular changes are secondary to neuronal damage. 
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Table 1.3: Evidence suggesting diabetes induces degeneration of human retinal 
ganglion cells 
Method Observation Reference 
Histology of autopsy 
samples 
Atrophy of RGC, 
degeneration of NFL 
Wolter JR,1961; 
Bloodworth JM jr, 1962 
Immunohistochemistry of 
autopsy samples 
Apoptosis of RGC, 
overexpression of Bax and 
activated caspase-9 and -3 
Barber AJ, 1998;  
Abu-El-Asrar, 2004;  
Abu El-Asrar, 2007; 
Oshitari T, 2008 
NFL defects detected by 
red-free photography 
Detectable in 20% of 
diabetics without and 57% 
with microaneurysms 
Chihara E, 1993 
NFL ―thickness‖ from 
scanning laser polarimetry 
Decreased in diabetic 
patients and related to 
severity of retinopathy 
Chihara, 1998;  
Ozdek, 2002;  
Takahashi, 2006 
NFL ―thickness‖ from 
scanning laser polarimetry 
Decreased in superior 
retina of diabetic patients 
Lopes de Faria JM, 2002 
Adapted from Kern TS, Barber AJ. (2008) 
Note: RGC: retinal ganglion cells, NFL: nerve fibre layer 
 
1.3.4.2 Circulatory changes: 
Altered retinal perfusion and haemodynamics occurs in diabetic macula even before 
microaneurysm formation and is associated with increased perifoveal inter capillary 
area as a sign of decreased capillary density. Various studies have found hyper/hypo 
perfusion to be pathogenic in patients with diabetes (Sakata K, 2006). There is evidence 
that decrease in retinal perfusion occurs before the onset of diabetic maculopathy 
followed by gradual increase as the disease progresses. Decrease in perfusion occurs by 
progressive capillary closure and increased resistance and decreased perfusion (Arend 
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O, 1991; Greene AS, 1989). This capillary loss and decreased perfusion is associated 
with decrease in visual function. The effects of hyperperfusion could be explained by 
the shear stress caused on the vessel walls and induction of humoral factors. (Bresnick 
GH, 1984; Ashton N, 1963).  
The macula has a pulsatile ophthalmic blood flow. Protein kinase C (PKC) and 
endothelins may play a key role in triggering vasoconstriction and diabetic 
maculopathy. In contrast, vascular endothelial growth factor (VEGF) released by the 
ischaemic retina stimulates retinal vasodilatation causing macular oedema and inducing 
neovascularisation. Although recent clinical treatments (Ford JA, 2013) have been 
established to reduce or prevent diabetic retinopathy by blocking the pathologic effects 
of ischaemia induced growth factors and deranged autoregulation, the precise 
mechanism of various stages of disease progression is not yet clear. VEGF may be the 
cause for increased choroidal blood flow and macular oedema, and overwhelm the 
vasoconstrictive effects of PKC and endothelins. There is a contradictory evidence of 
role of varying blood flow in the onset of diabetic macular oedema (Aiello LP, 2004; 
Campochiaro PA. 2004; Park JY, 2000; Yokota T, 2003; Aeillo LP, 1994; Chiarelli F, 
2000). But the demonstration of altered blood flow across various stages of 
maculopathy and macular oedema suggest that the growth factors attributed are a part of 
more complex autoregulatory system along with other unknown factors. The cellular 
and biochemical mechanisms involving early activation of PKC and endothelin-1 may 
cause focal vasoconstriction effects leading to focal ischaemia, despite overall increased 
choroidal circulation in the early stages of maculopathy. The ischaemia indused 
upregulation of VEGF may be responsible for acute increase in choroidal blood flow 
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and macular oedema formation in moderate to severe diabetic eye disease. (Savage HI, 
2004) 
 
1.3.4.3 Local effects of hypoxia on the rhodopsin cycle: 
Michaelson (1954) first identified the causative link between hypoxia and diabetic 
retinal complicaitons. Chronic retinal hypoxia induces several retinal factors (Cai J, 
2002), of which VEGF is the most important (Osborne NN, 2004; Stefansson E, 2006) 
(Figure 1.12). Tissue oxygen tension regulates the production of these growth factors. 
Improved oxygenation of the inner retina and relief of hypoxia lower retinal VEGF 
production and hinder further retinopathic changes (Stefansson E, 2006). Hyperoxia 
reduces VEGF production in the ischaemic retina, thereby decreasing endothelial 
proliferation (Pournaras CJ, 1997). Hypoxia as the most potent stimulus (Arden GB, 
2012), is caused by capillary shut down and also happens in later stages of 
pathogenesis. Experiments in rodent models have demonstrated early psychophysical 
changes and electrophysiologic changes before capillary loss could be seen. There is 
also evidence that hypoxia exists before the onset of capillary shut down (Feit-
Leichman RA, 2005; Segawa Y, 1998). 
In summary, retinal hypoxia stimulates progression of retinal pathology in two ways: by 
hypoxia-induced VEGF production and its effects on vascular smooth muscle cells and 
pericytes; and by autoregulatory dilatation of the capillaries, which directly stimulates 
growth. Hypoxia has many metabolic sequelae. Oxidative phosphorylation is affected 
and anaerobic metabolism dominates, leading to altered tissue pH, lactate, and 
adenosine levels. Hypoxia also induces expression of HIF-1 (Zhu H, 1999), which 
induces other growth factors, such as VEGF (Caro J, 2001), erythropoietin, basic 
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fibroblast growth factor, IGF, placental growth factor, and several other factors, to 
promote new vessel formation (Osborne NN, 2004). Hypoxia can also cause adenosine 
accumulation, which can lead to vasodilatation and endothelial stretch, thereby 
stimulating endothelial cell proliferation (Lutty GA, 2003). 
 
 
Figure 1.12: Haemodynamic model for pathogenesis of diabetic retinopathy. The 
purple region shows how early-stage hypoperfusion could lead to progressive hypoxia 
and increased leucocyte adherence to the retinal capillaries. As diabetes develops, the 
retinal microvasculature shows hyperperfusion, which leads to BM thickening, loss of 
arteriolar tone, microaneurysms, and capillary dropout. This process accelerates the 
hypoxic insult on the retina (adapted from Curtis TM, 2009) 
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1.3.4.4 Basement membrane thickening: 
Increased shear stress resulting from increased blood flow in DR leads to increased 
endothelial cell gene expression, which in turn causes production of more abnormal 
basement membrane fibrils and basement membrane thickening. Alterations in protein 
composition limit communication between cells and contribute to accelerate vascular 
death. Other underlying mechanisms for increased basement membrane thickening 
include oxidative stress, polyol pathway flux, activation of protein kinase C (PKC), and 
accumulation of advanced glycation end products (AGEs) (Stitt AW, 2002a). 
 
1.3.4.5 Loss of pericytes and vascular smooth muscle cells: 
In the normal retina, pericytes and endothelial cells exist in a 1:1 ratio. Two-way 
communication occurs between the endothelial cells and the vascular SMCs 
(VSMCs)/pericytes to maintain vessel integrity (Armulik A, 2005). Lack of insulin 
causes less release of IGF-1, which reduces the trophic stimulus to pericytes and leads 
to degeneration and cell death. Endothelial cells release PDGF for pericyte and VSMC 
survival (Lindblom P, 2003), whereas pericytes and VSMC in turn express VEGF and 
angiopoeitin for enhancement of survival and integrity of the endothelium. Basement 
membrane thickening limits communication between these cells and leads to early cell 
death. Loss of pericytes could be related to leucocyte adhesion to the vessel wall and 
accumulation of AGEs; because they express AGE receptors, pericytes may be 
susceptible to the damaging effects of AGEs (Curtis TM, 2009). 
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1.3.4.6 Acellular capillary formation:  
Pathological levels of shear stress caused by irregularities in blood flow induce 
endothelial cell death, which can lead to acellular capillary and microaneurysm 
formation. Leucocyte adhesion to endothelial cells can promote receptor-mediated cell 
apoptosis. The resultant ischemic environment strongly stimulates VEGF production 
from various retinal cells, including vascular endothelial cells of the dying capillaries. 
This VEGF stimulus causes cells to proliferate and form microaneurysms. Capillary 
drop out initiates from the arterial side, whereas microaneurysm formation develops on 
the venous side (Poulaki V, 2004). 
 
1.3.4.7 Blood-retinal barrier disruption:  
Endothelium, with its junctional proteins (Gardner TW, 1999), comprises the functional 
part of the BRB. The two most prominent of these proteins are occludins and claudins, 
which span the plasma membrane and limit fluid flow between the endothelial cells. 
Other proteins, including the zonula occludens (ZO 1, 2, and 3), organise to form tight 
junctions by multiple protein interaction domains. Endothelium has very few transport 
vesicles (Raviola G, 1977).  
Diabetes disorganises the functional aspects of the BRB (Antonetti DA, 1998; Barber 
AJ, 2000). Loss of BRB integrity leads to increased permeability and seepage of fluid 
into the extracellular spaces. The retinal pumps (RPE cells) can become compromised, 
which leads to failed maintenance of the retinal extracellular fluid composition, which 
in turn causes oedema and neuronal damage. The mechanism of BRB breakdown is 
multifactorial. It is secondary to changes in tight junctions, pericyte loss, endothelial 
cell loss, retinal vessel leucostasis, upregulation of vescicular transport, increased 
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permeability of the surface membranes of RPE cells, activation of the AGE receptor, 
downregulation of glial cell–derived neurotropic factor (GDNF), retinal vessel 
dilatation, and vitreoretinal traction (Gillies MC, 1997). 
 
1.3.4.8 Leukostasis and microvascular occlusion: 
Along with the impaired BRB, microvascular occlusion also plays an important role in 
the pathogenesis of DMO. Contributing factors include leucostasis (Barouch FC, 2000), 
microthrombosis (Boeri D, 2001), and extravascular events such as the invasion of 
Muller cells into the lumen of vessels (Bek T, 1997). It remains unclear whether these 
occlusions are primary or secondary to changes in neural metabolism. 
 
1.3.4.9 Microaneurysm formation:  
Microaneurysms (10-100 mm in size) are thought to result from pericyte loss (Stitt AW, 
1995) and vessel wall weakening, which lead to outpouching of the capillaries and 
breakdown of the inner BRB. 
 
1.3.4.10 Growth factors and proliferative changes: 
Progressive retinal hypoxia and ischemia causes release of various angiogenic factors, 
including cytokines and growth factors from neural, macroglial, and vascular 
endothelial cells. These factors promote formation of new blood vessels from the 
venous side and leaking of the capillaries. However, the resulting vessels are fragile and 
leaky; they bleed and can penetrate through the inner limiting membrane into the 
vitreous. If leakage is left untreated, the vessels may be replaced by a dense fibrous 
connective tissue, which adheres firmly to the posterior hyaloid membrane. When this 
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tissue contracts, it applies traction forces on the vitreal and retinal surfaces and can 
result in cystoid macular oedema, pre-retinal haemorrhages and traction retinal 
detachment (Curtis TM, 2009). 
 
1.3.5 Functional changes: 
Evidence that diabetic retinal change is an early neurologic pathology is substantiated 
by various neurophysiological, psychometric, histopathological, and biochemical 
experiments and can be assessed by electroretinography, visual fields, contrast 
sensitivity, and colour vision (Sokol S, 1985; Greenstein V, 1990; Falsini B, 1989). 
Verma A et.al (2009), demonstrated that early spectral domain OCT changes correlate 
with early functional visual loss, even before clinical signs of DMO develop. Chihara E 
et.al (1993) noted early nerve fibre layer defects with red-free photography before onset 
of clinical DMO. Electrophysiological changes in ERG noted in early maculopathy 
(before onset of microvascular changes) (Parisi V, 2001) are thought to predict 
worsening retinopathy better than clinically visible retinopathic characteristics 
(Bresnick GH, 1987). 
 
1.3.6 DMO formation: 
Many studies have shown the influence of vasodilatation, elongation, tortuosity, 
diameter, and transmural pressure on the formation of DMO (Gottfredsdottir MS, 1993; 
Kristinsson JK, 1997; Kylstra JA, 1986). The net flux of fluid and molecules across the 
blood vessel wall depends on the difference between the intraluminal hydrostatic 
pressure which pushes fluid out and plasma colloid osmotic pressure which pulls fluid 
in (as explained by Starling's law). Increased blood pressure, changes in retinal 
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metabolism, hypoxia, and other factors can increase the hydrostatic pressure, dilation, 
tortuosity and can cause blood vessel elongation as explained by LaPlace‘s law. 
Lumenal hydrostatic pressure is often increased in diabetic eyes, due in part to 
coexisting systemic hypertension and in part to the increase in hydrostatic pressure that 
arises from focal retinal hypoxia. The LaPlace‘s law states that a vessel will react to 
increased lumenal hydrostatic pressure by both dilating and becoming more tortuous. 
As a consequence, tight junctions between endothelial cells may become disrupted, 
again favouring fluid egress and macular oedema formation. Retinal swelling also 
initiates the intracellular swelling of Muller cells in the outer plexiform layer (Fine BS, 
1981).  
 
1.4 Current concepts postulating pathogenesis of DMO 
Various concepts have emerged regarding the pathogenesis of DMO. The two main 
concepts of interest to this study are whether DMO is a primary vasculopathy causing 
retinal neural swelling or a diabetic neuropathy causing retinal vascular changes. It is 
thought that the retinal circulation becomes compromised due to loss of Mural cells by 
the capillaries, which leads to the formation of ghost vessels. Lack of blood supply to 
the neural retina leads to necrosis of the neural and glial cells (Chihara E, 1993; 
Schellini SA, 1995). Dying neural tissue releases various vasoproliferative factors, 
which stimulate new blood vessel formation. These new blood vessels are incompetent 
and leak protein and fluid (Klein R, 1992). Impaired autoregulation due to hypoxia is 
another pathologic mechanism causing increased vascular permeability (Grunwald JE, 
1989). The current theories for DMO pathogenesis are classified below.  
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1.4.1 Theory 1: Diabetic maculopathy and macular oedema is a hyperglycaemia-
induced microvascular disease  
The first theory claims that hyperglycaemia, through its effect on various local 
biochemical and metabolic alterations, is the underlying cause for the changes observed 
in DMO (Figure 1.13, Figure 1.14). In this theory, the pathogenic pathways include:  
 Increased flux through polyol or hexosamine pathways: Such flux is associated 
with reduced co-factors required in redox reactions with subsequent alterations 
in the redox state and increased reactive oxygen species causing tissue damage 
(Tilton RG, 1989).  
 Increased accumulation of sorbitol: Sorbitol is dependent on the activity of 
aldose reductase and its accumulation may impinge on various pathways. Also, 
sorbitol can destroy pericytes of the retinal capillaries. 
 Increased synthesis of diacyl glycerol (DAG) and increased free fatty acids, 
together with oxidative stress: This combination leads to the overactivation of 
several isoforms of PKC(Curtis TM,2004; Koya D, 1998), particularly PKC b II.  
 Increased production of free radicals: (Figure 1.15) This situation leads to 
oxidative stress (Obrosova IG, 2001; Kowluru RA, 2006), changes in blood 
rheology and haemodynamics (Tooke JE, 2000; Schmetterer L, 1999), and 
overactivation of the renin-angiotensin system (Miyata T, 2003). Renin, 
angiotensin converting enzyme and angiotensin II receptors are widely 
distributed in the retinal and choroidal vessels and angiotensin has been shown 
to be angiogenic in animal experiments (Dancer AH, 1989). 
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 Increased accumulation of AGEs in the vitreous and vitreoretinal interface and 
activation of receptors for AGEs: These situations lead to increased activation of 
PKC and hypoperfusion. 
 
 
Figure 1.13: Assumed effects of hyperglycaemia (Arden GB, 2009).  
AGE: Advanced Glycation End products, DAG-PKC: Diacyl glycerol-Phospokinase C 
 
 
 
Figure 1.14: Hyperglycaemia-induced neuronal damage (Arden GB, 2009) 
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Figure 1.15: Pathways leading to oxidative stress in diabetic retinal changes (Arden 
GB, 2009). SOD: Superoxide dismutace, GSSG: Oxidized glutathione, ROS: Reactive 
oxygen species, GSH: Glutathion, AGE: Advanced glycation end products, DAG-PKC: 
Diacyl glycerol- Phospokinase C, VEGF: Vascular endothelial growth factor, TGF-β: 
Transforming growth factor beta IFG-1: Insulin like growth factor, NF-Kβ: nuclear 
factor kappa-light-chain-enhancer of activated B cells, DNA: Deoxyribo nucleic acid 
 
1.4.2 Theory 2: Diabetic macular oedema is a primary retinal neuropathy induced 
by insulin deficiency leading to vascular changes 
Neuronal changes in diabetic retina include apoptosis, glial cell reactivity, microglial 
activation, altered glutamate metabolism, and altered expression of GFAP in astrocytes 
and Muller cells. Insulin deficiency is thought to be the primary insult to cause retinal 
changes and apoptosis of neural cells (Li W, 1997; Barber AJ, 1998; Bloodworth, 
1962b; Wolter JR, 1961; Hammes HP, 1995; Barber AJ, 2005). On the basis of this 
information, others have hypothesised that diabetic macular change is a predominantly 
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neuronal pathology (Lieth E, 2000). Diabetes induces chronic neurodegenerative 
changes in the retina, as evidenced by decreasing ganglion cells and thinning of the 
neural retina on scanning laser polarimetry (Lopes de Faria JM, 2002). Loss of ganglion 
cells is followed by reduction in the number of axons in the optic nerve (Scott TM, 
1986), coupled with a deficit in retrograde transport in the optic nerve (Zhang L, 1998), 
which together cause functional loss of the retina.  
Over 50 years ago, Wolter JR, (1961) and Bloodworth JM (1962a) noted pyknosis in 
histological sections of the diabetic retina. Apoptosis was also noted in the endothelial 
cells in later studies (Mizutani M, 1998). Pyknosis is irreversible condensation of 
chromatin in cells undergoing apoptosis, which is a programmed cell death. Necrosis is 
a type of cell injury, which leads to premature death of cells in a living tissue. It is 
caused by factors external to the cell such as infection, toxins or trauma that result in 
upregulated digestion of the cell components. It could be that increased oxygen 
consumption in the metabolically highly active retina leads to a hypoxic environment in 
already compromised retina (Alder VA, 1997), which in turn causes neural cell death 
and release of various vasoactive factors. Immunohistochemical evidence that apoptosis 
occurs in the diabetic retina could be derived from the observed enhanced expression of 
Bax, caspase-9, and caspase-3 (Oshitari T, 2008). Structural remodelling of the 
dendrites and increases in the total length, density, and number of terminals are seen in 
large ON-retinal ganglion cells (Qin Y, 2006; Meyer-Rusenberg B, 2007).  
 
1.5 Current and new diagnostics  
Various diagnostic tools are used for the assessment of DMO severity. This section, 
discusses currently utilized and new diagnostics for DMO.  
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1.5.1 Clinical examination: 
Clinical examination for DMO is a subjective and highly variable assessment (Hee et 
al., 1998) that is no longer considered exclusively when making the decision to treat. 
Because clinical signs of retinopathy are only seen at the late stages, clinical exam 
findings represent the terminal stages of retinopathy. Functional losses, such as loss of 
colour and contrast sensitivities, have already occurred by the time clinical 
manifestations are seen. For these reasons, clinical examination alone is not useful for 
early screening and intervention. Table 1.4 shows the currently used classification 
scheme for DR severity by the early-treatment DR study (ETDRS). 
Diabetic macular oedema (DMO) is defined as retinal thickening as assessed by dilated 
examination using slit-lamp bio-microscopy and/or stereo fundus photography. 
According to the English retinopathy minimum grading classification, maculopathy 
(M1) is defined as: exudate within 1 disc diameter (DD) of the centre of fovea; circinate 
or group of exudates within the macula; retinal thickening within 1 DD of the centre of 
the fovea; and any microaneurysm or haemorrhage within 1 DD of the centre of the 
fovea only if associated with a best visual acuity (VA) ≤ 6/12. According to ETDRS, 
clinically significant macular oedema (CSMO) is defined as: retinal thickening within 
500 m of the fovea; hard exudates within the same 500 m, if associated with retinal 
thickening; and ≥1 DD of retinal thickening, if any part of the thickened retina is within 
1 DD from the fovea. 
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Table 1.4: Diabetic retinopathy disease severity scale  
Proposed Disease Severity 
Level 
Findings Observable on Dilated Ophthalmoscopy 
No apparent retinopathy No abnormalities 
Mild nonproliferative DR Haemorrhages and microaneurysms only 
Moderate nonproliferative DR
1
 Extensive microaneurysms, intraretinal 
haemorrhage, and hard exudates 
Severe nonproliferative DR Any of the following: >20 intraretinal 
haemorrhages in each of 4 quadrants; definite 
venous beading in 2 quadrants; prominent 
intraretinal microvascular abnormalities in 1 
quadrant; and no sign of proliferative 
retinopathy 
Proliferative DR One or more of the following: 
neovascularization and vitreous/preretinal 
haemorrhage 
Maculopathy Exudate within 1 disc diameter (DD) of the 
centre of fovea; circinate or group of exudates 
within the macula; retinal thickening within 1 
DD of the centre of the fovea; and any 
microaneurysm or haemorrhage within 1 DD of 
the centre of the fovea only if associated with a 
best visual acuity (VA) ≤ 6/12 
CSMO Retinal thickening within 500 m of the fovea; 
hard exudates within the same 500 m, if 
associated with retinal thickening; and ≥1 DD 
of retinal thickening, if any part of the thickened 
retina is within 1 DD from the fovea 
Adapted from ETDRS Research Group, 1991. 
1
Moderate nonproliferative DR 
was previously termed as ―mild preproliferative DR‖.  
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The International Clinical Classification of severity of DMO broadly categorises DMO 
into two main groups: absent or present. If DMO is present, then it is divided into three 
groups based on the location of retinal thickening or hard exudates from the centre of 
the macula.  
a) Focal or diffuse macular oedema: Areas of leakage, which may be well 
circumscribed or diffuse. Focal oedema is often associated with circiante rings 
of hard exudates, which are leaked out proteins from microaneurysms. Hard 
exudate is a sign of current or previous macular oedema and often is used as a 
surrogate marker of DMO on single or 2-field non-stereo photographs. Diffuse 
oedema represents more extensive break down of blood retinal barrier, with 
leakage from both microaneurysms and retinal capillaries. Cystic changes appear 
within the macula, representing coalescence of exudative fluid. 
b) Ischaemic maculopathy: the clinical appearance may be relatively normal but the 
visual acuity has dropped and ischaemia is seen on fluorescein angiography. 
c) Clinically significant macular oedema (CSMO): there may be thickening of the 
retina and hard exudates which, when found within a specific distance of the 
fovea or when found to be above a certain size, define CSMO. 
A severity assessment scale has been published recently for diabetic macular oedema 
using ETDRS data correlating visual acuities with retinal thickening. Progressive loss of 
visual acuities were noted with increased severity and duration of DMO, and concluded 
the likely cause for visual improvement in laser treatment patients is owing to decrease 
in retinal thickness and duration of diabetic macualar oedema. (Gangnon RE, 2008) 
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1.5.2 Imaging assessment tools: 
Several imaging assessment methods are used in the diagnosis of DMO, including 
clinical photography, vitreous fluorophotometry (Cunha-Vaz JG, 1979; Raines MF, 
1988), fundus fluorescein angiogram (FFA) (Gao LQ, 2008), and optical coherence 
tomography (OCT) (Verma A, 2009). These methods provide reliable and reproducible 
objective images that permit quantitative assessment of DMO (Forooghian F, 2008). 
However, none of them can be used to assess functional loss in the very early stages 
after diabetes onset, which typically takes the form of a reduction in night vision (Bailey 
CC, 2001). Such early functional deficits are thought to result from the direct effects of 
diabetes, with its dysregulation of insulin and IGF, on the neural retina (Lieth E, 2000).  
 
1.5.2.1 Stereo fundus photography: 
Stereo fundus imaging is a very sensitive tool for detecting macular oedema that serves 
as a commonly used screening method in the current management of diabetic 
maculopathy. However, stereo fundus imaging is associated with several disadvantages. 
Skilled personnel are required for obtaining and grading the fundus photographs. It is 
difficult to determine the fundus thickness precisely, and measurements are highly 
dependent on the subjective stereopsis and picture quality. Given the late onset of 
clinical signs, the 2-dimensional (2D) nature of the pictures may not be useful in the 
quantitative evaluation of DMO. This technique also does not provide information on 
the functional vision. 
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Figure 1.16: Fundus picture of diabetic macular oedema (DMO).  A left colour fundus 
photograph showing exudates, haemorrhages in the macular region. 
 
1.5.2.2 Optical coherence tomography (OCT):  
As a more objective assessment than stereo fundus imaging, OCT provides a 3D, cross-
sectional orientation of the retinal structures (Shahidi M, 1991)(Figure 1.17). Spectral 
domain OCT, a newer generation high-resolution OCT with high-speed data acquisition 
and 3D reconstruction of the acquired retinal images, allows improved visualisation of 
the retinal architecture (Wojtkowski M, 2003; Schmidt-Erfurth U, 2005). Late-onset 
macular changes can be assessed accurately with OCT; unfortunately, they do not 
correlate well with clinical changes, because there are high false positive and false 
negative rates in detecting DMO (Soliman W, 2008). Also, OCT findings do not 
correlate with functional visual changes, which happen much earlier than detectable 
macular structural changes. For these reasons, OCT analysis may not be accurate in 
depicting early functional loss. 
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Figure 1.17: OCT picture of DMO. Top left hand corner of the picture shows colour 
coding of the thickness, top right showing the thickness in microns. The bottom left part 
of the picture gives an optical cross section of the retina showing retinal cystic changes. 
The box at the bottom shows CST, macular volume and average thickness. 
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Scanning with the Cirrus HD-OCT (Cirrus, Carl Zeiss Meditec AG, Jena, Germany) 
was performed with the 512 × 128 scan pattern, in which a 6 mm × 6 mm macular grid 
was scanned with 128 horizontal B-scan lines, each consisting of 512 A-scans per line 
(total of 65,536 sampled points). The macular grid was centred on the intrinsic fixation 
target during OCT scanning. Decentration of the grid by the technician to centre the grid 
on the fovea was not allowed. Only patients with scans of signal strength ≥ 6 were 
included.  
The built-in software calculates the average macular thickness (AMT) of all 9 ETDRS-
like zones, CST (central subfoveal thickness), and the macular volume. Morphological 
characteristics of the intraretinal cysts (hyporeflective areas within the retina) were 
classified as ―present‖ or ―absent‖ at baseline, and improvement is defined as cysts 
becoming smaller in size, or disappearing altogether; and deterioration defined as 
appearance of new cyst or larger than baseline. Intrinsic retinal segmentation algorithms 
were used to define an internal and external retinal layer position from which retinal 
thickness and volume measurements were derived. In the computational software, the 
average retinal thickness is the mean thickness in the 9 retinal subfields in a 6-mm-
diameter circle centred on the fovea. The central subfield thickness was used for 
comparison. Figure 1.17 shows the OCT scan of foveal region. 
 
1.5.2.3 Fundus fluorescein angiogram: 
The FFA method is an objective assessment that provides very good evaluation of the 
structural integrity of the macula and angiographic evidence of early and late clinical 
changes. However, this method is time-consuming, requires technical expertise, and 
cannot be used in all cases because of systemic effects (Soliman W, 2008). 
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Figure 1.18: Fundus Fluoroscein Angiogram (FFA) of diabetic macular oedema 
(DMO). Areas of capillary drop outs can be seen at the top corner of the picture and in 
the middle disruption of foveal avascular zone and leakage from microaneurysms. 
 
1.5.3 Psychophysical tests: 
With the rise in Type II diabetes in obese adolescents due to dietary and lifestyle 
changes, the need for an optimal screening method for sight-threatening DR (STDR) 
has become imperative (Caprio S, 1999). Early treatment of proliferative DR and 
diabetic maculopathy improves visual outcome; however, STDR should be detected 
before visual damage has occurred, because few patients show improvement in vision 
after laser treatment (ETDRS report 1, 1985) 
 
1.5.3.1 Visual acuity: 
Detection of presymptomatic STDR remains difficult. Visual acuity (VA) is a poor 
predictor of the presence or absence of diabetic maculopathy (Ang GS, 2006); it gives a 
gross assessment of visual status, but does not correlate well with structural or other 
functional changes. Visual acuity is only affected in the late stages of DR, when there is 
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direct foveal involvement in DMO. In contrast with VA, colour contrast sensitivity 
(CS), achromatic contrast sensitivity, microperimetry (MP), and electrophysiological 
tests are clinically viable methods to detect functional visual loss before the onset of 
clinical DR. 
The VA measurements all through this thesis were done using ETDRS charts at 4-m 
distance. These charts are modified versions of the logarithm of the minimum angle of 
resolution (logMAR) charts designed by Bailey and Lovie. (Lighthouse International, 
New York, NY). Charts were presented in a light box (Lighthouse International) with a 
luminance of 150 cd/m
2
, as measured with a digital light meter. The settings were 
inspected regularly by the research standards committee. The authors also performed a 
random check of VA measurement and luminance. 
 
Figure 1.19: ETDRS chart (Image adapted from Colenbrander, ‗Measuring Vision and 
Vision Loss‘, www.ski.org/Colenbrander/Images/Measuring_Vis_Duane01.pdf. and 
pelli robson chart (Image provided by Denis Pelli.)  
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Patients were asked to read and guess each letter on the chart until they made ≥4 
mistakes on a single line. The ETDRS VA score was calculated by adding 30 to the 
number of letters read. If the patients read <4 letters, then adjustments were made for 
reading the chart from 1 m, according to the protocols. In this case, the final acuity 
score was obtained by adding the number of letters read correctly at 1 m (up to a 
maximum of 30 letters) to the number of letters correctly read at 4 m (Patel, 2008). This 
procedure was repeated at the 3- and 6-month follow-up visits.  
 
1.5.3.2 Chroma test:  
Colour-vision testing provides a sensitive, noninvasive method to assess macular 
damage. Deterioration in colour vision often precedes changes in other clinical 
measures, such as VA and morphological changes (Hardy KJ, 1992). Several studies 
have shown a correlation between tritan colour-vision deficiency and DR stage 
(Bresnick GH, 1985). There is evidence that protan and tritan colour vision is 
diminished in patients with diabetic maculopathy. However, testing with the FM100 hue 
and Farnsworth-Lanthony D-15 test are labour-intensive and time-consuming (Bresnick 
GH, 1985). Colour-vision testing with a computer graphics system is an effective 
alternative (Wong R, 2008).  
Although the mechanism of altered colour vision is unknown, there is evidence that 
reduced retinal oxygen saturation is associated with impaired colour vision in diabetics 
(Dean FM, 1997). Error scores in colour vision are directly correlated to the severity of 
macular oedema (Verriest G, 1982), and selective loss of short wavelength pathway 
sensitivity is associated with severity of DMO (Greenstein V, 1990; Ueda M, 1992). 
The chroma test can be used as a quick supplementary test for detecting and monitoring 
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sight-threatening pathology (Wong R, 2008). Because it measures visual function 
(rather than features associated with visual loss), the colour vision test could be used for 
the early identification of subjects who will progress to more severe retinal disease (Ong 
GL, 2003). 
 
Figure 1.20: Computer set up for Chroma test 
1.5.3.3 Contrast testing:  
S-cone pathway sensitivity is selectively decreased in the early stages of DR. The deficit 
in CS appears to be independent of vascular changes in the retina (Sokol S, 1985) and 
blood glucose levels (Dosso AA, 1998). In particular, blue-yellow contrast and night 
vision are affected. The fact that hyperoxia improves CS in early DR (Harris A, 1996) 
indicates that hypoxia could be playing major role in inducing early functional visual 
changes. Contrast sensitivity examination by Pelli-Robson charts is noninvasive and, in 
the case of good patient cooperation, can be used to identify functional insufficiency of 
the retina, which is a sign of initial diabetic changes in the foveolar and perifoveolar 
regions (Vujosevic S, 2008). 
 
A letter-by-letter scoring method was used to allow better assessment of the 
repeatability (Elliott, 1990). After corrective refraction (with +0.75 addition), 
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monocular CS was assessed by a standardized protocol with the Pelli-Robson chart 
(Clement Clarke Inc., Columbus, OH). Different charts were used for the left and right 
eyes, at a distance of 1 m and chart luminance of 80–120 cd/m2. The test was stopped 
when the patient failed to read ≥2 letters in a triplet (Patel, 2009). The settings were 
inspected by research standards committee regularly.  
 
1.5.3.4 Electrophysiologic tests:  
ERG measures electrical activity within layers of the retina. The ERG results, 
particularly the amplitude (Juen S, 1990), latency (Sakai H, 1995), and oscillatory 
potentials (Layton CJ, 2007), are altered in diabetics. These alterations are due to early, 
reversible physiological changes rather than to permanent structural compromises of the 
neural retina (Barber AJ, 2003). These changes appear before visible lesions are seen 
(Fletcher EL, 2007). Oscillatory potentials of ERG reflect the inner retinal 
neurotransmission (Dong CJ, 2004), mainly from synaptic activity between amacrine 
neurons and bipolar or retinal ganglion cells (Wachtmeister L, 1998). In diabetics, the 
oscillatory potentials show prolonged latencies and decreased amplitudes. There is also 
a progressive delay of visual evoked potentials (Anastasi M, 1985) in the early diabetic 
retina. 
 
1.5.3.5 Microperimetry: 
Microperimetry is a fundus-related perimetry that quantifies functional loss by 
determining the macular threshold (Okada K, 2006; Mori F, 2002). Although VA is 
used as the gold standard for visual function evaluation in diabetic patients, it frequently 
does not correlate with the perception of disability (Midena E, 2007). A better 
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correlation between early macular pathology and visual function may be achieved by 
retinal threshold quantification and fixation patterns determination (Carpineto P, 2007). 
In DR, retinal neurodegeneration may precede photoreceptor loss and reduction of the 
macular sensitivity may be observed before fixation impairment has occurred 
(Vujosevic S, 2008). 
Microperimetry was performed with the Nidek MP1 microperimeter (MP1 Nidek 
Technologies, Japan). Because this test requires pupil dilation, it was performed after all 
of the tests requiring undilated pupils had been completed. At 15 min before 
microperimetry, the pupils were dilated with a drop of tropicamide 1% and 
phenylephrine 2.5%. The test was done with one eye patched at a time. In a darkened 
room, after a briefing trial test was initially performed, the test was performed with a 5-
min gap between tests on each eye. All patients had a 30-s fixation test. A 2° red-cross 
was used as the fixation target. The test stimulus colour was white, Goldmann III size 
(26 min arc or 0.4°), and duration was 200 ms. Background illumination was set at 1.27 
cd/m
2
. The intensity of the stimulus ranged 0–20 db, in which ―0‖ represents the 
brightest luminance (127 cd/m
2
).  
The perimetric strategy of the MP1 starts at an initially defined threshold level (12 dB) 
for each stimulus. A 62-loci grid covering central 20° was manually centred on the 
fovea. If the foveal landmark was not visible on the infrared fundus image, then the 
foveal centre was located 2 DD temporal and one-third DD inferior to the disc centre, 
according to the algorithm recommended by Sunness et al, 2007. A 4-2 step strategy 
was used to reduce the test time and influence of fatigue on the results. The recorded 
fixation points were classified as ―stable‖ if >75% of the fixation points were inside the 
2°-diameter circle; ―relatively unstable‖ if <75% were inside the 2°-diameter circle, but 
  61 
>75% were inside the 4°-diameter circle; and ―unstable‖ if <75% of the fixation sites 
were inside the 4°-diameter circle (fujiii, 2003). 
Because the mean sensitivity of the perimetry does not provide spatial information, the 
decision to treat macular disorders is usually based on proximity of the lesion to the 
centre of fovea. Mean sensitivity of the perimetry was determined as the mean 
sensitivity of the 62 stimuli. The microperimetry thresholds were also divided based on 
the 9 ETDRS grid zones. An ETDRS grid was overlaid onto the microperimetry report 
chart, and thresholds were calculated separately for the central 1-mm zone and 
remaining 8 zones individually (Figure 1.21). Pointwise sensitivities of all of the points 
in the outer zones were summed to determine the peripheral sensitivity. The 5 points 
within the central 1-mm zone were summed to get the central zone sensitivity. Zones 2 
to 5 were summed to get the parafoveal sensitivities and zones 6 to 9 for the perifoveal 
sensitivities. The follow-up protocol at 6 months was similar to the first. Automated 
alignment of the infrared images was ensured either automatically by the software or by 
manual registration. The central macular sensitivity, defined as the central 16 loci 
comprising a 4 × 4 grid (5° circle around central of macula) was recorded, because this 
area corresponded best with the OCT characteristics. 
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Figure 1.21:  ETDRS grid overlap on MP1. Inner circle represents central 1 mm of 
macula, and the outer most circle covers 6mm. The numerals represent point wise 
sensitivities. Central blue dots represent patient eye tracking. 
 
 1.6 Current and new treatments 
All of the current treatments for DR are based on addressing visible clinical 
manifestations. Although laser photocoagulation is the gold standard for DR treatment, 
it is associated with certain disadvantages. New pharmaceutical modalities are under 
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investigation, including steroids, anti-VEGF antibodies, PKC inhibitors, VEGF 
aptamers, aldose reductase inhibitors, and antihistamines. Surgical innovations to treat 
DR have been evaluated, such as pancreatic transplantation (to increase endogenous 
insulin) and bariatric surgery (to increase GLP-1). The hypothesis underlying these 
treatments is that insulin deficiency is the primary insult that causes retinal changes. 
However, it is difficult to separate insulin deficiency from hyperglycaemia.  
Although some of the above treatment modalities have shown promising effects on DR 
of various stages, their influence on retinal neural tissue and ability to preserve 
functional aspects of vision have yet to be evaluated. In this section, current and new 
treatments for DR are discussed.  
 
1.6.1 Laser photocoagulation: 
Although various theories have been offered to explain the actual effect of laser 
photocoagulation on DR, it remains unclear how this treatment modality works. 
Michaelson (1948) proposed that the ischaemic retina produces a growth factor that 
promotes neovascularisation. By destroying the ischaemic retina, laser treatment is 
thought to reduce expression of the neovascularising growth factor and to reverse 
proliferative changes (Patz A, 1980). However, various post–laser treatment histological 
studies have suggested that mild to moderate laser destroys the outer retina and pigment 
epithelium, but does not affect the inner retina (Novack RL, 1990). A second theory 
proposes that laser-damaged recovering pigment epithelium produces a factor that 
inhibits neovascularisation (Del Priore LV, 1989, Steffanson E, 2006). A third theory 
postulates that laser destruction of the photoreceptors reduces oxygen consumption by 
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the outer retina and increases oxygenation of the inner retina. Choroidal oxygen is 
believed to diffuse through the laser scars to the inner retina (Stefansson E, 2006). 
Regardless of the mechanism, laser increases oxygen tension in the inner retina. The 
retinal blood supply is largely autoregulated by the chemical composition, mainly 
oxygen tension (Tomic L, 2005). Increased oxygen tension leads to auto regulatory 
constriction of the arterioles and reduction of the intravascular hydrostatic pressure, 
which results in constriction of the capillaries and venules (Wolbarsht ML, 1981). The 
resultant decreased blood flow (Grunwald JE, 1989) further reduces endothelial 
stretching, thereby reducing the endothelial growth potential (Stefansson E, 1983). 
Before a patient receives laser treatment, irreversible functional visual loss has already 
occurred. Laser photocoagulation reduces the risk of moderate vision loss by 50%, but 
only 3% of patients show any improvement; most remain unresponsive (ETDRS Report 
1, 1985). Laser photocoagulation can prevent further vision loss in a few, but cannot 
reverse vision loss and must be repeated (Blankenship GW, 1991). Laser treatment 
itself is not without adverse effects, including inadvertent foveal burn, central visual 
field defect, paracentral scotomas, colour vision abnormalities, retinal fibrosis, and 
spread of laser scars (Lovestam-Adrian M, 2000).  
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Figure 1.22: Possible therapeutic interventions to prevent DR (Arden GB, 2009) 
 
1.6.2 Addressing dark adaptation induced hypoxia: 
It has been proposed that reducing the dark currents of rods can decrease hypoxia and 
prevent progression of DR (Arden GB, 2005). Rods have the highest metabolic rate of 
any cell in the body. In the dark, the outer limb membrane leaks, causing an inward dark 
current of Na
+
 and water, which are pumped out in the inner limb. This process is 
regulated by cGMP and requires substantial energy and a large oxygen supply. Pores in 
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the rod outer limb membrane close under the influence of light, Ca
2+
 entry is reduced, 
and the activity of the Na-Ca exchanger diminishes, thereby limiting cGMP utilisation. 
Results of a Phase I clinical trial indicate that reducing rod cGMP activity by preventing 
full dark adaptation (i.e., through maintenance of a continuous low level of background 
light with a light mask at sleep) should decrease peak outer limb retinal oxygen demand, 
thereby slowing the progression and reversing early changes of DR. (Arden GB, 2010) 
 
1.6.3 Anti-VEGF agents: 
Several proinflammatory cytokines (including, in particular, VEGF) are involved in the 
onset and progression of DMO (Aiello LP, 1997; Poulaki V, 2007). VEGF inhibits 
endothelial-occludin protein synthesis, causes microvascular leakage, and promotes 
neovascularisation. Inhibiting VEGF provides an alternate treatment approach to 
treating DMO. One example therapy is ranibizumab, which is a fully humanized 
monoclonal antibody fragment (Fab). Various randomised control trials have shown that 
intravitreal injection of this drug is efficient in reducing DMO and improving visual 
potential (Nguyen QD, 2010; Massin P, 2010). 
 
1.6.4 Corticosteroids: 
There is evidence that inflammation and resulting leukostasis play a vital role in the 
onset of diabetic macular oedema. Through the release of free radicals, enzymes and 
cytokines, leukocytes can damage the endothelial cells and there by integrity of the 
blood retinal barrier. Cytokines released by leukocytes include VEGF, IL-6, TNF- α 
(Ehrlich R, 2010). ICAM-1 plays a major role in cell-to-cell adhesion and leukostasis. 
Given the role of inflammation in the pathogenesis of DMO, steroids have been utilized 
to treat DMO, for its ability to inhibit VEGF production. Corticosteroids mainly act by 
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interfering and inhibiting expression of proinflammatory genes for TNF α, VEGF and 
other cytokines (Nauck M, 1998). They also inhibit the phospholipase A2 
pathway, and reduce leucocyte chemotaxis. 
 
1.6.5 Glucagon-like peptides: 
The retina contains glucagon-like peptide receptors (GLP)-1R, more so in the inner 
retina, which creates a trophic stimulus on the retinal tissues. This observation has 
attracted substantial interest, owing to the introduction of synthetic incretins, which are 
GLP agonists, as part of the treatment armamentarium for diabetes. These GLP agonists 
can increase insulin sensitivity in the retina, prevent retinal cell death, and maintain 
normal thickness and so might have an effect on the progression of DR (Zhang Y, 
2009). 
 
1.6.6 New antidiabetic drugs: 
Table 1.4 shows the latest groups of drugs that are being used in or evaluated for 
clinical practice (Israili ZH, 2011). Although insulin is the primary target for diabetes 
treatment, newer antidiabetic agents that only indirectly affect insulin secretion are now 
available. Some of these agents, such as glitazones, adversely affect DMO. These drugs 
do not significantly differ from insulin in the control of HbA1C, but have additional 
effects. Comparison of the effects of these treatment options with insulin on DR may 
help us to understand the direct effects of insulin on the retina.  
Incretin receptor agonists (i.e., exenatide) and enhancers (i.e., sitagliptin) are 
pharmaceuticals that increase the activity of GLP-1. GLP-1 is an insulinotropic gut 
peptide that is secreted from the L-cells of the gastrointestinal tract in response to food. 
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GLP-1 normalizes the blood glucose level, stimulates insulin synthesis, inhibits 
glucagon secretion, delays gastric emptying, and may promote satiety. It has potent 
effects on glucose-dependent insulin secretion, insulin gene expression, and pancreatic 
islet cell formation (Xu G, 2009).  
GLP-1R is predominantly expressed in the inner layer of the retina (Zhang Y, 2009), as 
well as in various other tissues, including pancreatic endocrine cells, intestinal epithelial 
cells, brain, lung, kidney, heart, mouse skin and primary porcine proximal tubular cells 
(Baggio LL, 2007). In experimental diabetic rats, the E4 (GLP-1) analogue was found 
to influence positively retinal electrical responses and to increase thickness of the nerve 
fibre layer. Thus, GLP-1 analogues might be able to rescue degenerating neurons of 
DR. Further exploration is needed to determine whether the protective mechanisms 
come from its glucose-normalising effect or a direct effect on the retina (Zhang Y, 
2009). 
 
Table 1.5: Antidiabetic agents and their mode of action (Israili ZH, 2009) 
Mode of action Category of drugs 
Peroxisome proliferator–activated receptor 
gamma agonists; increase peripheral glucose 
disposal 
thiazolidinediones, pioglitazone, 
and rosiglitazone 
Incretin (GLP-) receptor agonists; incretin-
mimetics 
exenatide and liraglutide 
Inhibitors of dipeptidyl-peptidase-4; incretin 
enhancers 
sitagliptin, and vildagliptin 
Short-acting, nonsulfonylurea secretagogue; 
increase pancreatic insulin secretion 
meglitinides (repaglinide and  
nateglinide 
Amylin analogue; inhibits glucagon secretion, 
delays gastric emptying, and acts as a satiety 
agent 
pramlintide 
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 1.7 Conclusions drawn from literature review 
With the global incidence of DM expected to reach 5.4% by 2020, combined with the 
rise in Type II diabetes among obese adolescents, strategies for managing diabetic co-
morbidities such as retinopathy are acutely needed. Macular oedema is the primarily 
cause of visual impairment in DR, the clinical hallmarks of which include micro-
aneurysms, haemorrhages, and exudates resulting from increased vascular permeability 
and new vessel proliferation. Accumulating evidence indicates that DMO is probably 
not primarily because of vascular disease, but rather a neurologic disease with far 
ranging neuro-pathologic, inflammatory, and vasculopathic effects. Early neurologic 
changes of DR, including functional visual loss, occur much earlier than clinical 
presentation. Such early effects are thought to result from the direct effects of DM, 
including hyperglycaemia and/or insulin insufficiency, rather than breakdown of the 
BRB. Recent successful trials with antibodies to VEGF in diabetic macular oedema 
indicate the early role of this cytokine in the pathogenesis of DMO. The mechanisms for 
the raised VEGF levels in diabetic retina are still not clear. Several theories that hypoxia 
and associated increased reactive oxygen species, collectively referred to as oxidative 
Alpha-glucosidase inhibitors; competitive 
inhibitors of enzymes needed to digest 
carbohydrates, reduces carbohydrate metabolism 
miglitol and voglibose 
Bile acid sequestrant;  bind bile acids in the gut 
and interrupts enterohepatic recirculation of bile 
acids, effects on hepatic lipoprotein metabolism 
colesevelam 
Sulfonylureas (SUs); increase pancreatic insulin 
secretion 
glipizide, glyburide 
Biguanides; decrease hepatic glucose production metformin 
  70 
stress, could be one of the main causes for early increase in VEGF levels and diabetic 
macular oedema.  
Given the early presentation of functional retinal deficits among patients with diabetic 
maculopathy, there is a crucial need for early screening methods for sight-threatening 
DR. Currently used screening methods are based on clinical examination. However, 
functional vision loss can precede clinical manifestations of DMO by many years. 
Moreover, use of clinical examination to screen for maculopathy is insufficient. Visual 
acuity is not a very reliable or functional measure of vision, and no correlation has been 
found between microvascular changes and VA. Other diagnostic modalities, such as 
stereo fundus imaging, OCT, and FFA, allow quantitative assessment of DMO; 
however, they are not appropriate for assessing very early functional loss after onset of 
maculopathy. Further research is needed to improve diagnostic modalities, so that early 
intervention can be offered. 
In terms of DMO treatments, laser photocoagulation is currently the gold standard. 
However, laser treatment is not as effective in real-life scenarios as had been predicted 
from trial setups (DRCRN trials). Although able to reduce the risk of moderate vision 
loss by 50%, laser photocoagulation improves symptoms in only 3% of patients with 
DMO (ETDRS Report 1, 1985). The mechanism of action of laser photocoagulation 
remains unknown, and treatment is associated with important collateral damages, 
including inadvertent foveal burn, central visual field defect, para central scotomas, 
colour vision abnormalities, retinal fibrosis, and spread of laser scars (Lovestam-Adrian 
and Agardh, 2000). Other treatment modalities currently being investigated include the 
anti-VEGF agent ranibizumab, antidiabetic medications, as well as incretin receptor 
agonists (exenatide) and enhancers (sitagliptin). Given the emergence of trials assessing 
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the role of anti-VEGF agents in DMO, there is hope that early diagnosis and 
intervention are within reach to improve treatment and prevent early functional loss. 
 
1.8 Hypothesis 
H1) Laser photocoagulation increases oxygen tension in the inner retina and improve 
psychophysiologic functions. A long-term laser outcome study is conducted to 
test this hypothesis (section 2.1)  
H2) Hypoxia contributes to the pathogenesis and aggravation of DR and DMO, and 
photoreceptors utilize oxygen maximally during dark adaptation. So 
thereotically decreasing oxygen consumption of the photoreceptors by reducing 
dark adaptation should have a positive impact on diabetic maculopathy. This 
hypothesis is tested by light adapting the rods and assessing the impact on 
diabetic maculopathy (Section 2.2) 
H3) Neuronal changes precede vascular changes in DMO. This is tested by 
correlating functional and anatomical changes as described in section 3. 
 
 
1.9 Aims, objectives and Methodology  
1.9.1 Aims:  
The aims of the projects contributing to this thesis were to:  
1) Assess the efficacy of laser treatments (standard of care) for diabetic 
maculopathy; 
2) Investigate new treatment strategies that reduce the hypoxic insult in diabetic 
eyes; 
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3) Assess new diagnostic methods in evaluating the progression of diabetic 
macular oedema.  
 
1.9.2 Objectives and proposed methodology:  
1) To test H1, we assessed the long-term (5-year) outcome of laser 
photocoagulation. This was achieved by a retrospective analysis of the outcome 
of laser treatment in over 100 patients. 
2) To test H2, we conducted a trial to enhance oxygen availability through 
inhibition of rod dark adaptation, and assessed whether this approach has any 
influence on the progression of diabetic maculopathy. This was achieved by a 
prospective clinical trial performed on 40 patients with early diabetic 
maculopathy with the use of light-masks to decrease dark adaptation.  
3) To test H3, we assessed whether Contrast sensitivity (CS), Colour vision 
(Chroma test) and Microperimetry (MP) could detect diabetic macular oedema 
before clinical changes happen and if these tests could be used as screening tools 
for assessing diabetic macular oedema. 
 
1.9.3 Organization of the thesis:  
The overall aim of this thesis is to investigate novel concepts in the diagnosis and 
treatment of DMO. The thesis is organized as follows. In Chapter 2, I discuss treatment 
methods for DMO. Section 2.1 presents the long-term (5-year) results of a laser 
photocoagulation study for DMO and tests hypothesis H1. In Section 2.2, I propose a 
rod dark adaptation approach for early intervention of diabetic maculopathy. A clinical 
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trial (phase II) was performed to see if inhibiting rod dark adaptation activity by light 
exposure would influence diabetic maculopathy, thus testing hypothesis H2.  
In Chapter 3, I discuss the diagnosis of early diabetic maculopathy. I assess use of MP1, 
colour vision testing, and chroma test (section 3) for ascertaining early functional vision 
loss before major clinical changes are noted as a test for H3. Also in this chapter I 
monitor the structural and functional changes in eyes with mild maculopathy (with 
cysts) over 6 months. Chapter 4 discusses the implications of the collective findings, 
and Chapter 5 concludes the work.  
 
 
 
 
 
 
 
 
 
 
2:  TREATING DIABETIC MAULAR OEDEMA 
2.1 Five-year visual outcome following laser photocoagulation of 
diabetic macular oedema 
 
2.1.1 Introduction:  
Diabetic maculopathy continues to be a leading cause of new onset vision loss 
worldwide among working age populations (Aiello LP, 2010). The ETDRS 
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demonstrated that focal or grid laser photocoagulation reduced the risk of moderate 
visual loss in patients with CSMO by approximately 50% (from 24% to 12%) at 3 years 
(section 1.7.1), although VA improvement was observed in <3% of cases, based on 15-
letter gain at 3 years (ETDRS report 9, 1991). Despite the unsatisfactory outcomes, this 
treatment remains the gold standard of treatment for CSMO. Indeed, recent clinical 
trials conducted by the Diabetic Retinopathy Clinical Research Network (DRCRN.net) 
indicate that the outcomes associated with macular laser treatment have improved 
significantly (Bressler NM, 2009; DRCRN, 2008). Advances in laser technology and 
optimisation of glycaemia and blood pressure (BP) control have been attributed to these 
beneficial outcomes (Browning DJ, 2008). Similarly, contemporary prevalence studies 
also suggest that the prevalence of DR and its complications is decreasing when 
compared to the Wisconsin Epidemiologic Study of Diabetic Retinopathy published in 
1984 (Klein R, 2008). This decline in DR prevalence is also thought to be due to the 
enhanced control of systemic factors (Brown JB, 2003; Kempen JH, 2004; Wong TY, 
2006).  
For over two decades, lessons from the UK Prospective Diabetes Study (UKPDS VIII, 
1991) and the Diabetes Control and Complications Trial (DCCT, 1986) studies have 
governed our clinical practice with regard to the management of DMO. Strict glycaemic 
and blood pressure control remain the most effective interventions to date. Given that 
laser increases oxygen tension in the inner retina (Stefansson, 2006), the aim of the 
study was to test the hypothesis that VA may continue to improve in eyes with laser-
treated maculopathy (H1). Given that contemporary clinical trials and prevalence data 
suggest an improvement in visual outcomes and better control of risk factors, we 
conducted a retrospective study to assess the 5-year visual outcome associated with 
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macular laser photocoagulation (2003-2009) in a clinic-based setting in a multi ethnic 
inner city population. We also determined the effect of systemic factors on visual 
outcomes to evaluate whether similar outcomes are obtained in a setting where patients 
have not been standardized, as they would have been in a clinical trial, representing a 
real-life clinical situation.   
 
2.1.2 Methods:  
The Chair of the Institutional Ethics, Research and Development Committee approved 
the protocol for this study (Appendix J: Kings Research and Development Committee 
approval). The project was also registered in the Clinical Effectiveness Department of 
the institution (Kings college Hospital NHS Trust). The study adhered to the tenets of 
the Declaration of Helsinki. All the laser procedures in the study were carried out either 
by the trainees at registrar grade, under supervision, or by the consultant 
ophthalmologists.  
 
2.1.2.1 Study population: 
This study was carried out at King‘s College Hospital, London, where an established 
diabetic retinopathy-screening programme caters to a 700,000 multiracial community 
with high levels of social and material deprivation. One-third of the total study 
population was drawn from black and ethnic minority groups. Individuals were graded 
as having DMO based on post-mydriatic 2-field colour fundus photographs. Screen-
positive patients were referred to retinal clinics, where a clinical examination and 
additional investigations (e.g: FFA) were performed before laser photocoagulation. 
OCT was not available at baseline examinations. 
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2.1.2.2 Study design: 
Consecutive patients with Type 2 diabetes and DMO who required their first macular 
laser photocoagulation in 2003-2004 were identified from the laser register. In bilateral 
cases, the first eye treated in each patient was included in the study. In cases where both 
eyes were treated during the same session, the eye with the poorer baseline VA was 
included. Patients who did not complete the 5-year follow-up were excluded from the 
study and the reasons for being lost to follow-up were recorded.  
 
2.1.2.3 Laser photocoagulation: 
The focal/grid photocoagulation protocols used in the department mirror the 
DRCRN.net protocols (modified from the original ETDRS protocol) (Aiello LP, 2010). 
In brief, treatment was performed with a 532-nm green laser light Iridex Oculite GLx 
(Iridex Corp, California, USA) with a spot size of 75–125 μm and exposure time of 100 
ms to obtain a light grey-white (just visible) burn and applied in a focal or grid pattern 
to cover the area of oedema.  
Patients were reviewed every 4–6 months, unless they failed to attend an appointment. 
Laser treatment was repeated if clinical, angiographic, and, more recently, OCT 
evidence indicated persistence of macular thickening. No distinction was made between 
focal or grid lasers in this study, because in clinical practice, many patients tend to have 
both on long-term follow-ups.  
 
2.1.2.4 Visual acuity: 
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Initially, VA was recorded with Snellen VA charts, followed by the ETDRS charts at 2 
m. All VA recordings were converted to ETDRS scores for this study. The mean annual 
visual outcome was defined as the average of all VA measurements recorded per year.  
 
2.1.2.5 Co-morbidity: 
All annual clinical data regarding ocular and medical history, including laboratory 
values, were obtained retrospectively from the electronic patient record, clinical files, 
and laboratory records. Data collected that was related to systemic factors included age 
at first laser treatment, gender, ethnicity, length of duration of diabetes at baseline, date 
of initiating insulin therapy, average annual HbA1C levels, mean annual systolic and 
diastolic blood pressure, number of anti-hypertensive medications at baseline and 
annually, average annual BMI, history of being on statins, history of cardiovascular co-
morbidity, peripheral neuropathy, and foot ulcers. Data collected that was related to 
ocular features included mean annual visual outcome, grade of DR, date of cataract 
surgery (if done), number of macular laser treatments in 5 years, date of initiating pan-
retinal photocoagulation (if required), history of any other surgical procedures including 
date, other ocular co-morbidity, number of retinal clinic appointments in 5 years, and 
the number of appointments the subject failed to attend in 5 years.  
 
2.1.2.6 Statistical analysis: 
The primary outcome measures in our patients (KCH cohort) included the mean final 
change in visual outcome and the annual outcomes up to 5 years; the 3-year outcomes 
were compared to the outcomes of the laser arm in the DRCRN randomised controlled 
study that compared intravitreal triamcinolone IVTA with laser photocoagulation for 
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DMO (DRCRN, 2009). Covariates for the analysis included baseline age, gender, 
ethnicity, BMI, baseline VA, baseline HbA1C and mean baseline diastolic and systolic 
BP. The last observation carried forward method was used to assign 45 missing values 
over the 5-year study period. Data were expressed as percentages, mean values (with 
standard
 
deviations) or median values. In the univariate analyses, we compared each of 
these variables using appropriate statistical methods. After the univariate analysis, a 
multiple regression model of patient characteristics and outcomes was performed to 
identify the clinical variables associated with gain and loss of vision. ―Gain‖ is 
considered to be improvement of 10 or more letters, whilst ―Loss‖ of vision is losing 10 
or more letters (Aiello LP, 2010). To correct for multiple comparisons, results were 
only included in the multivariate analyses when the corresponding P values were 
<0.01(Aiello LP, 2010).  For univariate analysis patients were stratified by visual acuity 
letter score as >74, 73-69, 68-59, 58-49, 48-39, 38-24, <23 and categorised into one of 3 
age groups:  18 to <60, 60 to <70, 70 and older. This strata was chosen to divide the 
cohort into equivalent size subgroups as done in DRCRN study (Michael S I, 2008). 
Multiple regression model with backward selection process was used to analyse 
variables that were significant (P<0.05) in univariate analysis.  
 
 
2.1.3 Comparison to DRCRN trial outcome:  
Baseline characteristics of the study cohort (KCH) are summarised and compared to the 
DRCRN study population in Table 2.1. The mean age of the patients at study baseline 
was 68.8 years (range 38–91yr, 95% CI  66.6 to 70.9, SD 10.78), with 47 (31%) female 
and 53 (69%) male patients (Figure 2.1). A total of 201 clinical notes were examined to 
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identify patients who met the criteria for enrolment; causes for exclusion included: lack 
of adequate follow-up (n = 54), lost to follow-up (n = 32), and mortality (n = 15).  
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Figure 2.1: Box and Whisker plot of KCH cohort age group. 
 
 
 
 
Table 2.1. Baseline characteristics of the KCH cohort-DRCRN laser group 
 DRCRN 
laser arm 
KCH cohort P(one sample t test, 
    Comparison of     
    proportions) 
Number of patients 115 100  
Median age(25
th
,75
th
 percentile) 63(57,69) 60(52,66) 0.0009 
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Median duration of diabetes at 
baseline in years (25
th
,75
th
 percentile) 
15(10,22) 12(10,17) =0.07 
Mean HbA1C % ± SD 7.9 ± 1.8 9.5 ± 1.9 <0.0001 
Prior macular laser at baseline 
Prior PRPC 
Combination PRPC with focal 
60% 
16% 
None 
3%  
6% 
<0.0001 
=0.0013 
Median baseline VA(25th,75th percentile) 62(53,67) 70(60,75) =0.0008 
Ethnicity at baseline 
White 
Black 
Asian 
Others 
 
74% 
9% 
2% 
15% 
 
38% 
47% 
13% 
2% 
 
<0.0001 
<0.0001 
<0.0001 
=0.0009 
Sex (M: F%) 
Type of diabetes: Type I 
                             Type II 
51:49 
4% 
96% 
54:46 
0% 
100% 
=0.68 
=0.08 
=0.08 
Phakic at baseline 79% 91% =0.01 
Retinopathy status at baseline 
Mild 
Mod 
Severe 
PDR 
Hypertensive at baseline 
CRF 
Cataract surgery 
 
58% 
14% 
28% 
16% 
81% 
None 
21% 
 
85% 
6% 
6% 
3% 
86% 
11.5% 
8% 
 
<0.0001 
=0.048 
<0.0001 
=0.0013 
=0.31 
<0.0001 
=0.0048 
HbA1C: glycosylated haemoglobin; VA: visual acuity; PDR: proliferative diabetic 
retinopathy. 
2.1.4 Results:  
2.1.4.1 Visual outcomes: 
The mean change in VA at 3 years was -4.15 ETDRS letters in the KCH cohort relative 
to a gain of 5 ETDRS letters in the DRCRN study. In the first year, the percentages of 
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gainers were similar in both groups (73% in the KCH cohort versus 74% in the DRCRN 
laser group). However, by the 3
rd
 year, only 50% of the KCH group patients were 
gainers compared to 83% in the DRCRN laser group. The proportion of gainers in the 
KCH cohort was relatively similar from the 3
rd
 to 5
th
 years after the first laser treatment 
(47–50%; Table 2.2). Only one out of 10 KCH cohort members gained ≥15 ETDRS 
letters at year 1, and this result was maintained to year 5. However, in the DRCRN laser 
group, the number of patients that gained ≥15 ETDRS letters nearly doubled from 14% 
in the first year to 26% in the 3
rd
 year. However, the results with the KCH cohort are 
superior to those of the ETDRS study, in which only 3% gained ≥ 15 ETDRS letters. 
When we consider the proportion of patients with moderate visual loss at 3 years (loss 
of ≥ 15 ETDRS letters), the outcomes with the KCH cohort are inferior (27%) to those 
of the DRCRN laser group (8%). Taken together, the results of these comparisons show 
that the visual outcomes of the KCH cohort are inferior to the visual outcomes of the 
laser group in the contemporary DRCRN study (Figure 2.2).  
 
2.1.4.2 Mean number of laser treatments: 
The mean number of laser treatments over the 5-year study period for the KCH cohort 
was 2.74 ± 1.6. Table 2.3 shows the number of laser treatments for the KCH cohort 
compared to the DRCRN laser group. The mean number of laser treatments performed 
was less for the KCH cohort, and more patients in the KCH cohort had only one laser 
session compared to the DRCRN laser group, despite the fact that 60% of the DRCRN 
group had prior laser treatment and 13% of the DRCRN group had additional treatments 
other than laser (e.g., IVTA and bevacizumab). All of the patients in the KCH cohort 
were treatment-naïve, and none of the KCH cohort patients received any additional 
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intravitreal treatments. Notably, the proportion of patients having ≥4 laser sessions in 
the KCH group was less than that in the DRCRN group.  
 
 
Figure 2.2. Comparison of annual changes in VA between KCH cohort and DRCRN 
laser group 
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Table 2.2: Annual mean visual outcomes of the KCH cohort compared to the DRCRN laser group outcomes (DRCRN, 2009)  
 KCH 
1
st
 year 
DRCRN 
1
st
 year 
KCH 
2
nd
 year 
DRCRN 
2
nd
 year 
KCH 
3
rd
 year 
DRCRN 
3
rd
 year 
KCH 
4
th
 year 
KCH 
5
th
 year 
Changes in VA:          
Mean ± SD -0.48 ± 11.74 1 ± 16 -2.08 ± 14.62 2 ± 17 -4.15 ± 15.2 5 ± 17 -4.03 ± 15.34 -5.23 ± 17.2 
Median (95% CI) 0 (-2.7, 1.8) 3 (-5, 10) 0 (-4.9, 0.79) 5 (-5, 12) -4 (-7, -1) 8 (-2, 15) -5 (-7, -1) -5 (-8.6, -1.8) 
≥15 letter gain 10% 14% 10% 20% 9% 26% 13% 12% 
10-14 letter gain 11% 14% 6% 14% 5% 18% 2% 4% 
5-9 letter gain 10% 17% 18% 17% 14% 18% 12% 9% 
no change ±4 
letters 
42% 29% 27% 22% 22% 21% 20% 22% 
5-9 letter loss 6% 9% 8% 9% 12% 4% 17% 16% 
10-14 letter loss 7% 3% 10% 6% 11% 4% 8% 10% 
>15 letter loss 14% 14% 21% 13% 27% 8% 28% 27% 
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Table 2.3: Number of laser treatments in KCH cohort compared to DRCRN laser group 
Number of laser 
treatments 
DRCRN laser group 
(3rd year) 
KCH cohort 
(3rd year) 
KCH cohort 
(5th year) 
1 session 19 32 23 
2 sessions 24 28 32 
3 sessions 25 20 21 
4 sessions 18 5 8 
5 sessions 10 7 8 
6 sessions or more 4 8 8 
Mean laser sessions 2.9 ± 1.4 2.54 ± 2.0 2.74 ± 1.6 
 
2.1.4.3 Influence of systemic factors on visual outcome at 5 years 
Table 2.4 shows the mean annual changes in HbA1C and systolic and diastolic blood 
pressure in the KCH cohort over 5 years in the current era of improved glycaemia and 
blood pressure control relative to the DRCRN cohort. Although the mean HbA1C and 
blood pressure values in the KCH cohort improved slowly over the 5-year study period, 
the overall control of risk factors for the KCH cohort was inferior to the baseline data 
for the DRCRN laser group. There were no differences in demographic and systemic 
parameters between various ethnic groups in the KCH cohort excepting significantly 
lower diastolic blood pressure in Asian cohort (Table 2.5).  
Univariate analyses of the known risk factors are shown in Table 2.6. For this analysis 
the visual outcome is categorised ―Gainers‖ who were defined as those gaining 10 or 
more ETDRS letters; whilst ―Losers‖ were those who lost 10 or more letters. Insulin 
users, base line BMI, baseline VA, number of laser treatments (a surrogate marker of 
  85 
DMO severity), number of anti hypertensives and more failed appointments were 
significantly correlating with change in visual outcome. However, the multivariate 
model showed that better visual acuity at baseline, worsening of HbA1c, baseline lower 
diastolic blood pressure and further reduction of diastolic blood pressure were the only 
poor prognostic indicators (Table 2.7).   
 
Table 2.4: Changes in HbA1C and BP in KCH cohort over the 5-year study period. 
 Baseline Year 1 Year 2 Year 3 Year 4 Year 5 
HbA1C 9.25±1.99 
(5.7–15.4) 
9.17±2.09 
(5.6–18.6) 
9.4±2.06 
(5.8–15.6) 
8.82±1.87 
(4.4–13.5) 
8.85±1.82 
(5.5–16.8) 
8.7±1.81 
(6.2–16.8) 
Systolic 
BP 
143±23.37 
(93–234) 
142±21.31 
(94–195) 
144±22.36 
(82–200) 
142±19.70 
(95–190) 
140±21.76 
(92–200) 
141±21.57 
(84–204) 
Diastolic 
BP 
80 ± 11.56 
(50–122) 
79 ± 11.88 
(52–110) 
78 ± 12.15 
(43–105) 
77 ± 10.7 
(46–105) 
75 ± 11.51 
(50–108) 
77 ± 11.59 
(50–108) 
SD: standard deviation; HbA1C:  glycosylated haemoglobin. Data are shown as mean ± 
SD (range) 
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Table 2.5: Differences in demographic and systemic parameters between various ethnic 
groups in the KCH cohort. 
 
 Caucasians Blacks Other 
ethnic 
groups 
P(one way 
ANOVA) 
No: at baseline (N) 37 47 16  
Age at first laser 59.5 59 60.25 =0.9 
Duration of DM in years 
Mean 
(range) 
Median 
 
 
14 
(2–50) 
12 
 
13 
(1–40) 
12 
 
14 
(1–34) 
13 
 
Time gap between macular 
laser and PRP in months 
 
35 30 26 =0.9 
No: macular lasers 2.5 3 2.4 =0.7 
No: PRP lasers 2.8 2 1.5 =0.7 
No: clinic appointments 20 18 19 =0.4 
No: failed clinic appointments 
Mean 
(Range) 
 
3.2 
(0–12) 
 
3.5 
(0–8) 
 
3.7 
(0–6) 
 
=0.7 
Change in VA  
(ETDRS letters) 
-4.7 -5.7 -4.8 =0.9 
Other ocular problems 2 glaucoma 8 glaucoma 1 CRVO  
Mean number of anti HTN 
drugs 
2.3 1.9 1.8 =0.2 
Anti DM drugs 
Oral + Insulin 
Insulin 
Oral only 
 
20 
11 
6 
 
26 
9 
9 
 
8 
5 
3 
 
Baseline HbA1C 8.87 9.5 8.6 =0.15 
Baseline Sys BP 140 148 138 =0.16 
Baseline Dias BP 80 83 72 =0.003 
Baseline BMI 29.7 29.7 27.3 =0.2 
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Table 2.6 a: Univariate analysis of the prognostic systemic and ocular factors for gain 
in vision after macular laser treatment for DMO 
 
SYSTEMIC FACTORS Gainers 
(n = 16) 
Losers 
(n = 37) 
Odds ratio 
(95% CI) 
P  
( Fisher’sexact ) 
Age at baseline (years) 
<60 
≥60 
 
8 
8 
 
13 
24 
 
1.8 
(0.5-6) 
 
0.4 
 
Ethnic groups 
Caucasians  
Non-Caucasians 
 
4 
12 
 
10 
27 
 
0.9 
(0.2-3.4) 
 
1 
 
Gender 
Male 
Female 
 
12 
4 
 
19 
18 
 
2.8 
(0.7-10.4) 
 
0.1 
Duration of diabetes 
(years) 
< 15 
≥ 15 
 
 
10 
6 
 
 
26 
11 
 
0.7 
(0.2-2.4 
 
0.7 
 
Diabetic medications 
Oral 
Insulin/ oral +insulin 
 
6 
10 
 
3 
34 
 
6.8 
(1.4-32.2) 
 
0.01 
 
Baseline HbA1C 
< 7.5 
≥ 7.5 
 
5 
11 
 
8 
29 
 
1.64 
(0.4-6.1) 
 
0.5 
 
Baseline systolic BP 
< 140 
≥ 140 
 
 
4 
12 
 
16 
21 
 
0.4 
(0.1-1.6) 
 
0.2 
 
Baseline diastolic BP 
< 100 
≥ 100 
 
 
13 
3 
 
 
34 
3 
 
0.4 
(0.06-2.1) 
 
0.3 
No: anti-hypertensives at 
end of follow-up 
0–2 
≥ 3 
 
 
 
4 
12 
 
 
23 
14 
 
 
4.9 
(1.3-18.3) 
 
 
0.01 
Baseline BMI 
< 30 
≥ 30 
 
7 
9 
 
29 
8 
 
0.2 
(0.06-0.7) 
 
0.02 
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Table 2.6 b: Univariate analysis of the prognostic systemic and ocular factors for gain 
in vision after macular laser treatment for DMO. 
OCULAR FACTORS 
 
Gainers 
(n = 16) 
Losers 
(n = 37) 
Odds ratio 
(95% CI) 
P value 
Baseline VA (ETDRS 
letters) 
< 60 
≥ 60 
 
 
10 
6 
 
 
8 
29 
 
 
6.04 
(1.6-21) 
 
 
0.01 
 
Lens status:  
Phakic 
Prior pseudophakia 
Pseudophakia during 
study  
 
44 
3 
2 
 
48 
5 
5 
  
0.2 
DR status at baseline 
Non-PDR 
PDR 
 
15 
1 
 
32 
5 
 
0.4 
(0.04-3.9) 
 
0.6 
Number of macular laser 
treatments 
1–3 
> 3 
 
 
7 
9 
 
 
16 
21 
 
 
1.02 
(0.3-3.3) 
 
 
1 
Number of clinic 
appointments 
mean   
range 
 
 
19.23 
4–34 
 
19.6 
3–39 
  
 
1 
Number of failed clinic 
appointments  
Mean  
Range 
 
3.02 
0–7 
 
 3.75 
0–12 
  
0.009 
Gainers: gain of 10 or more ETDRS letters; Losers: loss of 10 or more ETDRS letters. 
Abbreviations: PRP: pan-retinal photocoagulation; ETDRS: early treatment diabetic 
retinopathy study; HT: hypertension; DM: diabetes mellitus; BMI: body mass index 
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Table 2.7: Multiple regression model for visual outcome at 5 years 
INDEPENDENT 
VARIABLES 
 
Coefficient Std. Error r t P 
(Constant) -7.2531     
Dias_BP_baseline 0.7058 0.2614 0.3664 2.700 0.0096 
Diff_in_dias_BP 0.8148 0.3085 0.3595 2.641 0.0112 
Diff_in_HbA1c 2.3180 1.1078 0.2919 2.092 0.0418 
Diff_in_syst_BP -0.1791 0.1065 -0.2381 -1.681 0.0994 
VA_at_baseline__
pre_laser_ 
-0.8700 0.1714 -0.5951 -5.076 <0.0001 
  BMI: body mass index; VA: visual acuity; CI: confidence interval.
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2.1.5 Discussion  
The aim was to test the hypothesis that VA may continue to improve in eyes with laser-
treated maculopathy (H1). I investigated the long-term (5-year) outcome of laser 
photocoagulation in a real-life, inner-city population. I was successful in recruiting 100 
subjects who were followed-up for 5years after their initial laser treatment for diabetic 
maculopathy. The mean annual visual outcomes and systemic parameters were collected 
retrospectively and compared to outcomes of the laser arm of the DRCRN trial in this 
section. The mean change in VA at 5 years was found to be -5.23, with the 3-year 
outcome being inferior to the clinical trial results, with more people gaining vision (≥15 
letter gain) in the DRCRN group compared to this cohort (26% versus 9%)(section 2.1). 
Furthermore, 3 times more patients lost vision (>15 letter loss) in the real-life setting of 
this cohort compared to the clinical trial results of the DRCRN group (27% versus 8%, 
respectively). These results suggest that laser treatment is only effective at halting—and 
not reversing—retinal deterioration. It can be argued that these patients are not trial 
patients and so not standardized with regard to age; race; sex; diabetic control; other 
associated systemic conditions, but the outcome suggests a real life scenario, where 
there is no standardization of the patients. The study has adequate power (sample size 
calculated for 95% confidence), regular follow-up for 5years, availability of visual 
acuities for all the visits, and other systemic functions including blood pressure, blood 
glucose levels for each visit. Visual acuities were tested by Snellen charts according to 
clinic protocols and were later converted to logmar for data processing. Errors may 
therefore have occurred whilst assessing vision, and to help compensate for these 
variations, we considered annual mean visual acuities. 
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This long-term laser outcome study (chapter 2) assessed a number of factors that may 
determine the poorer outcome. The VA examiners were not certified, and VA 
measurements were recorded in busy clinic settings, patients weren‘t tested with their 
updated refraction. Also under these circumstances, it is possible that the examiner did 
not spend enough time encouraging the patient to read as far as possible. As a result, the 
best-corrected VA (BCVA) may have been underestimated at times. Further overall 
discussion and the attributes and deficits of the study are carried out in chapters 4 & 5. 
 
2.2 Prevention of dark adaptation causes regression of diabetic 
macular oedema 
 
2.2.1 Introduction:  
The understanding of pathophysiology of DMO is still ill understood. Though it is 
generally considered that damage caused by reactive oxygen species is central (Kowluru 
RA, 2007; Brownlee M, 2005), recent reports that intravitreal injection of anti-VEGF 
drugs improves diabetic maculopathy (Elman MJ, 2012; Massin P, 2010; Boscia F, 
2010; Nguyen QD, 2009, 2010; Shetty R, 2008; Kumar A, 2007; Solaiman KA, 2010; 
Funk M, 2010; Goyal S, 2010; Michaelides M, 2010) suggest alternative mechanisms 
for formation of DMO. A finding which supports this hypothesis is that retinal 
endothelial cells in culture do not show signs of oxidative stress when exposed to high 
concentrations of glucose (Busik JV, 2008). In addition, there are other findings that are 
difficult to reconcile with the idea that oxidative stress is the primary cause of DMO 
(Brownlee M, 2005; Arden GB, 2011).  
Another school of thought is that the large demand of dark adapted rods for oxygen is 
important in pathogenesis of DMO, and a proposed mechanism is that up-regulation of 
VEGF, which is induced by retinal hypoxia (Aiello LP, 1995; Miller JW, 2012) can 
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directly and adversely damage small vessels, which would reduce local capillary blood 
flow and increase hypoxia in a positive feedback cycle (Arden GB, 1998, 1999, 2001, 
2004, 2005). There are indirect evidences that support this view (Nguyen QD, 2004; 
Kern TS, 1996; Shiba T, 2009; West SD, 2010). Nguyen QD et al confirmed that 
breathing 100% oxygen reverses contrast sensitivity and vascular perfusion changes in 
patients with minimal maculopathy suggesting hypoxia may also contribute to 
functional changes in pre-retinopathy stage of the disease (Nguyen QD, 2004). Because 
the oxygen demand of rods is very much increased in darkness (Hagins WA, 1989; 
Hamer RD, 2005; Braun RD, 1995; Linsenmeier RA, 1998; Birol G, 2007), it was 
hypothesised that prevention of dark adaptation should reduce the rate of progression of 
DMO. Most of the dark adaptation occurs during sleep. Therefore, by sleeping under 
conditions in which there is sufficient light to maintain the rods in a semi–light adapted 
state, decreasing the oxygen consumption might reduce DMO. A phase I clinical trial 
involving 12 patients with mild background DR showed that trans–lid illumination of 
the retina during sleep was acceptable by patients, who reported no ill effects and 
showed improved retinal appearance and function (Arden GB, 2010; Jyothi S, 2010; 
Arden GB, 2010). In light of this finding, a further investigation (Phase II trial) was 
conducted to provide ―proof of principle‖ for this concept. This trial was conducted in 
accordance with the Declaration
 
of Helsinki and guidelines on good clinical practice. 
Approval was obtained from King‘s College Hospital Ethics Committee 
(ISRCTN34037927; R&D 08/H0808/198)(approval letter in appendix Chapter 7). 
Written informed consent was obtained from all participants.
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2.2.2 Methods : 
2.2.2.1 Participants: 
Patients for this study were recruited from diabetic clinics at ―Laser and Retinal 
Research Unit of King‘s College Hospital, London‖ that assessed the effect of light 
therapy for diabetic maculopathy. Patients were all referred to the Medical Retina 
Department of KCH by the DR screening service, as a result of grading of standard 2-
field fundus photographs (Harding S, 2003). Diabetic maculopathy on 2-field colour 
photography was defined as the presence of exudate within 1 DD of the centre of the 
fovea, circinate, or group of exudates within the macula, retinal thickening within 1 DD 
of the centre of the fovea (if stereo available), or any microaneurysm or haemorrhage 
within 1 DD of the centre of the fovea only if associated with a best VA of ≤ 6/12. Eyes 
with clinically significant DMO that were eligible for laser treatment were excluded. 
Those with clinical evidence of focal macular thickening and those with small ―dark 
retinal anomalies‖ very near the fovea in at least one eye were recruited. This group, 
defined as non-significant macular oedema (M1), consisted of persons who were much 
less severely affected than those recruits for recent trials of anti-VEGF agents for DMO 
(Massin P, 2010; Boscia F, 2010; Nguyen QD, 2009, 2010; DRCRN, 2010; Shetty R, 
2008; Kumar A, 2007; Solaiman KA, 2010; Funk M, 2010; Goyal S, 2010; Michaelides 
M, 2010). Patients in the M1 group are those who are not usually treated immediately, 
but who are watched until the condition progresses, when laser treatment is offered.    
All study participants provided informed consent for the clinical trial. Patients 
underwent a full ophthalmic examination, including objective and subjective refraction, 
contrast and colour contrast sensitivity, microperimetry, and slit-lamp biomicroscopy 
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and OCT at baseline, 3, and 6 months. Glycosylated haemoglobin was also estimated at 
baseline visit and at 6 months reviews at the hospital laboratory.  
The study was designed to test the primary hypothesis that
 
the light-masks would delay 
or reverse the progression of DMO. Participants met all of the following
 
entry criteria in 
at least 1 eye: (1) exudates or thickening within 2 optic DD of the centre of the macula 
(1 optic DD is
 
defined as 1500 µm) graded on 2-field photography, one centred on the 
optic disc and the other on the macula; (2) no history of scatter (pan-retinal) or 
focal/grid photocoagulation
 
for DR; and (3) no evidence of any other ocular pathology 
that could interfere with ocular examination and VA assessment during the 6-month 
study period.  
Participants
 
were excluded if they had: (1) clinically significant DMO, that was 
amenable to laser photocoagulation at baseline according to ETDRS guidelines; (2) 
highly asymmetric grades of DR between eyes; (3) VA reduction that could not be 
attributable to DR; (4) any other concomitant ocular or systemic condition that could 
influence the natural course of DR.   
The eye of each participant that met all of the inclusion criteria was designated as the 
―study eye,‖ and a light-mask was applied during the sleeping hours for the period of 
the study.   
 
2.2.2.2 Construction and design of light-masks: 
Light was provided by four light-emitting diodes (Nichea NESE021T rank E) of 1 × 1 
mm in diameter, surface-mounted 5-mm apart in a square array on a thin, flexible, 
printed circuit board.  Diodes were encapsulated in a plastic cup of transparent silicone 
rubber, of a quality certified as medically inert. The concave surface of the cup fitted on 
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the closed lid, thus centring the light in the optic axis. The diodes were fitted to either 
the left or right eye, not both. The flexible circuit board was joined to a rigid board that 
contained the driving electronics.  
The peak light output was at 505 nm, which was chosen to maximise the preferential 
light absorption by rods, rather than cones. In preliminary results (not reported) that 
were similar to those described before (Arden GB, 1999), we determined that the light 
used increased the rod threshold by 3-4 log units before the increment threshold for 
cones increased. (Arden GB, 2010) 
The device was driven by a 3v (nominal) rechargeable battery (Panasonic UL23300), of 
50 mA h capacity. It was connected to a charge pump chip (Maxim 1573) that stabilised 
the battery voltage and also provided four independent drivers for the LEDs. A 
multivibrator circuit produced a train of short light-pulses, the mark-space ratio of 
which could be altered to regulate the light output. Each LED drew approximately 200 
µA current. The light output remained nearly constant for >50 h without recharging the 
battery. Patients were instructed to recharge the battery each morning, by placing the 
unit on a box that contained the primary of an induction charger. The secondary was on 
the light-mask printed circuit board, which also contained a rectifying circuit. A relay 
on the circuit board was activated when the mask was placed on the box, and when the 
mask was positioned correctly; the light from the diodes gets turned off. Masks were 
covered in a plasticized thick cotton cover (the plastic was inert) such that no electrical 
part was exposed (Figure 2.3). This cover was held against the eyes by an elastic 
headband. The light output intensity of 505 nm light required causing rod semi 
saturation was established in the Phase I trial (Arden GB, 2010). 
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Figure 2.3: light mask with LED lights 
The design had 2 faults that could influence the results. One was that, in use, the 
electronics failed in around half the units; therefore, many patients had interruptions of 
a few days in their treatment (maximum 7 d; range 3-7 d). The second was that the 
plastic cup could slip from the central position whilst asleep; in such a case, retinal 
illumination was reduced to an unknown extent.  
 
2.2.2.3 Study design: 
The study was at a single centre and was single-masked (optometrists and 
photographers were masked of the study eye). The chosen eye to be illuminated was 
always the worst. In many cases, the fellow eye showed minimal changes of DMO, as 
reported below. Eligible patients were provided with the information leaflet and allowed 
to use the eye mask in one eye for a week before consenting to the trial. They were 
screened if they agreed to continue. Following this baseline first visit, patients returned 
after 3 and 6 months. Reasons for dropout were noted. Patients were contacted between 
visits to ensure compliance and encouraged to return to the trial centre if they had any 
trouble with the masks (electrical failures occurred in 30% of masks). Patients were 
questioned about any sleep disturbance, but formal questionnaires were not used. An 
ophthalmologic examination was performed at baseline, 3, and 6 months. All tests were 
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carried out according to standardized protocols by optometrists and photographers who 
were accredited for clinical trials. None of the patients had any previous experience of 
performing the tests.  
2.2.2.4 Refraction: 
Overcorrection or undercorrection of refraction can lead to assessment errors; therefore, 
assessment distances for various charts were followed strictly according to the 
manufacturers‘ protocols, and corrections were made to the prescription accordingly to 
maintain repeatability of vision (Blackhurst, 1989). A certified optician performed non-
cycloplegic subjective refraction if updated prescription was not available. ETDRS 
chart R was used for refraction. If the subjective refraction agreed with the prescription 
of the patient, then they were allowed to wear their prescription glasses. During the 
tests, which were done from nearer distances, the prescription of the patient was 
appropriately corrected for distance (i.e., +0.75 was added for tests done from a 1-m 
distance). This situation best reflects the true clinical trial setting, in which many 
measurements are taken by several observers according to set protocols, but often 
without formal assessment of intersession repeatability. 
 
2.2.2.5 Vision: 
The VA was measured with ETDRS charts at 4-m distance as described in the earlier 
sections (1.5.3.1). This procedure was repeated at the 3- and 6-month follow-ups visits 
by a certified research optician. 
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2.2.2.6 Optical coherence tomography: 
Scanning with the Cirrus HD-OCT (Cirrus, Carl Zeiss Meditec AG, Jena, Germany) 
was performed with the 512 × 128 scan pattern, in which a 6 mm × 6 mm macular grid 
was scanned with 128 horizontal B-scan lines, each consisting of 512 A-scans per line 
(total of 65,536 sampled points) as described in chapter 1 (section 1.5.2.2). The central 
subfield thickness was used for comparison. Figure 2.4 shows the OCT scan of foveal 
region. 
 
Figure 2.4 Morphological appearance of parafoveal intraretinal cyst on OCT (top 
image) compared to a normal OCT (bottom image). 
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2.2.2.7 Chroma test: 
The test was exclusively carried out by the author (SJ) to a standardised protocol as 
described in section 1.5.3.2 of chapter 1. The diabetic module of the Chroma test was 
used for assessment. The protan and tritan retinal sensitivity thresholds were noted 
(Wong, 2008.). The test was exclusively carried out by the author (SJ) to a standardised 
protocol. With undilated eyes, colour contrast sensitivity was tested in each eye 
monocularly by using the diabetic module of the Chroma test software program. With 
appropriate refractive correction, the subject was seated at a fixed distance of 1 m from 
the monitor, so that the alphabetical letter displayed on the computer screen subtends a 
constant angle on the retina. The letter size creates an image that tests the central 6.5° of 
the retina. Letters were displayed on a background of equiluminance. Luminance of the 
screen was calibrated before the start of each session. The computer finds the endpoint 
of the test by a Modified Binary Search method. The protan and tritan retinal sensitivity 
thresholds were noted (Wong, 2008.). 
 
2.2.2.8 Contrast sensitivity (CS):  
After corrective refraction (with +0.75 addition), monocular CS was assessed by a 
standardized protocol with the Pelli-Robson chart (Clement Clarke Inc., Columbus, 
OH). Different charts were used for the left and right eyes, at a distance of 1 m and 
chart luminance of 80–120 cd/m2.  
 
2.2.2.9 Nidek microperimetry 1:  
Microperimetry was performed with the Nidek MP1 microperimeter (MP1 Nidek 
Technologies, Japan).  
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2.2.2.10 Fundus photograph:  
Fundus stereographic pictures were taken with the Topcon TRC 50IX mydriatic fundus 
camera. Images were captured on the posterior pole at 50° and on the fovea at 20°. Two 
observers graded the OCT and fundus photographic images. Kappa statistics of 
interobserver agreement showed good agreement (K=0.8). 
 
2.2.2.11 Decision to treat: 
Decisions regarding application of macular laser photocoagulation resided with the 
principal investigator, but laser was applied only if the retinal thickening progressed to 
within 500 µm of the centre of the macula, with no angiographic evidence of macular 
ischaemia. Pan-retinal photocoagulation for DR was initiated at the investigator's 
discretion, but it was expected that it would not be applied before development of 
retinal or optic disc neovascularisation (proliferative DR defined as ETDRS level ≥ 65).  
 
2.2.2.12 Safety assessments: 
Appropriate channels were ensured in place to report any adverse events. 
 
2.2.3 Statistical analyses  
We performed statistical analyses using 2-tailed paired t-test
 
to explore changes in CST, 
AMT, total macular volume, VA, contrast sensitivity, tritan and protan threshold, and 
mean retinal sensitivity at 3 and 6 months after starting treatment. The change in 
individual eyes varied considerably and was not normally distributed (SD > mean). 
Therefore, eyes were classified as ―improved‖, ―unchanged‖, or ―deteriorated‖. The 
binomial probabilities of the numbers changed were calculated (Table 2.8) by assuming 
that the probability of improvement or deterioration was equal to 0.5. This assumption 
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is very conservative, because most patients would continue to deteriorate if untreated. 
An estimate of the true probabilities and the consequence is given in the text. The Fisher 
exact
 
test was used to compare categorical outcomes where appropriate. All analyses 
were carried out after the end of the trial. The null hypothesis
 
was rejected for P < 0.05.
  
 
2.2.4 Results: 
The trial enrolled 40 patients, 5 were with Type I DM (12%) and the remainder with 
Type II DM. Ages ranged 33–75 years (mean: 56 years). Glycated haemoglobin 
(HbA1C) levels ranged 6.0-11.6% (mean: 8.21% at baseline). The mean change in 
HbA1C at 6 months was -0.17 ± 0.88.  
 
2.2.4.1 Dropouts:  
Out of the 40 individuals recruited for the study, light-masks were not given to 5 
individuals at baseline, due to defective masks. Three patients failed to complete the 
study; one due to ill health, one withdrew after 3 months due to inability to keep 
hospital appointments, and one failed to use the light-mask. A total of 65 eyes were 
included for baseline studies and analyses of changes at 3 and 6 months (65 eyes studied 
out of 70 eyes; 5 non trial eyes were excluded because of planned interventions or 
already had intervention). Inter eye comparisons were not done in patients who received 
laser/intravitreal bevacizumab for progression of DMO in the fellow eyes during the 
study. None of the illuminated eyes required such treatment during the trial. Of the 35 
trial eyes followed-up for 6 months, only 27 eyes had microperimetry results at 3 
months (7 eyes couldn‘t be completed). At the end of 6 months visits 34 trial eyes had 
microperimetry available for assessing progression (MP1 on one eye couldn‘t be 
completed). Data for only twenty eyes were available in non-trial eyes at 3
rd
 and 6
th
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month follow-up for microperimetry for inter eye comparison as others found this test 
too difficult and did not want to repeat the test in non trial eyes after their baseline 
visits.  
 
2.2.4.2 Adverse effects: 
None of the recruited subjects reported mood alteration or any difficulty in wearing the 
masks or sleeping. 
 
2.2.4.3 Morphological changes on OCT: 
Figure 2.5 shows nonparametric assessment by OCT images representative of the 
findings in the treated eyes. Areas of thickened retina decreased during the period of the 
trial and the average macular thickness returned toward normal. In the cross-sectional 
image, diminution of cysts can be seen. The OCT images were classified into three 
groups: those in which the DMO regressed, those in which it advanced, and those in 
which no definite change could be observed. The number of cases in each group is 
shown in Table 2.8. Trial and fellow eyes differed considerably in the proportion with 
cysts at baseline recruitment. In addition, the degree of swelling was greater in almost 
all trial eyes than in the corresponding fellow eye (p = 0.0015). In trial eyes, 27 out of 
35 had baseline cysts, whereas in fellow eyes only 8 had baseline cysts out of 30 eyes.  
A number of trial eyes were judged to have improved during the trial. Diabetic eye 
disease is usually progressive; if it were stationary, then the probability that 
improvement would be (erroneously) detected would be equal to the probability that the 
eye would be considered to have deteriorated. In such a case, the binomial probability 
of obtaining the result is small, as indicated in Table 2.8, both for changes in cyst size 
  103 
(1) and overall area of abnormal swelling (2). If the cases scored as ―no change‖ are 
assigned equally to the 2 groups, then the probabilities remain low.  
 
Table 2.8: Changes in OCT appearances from beginning to end of the trial. 
Improvement and worsening is determined based on consensual agreement between two 
independent observers. In case of disagreement, an arbitration was taken from a third 
independent observer. 
 
 
 
 
 
 
 
 
 Trial eyes with cysts Fellow eyes with cysts 
TOTAL 27
 
 8 
Improved 19
 
1 
Worsened 4 3 
No change 4 4 
 Overall grading Overall grading 
Improved 19
 
 3 
Worsened 7
 
 3 
No change 9 24 
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Figure 2.5: OCT changes over 6 months. a) cross section raster images through the 
fovea depicting pre and post treatment cyst changes. b) Computed 3-D OCT false 
colour images in representative patients, showing changes in retinal thickness. Blue and 
dark green colours are within normal limits, and green, yellow, red, pink, and white 
represent regions of increased thickness, which varies between patients. Swelling 
diminishes during the trial. Quantitation of such results was achieved by using the 
separation of different zones, included in the OCT report, which are indicated for 
one eye, in the figure. These are based on the ETDRS zones, and results are given in 
the Table 2.9. Zone 1 is the subfoveal zone for the left-handed patient, the zone 
measured was zone 2, and measurements are also presented from zone 4, opposite 
it, which is called the ‘mirror zone’. For the right-most pair of images, 
measurements would be taken from zone 5 and its mirror zone, ETDRS zone 3. 
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2.2.4.4 Quantitative comparisons: 
The area of retinal swelling associated with early DMO was, in our patients, highly 
localised (Figure 2.5). Therefore, the average change in retinal thickness or volume in 
the entire area under investigation, which is a criterion used in other trials with more 
advanced disease (Massin P, 2010; Boscia F, 2010; Michaelides M, 2010), was 
inappropriate.  
We recorded retinal thickness in the central subfield (1) and in the zone where thickness 
was greatest. This location was always in the intermediate zones, 2, 3, 4, or 5, and 
varied from patient to patient. A third measurement was made in the zone at 180° from 
the most thickened zone, where the swelling was usually much less or even absent 
(Figure 2.6). Table 2.9 shows the means and variation in thickness of the patients‘ 
retinas at the initial measurement. These values were compared with the similar values 
after 6 months.  
 
Table 2.9: Changes in OCT average macular thickness measurements (ILM-RPE)  
ILM: Internal limiting membrane; RPE: retinal pigment epithelium 
 Trial eyes with cysts Fellow eyes with cysts 
TOTAL 
() 
Zone 1 Worst 
zone 
Zone 
opposite to 
worst zone 
Zone 1 Worst 
zone 
Zone 
opposite to 
worst zone 
Initial 2739.3 3384.6 3153.5 25711.4 3346.9 3095.6 
6m 2689.3 3284.9 3153.2 2527.2 3245.3 3055.5 
P value 0.2 0.007 0.8 0.7 0.09 0.4 
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All 3 zones included in Table 2.9 were slightly thickened, both in comparison to 
machine normal values and in comparison to fellow eyes. The central subfield 
thickening was slightly and insignificantly reduced during the course of the trial. In the 
most thickened zone (2, 3, 4, or 5), the mean retinal thickness significantly decreased by 
10 mm during the course of the trial. For the opposite zones, the ILM to RPE depth did 
not change during the trial. There were no significant changes in the untreated eyes.  
The zone of maximum swelling (2, 3, 4, or 5) decreased by an average value of 12 mm 
over 6 months.  The zone at 180° relative to the swollen zone showed no change. The 
reduction in swelling was significantly different from zero. In almost all patients, 
intermediary OCT examinations were made, and differences between 1 and 3 months 
and between 3 and 6 months were calculated; these values were significant only for the 
zone of maximum swelling. When results from untreated eyes were examined, changes 
in thickness were all insignificant. Therefore, instrumental errors cannot account for 
shrinkage in trial eyes.  
The shrinkage differed remarkably in different patients; the distribution is shown in 
Figure 2.5 for the zone of maximum swelling. Similar results were calculated for the 
other zones of the treated eyes and were not significant. In the few cases in which the 
untreated eyes changed during the trial, the number in which the oedema grew worse 
was larger than the number of improvements (Table 2.8). Fundus photographs were 
graded with standard photographs according to the National Screening Grading system.  
No significant change in severity of retinopathy occurred during the course of the trial.    
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2.2.4.5 Psychophysical testing: 
The summary of the results for colour vision, VA, and achromatic contrast sensitivity 
testing were given in Table 2.10. In the trial eyes, changes in protan sensitivity were not 
significant, but the tritan threshold decrease and the increase in the number of ETDRS 
letter and Pelli-Robson letters were significant. The average final VA > 80 letters read 
corresponds to a value that is slightly better than 20/20 or decimal 1.0.  During the same 
period of time, the VA of the control eyes fell slightly but significantly. In the second 
half of the trial, the only significant fall in treated eyes was in the tritan threshold.  
Table 2.11 summarise the results from microperimetry. Sensitivity of the central area 
and peripheral zones of the treated eyes increased, and the number of patients showing 
improvements increased during the second half of the trial. Changes obtained from 
untreated eyes were smaller and inconsistent. There was no significant difference 
between the initial microperimetry results of the 2 groups. 
 
Table 2.10: Summary of psychophysical tests 
 Trial eyes  Fellow eyes 
Test Protan Tritan ETDRS Contrast Protan Tritan ETDRS Contrast 
Initial 
(mean) 
7.5 28.2 78.3 31.2 8.8 29.4 76.4 31.7 
6m 
(mean) 
6.5 22.4 80.7 33.3 7.7 26 74.1 30.8 
No: 
improved 
20 22 16 16 11 17 10 14 
No: 
deterioratd 
9 8 7 6 17 10 18 15 
P binomial 0.01 0.005 0.02 0.01 0.08 0.06 0.04 0.14 
P value 0.10 0.17 0.11 0.09 0.05 0.21 0.23 0.34 
T-test between trial and control eyes (P value) 0.95 0.75 0.05 0.01 
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Table 2.11: Microperimetry: dB attenuation for threshold 
 
 
 
 
 
 
 
 
 
 
2.2.4.6 Summary of results: 
In the eye exposed to light during sleep, reversal of early morphological changes 
occurred: cysts and generalised oedema were markedly reduced and, in local areas of 
maximum swelling, the decrease was significant. In untreated eyes, no such changes 
occurred.  
This relatively small study has provided evidence that in patients with very early DMO, 
significant local morphological and functional improvements occur in the eye exposed 
to light during sleep. In untreated eyes, any morphological change is a deterioration. 
The natural progression of the diabetic maculopathy is generally to deteriorate, but in 
treated eyes the cystic changes disappeared whilst no new lesions developed in contrast 
to non treated eyes. Standard statistical methods thus show that the changes associated 
with treatment are unlikely to be due to chance. The visual acuity improvement was not 
statistically significant when treated eyes were compared to non treated eyes because of 
―ceiling effect‖, since most of the recruited eyes have only early maculopathy and as it 
 Central zone (zone 1) Mean of zones 2-9 
 Initially  3 months 
later 
Initially  3 months 
later 
Number 35 27 35 27 
Mean  SE 13.2  0.6 15.5  0.5 13.3  0.5 15.7  0.5 
Number improved  14  16 
Number worsened  5  4 
Binomial probability  0.0187  0.0001 
Paired t-test  0.0030  0.0008 
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is, the visual acuities were near normal. The study is limited by lack of double masking 
and randomization, not a robust design of the mask, which can ensure proper placement 
of the light source in papillary axis.  
Even if all the electricity produced by the source were converted into photon energy, the 
resultant retinal illumination would be 1 mW/cm
2. Such minimal intensities wouldn‘t 
cause any retinal damage nor cause any disturbances of diurnal rhythm. The retinal 
illumination (480 nm) required to cause a 50% reduction in the night-time increase of 
melatonin is 25 mW/cm
2 
(Young RW, 1971). Further large-scale fully randomised and 
controlled clinical trials are required to establish the efficacy of this method of 
treatment, the quantity of light required, the long-term effects. 
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3: DIAGNOSING EARLY DIABETIC MACULOPATHY 
 
3.1 Short-term changes in visual function and macular thickness in 
patients with no or minimal diabetic retinopathy 
3.1.1 Introduction: 
Diabetic retinopathy is defined and graded by the presence of clinically visible retinal 
vascular changes. However, there is sufficient evidence that neurodegenerative changes 
precede or accompany these vascular changes in histological examinations of the retina 
(Barber AJ, 1998). Furthermore, changes in visual function occur before the onset of 
any clinically visible vascular changes in the macula (Westall CA, 2005; Lopes de Faria 
JM, 2001; Brinchmann-Hansen O, 1993; Lieth E, 2000). The relationship between the 
neuronal and vascular changes is complex (Chen FK, 2011; Kube T, 2005; Okada K, 
2006; Rohrschneider K, 2008; Vujosevic S, 2006; Trick GL, 1988; Alkuraya H, 1989; 
Brinchmann Hansen O, 1993) and a varying correlation was found between structural 
and functional assessments (Chen, 2011; Kube, 2005; Okada, 2006; Rohrschneider, 
2008; Vujosevic, 2006; Trick, 1988; Alkuraya, 1989; Brinchmann Hansen, 1993). The 
relative rate of progression of the neuronal and vascular components also remains 
unclear. The processes involved with cell-death can have a slow and insidious course 
and so short-term studies on visual function changes are unlikely to reflect the rate of 
neuronal cell death. However, several investigators have demonstrated short-term or 
acute changes in retinal neuronal function in diabetes. Shirao and Kawasaki showed that 
oscillatory potentials that originate in the amacrine cells are prolonged in the pre-
retinopathy stage and this response correlates to the acute deterioration of non-photic 
electro-oculogram to intravenous 7% sodium bicarbonate in these patients (Shirao Y, 
1998). These electro-oculogram changes suggest retinal pigment epitheliopathy in the 
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pre-retinopathy patient. Similarly, breathing 100% oxygen reverses contrast sensitivity 
and vascular perfusion changes in patients with minimal retinopathy suggesting hypoxia 
may also contribute to functional changes in pre-retinopathy stage of the disease 
(Nguyen QD, 2004; Dean FM, 1997). Other changes including loss of synaptic proteins, 
changes in intracellular signalling and extracellular glutamate activity that signify 
retinal neuronal dysfunction have also been reported in diabetic animals (Lorenzi M, 
2001). So, in order to assist with clinical decision-making process, it is important to 
differentiate between a change criterion induced by real short-term biological changes 
due to diabetes and within-subject variability (measurement error).  (Hypothesis H3) 
The purpose of this part of the study was to determine whether patients with no or very 
minimal retinopathy demonstrate changes in visual function over 6 months despite no 
detectable changes in retinal vasculature or blood sugar levels. We then compared the 
changes to published data on the repeatability of each visual function to establish 
whether the change criterion detected could be considered as genuine beyond 
measurement errors.  
3.1.2. Materials and methods: 
The data of contralateral eyes of subjects recruited to a clinical trial 
(ISRCTN34037927) was analysed retrospectively. The clinical trial assessed the effect 
of a specially designed light mask for the treatment of early maculopthy in one eye for 6 
months. The patients were reviewed at 3 and 6 months. All the contralateral eyes with 
no or early diabetic retinopathy, with no maculopathy defined as central subfield 
thickness (CST) <308 µm on Cirrus OCT at all 3 visits were included. This ensured that 
all anatomical changes in the central subfield were within the normative range of central 
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subfield thickness on Cirrus OCT.  Excluded were those with ocular co-morbidity and 
those with central subfield thickness of ≥ 308 µm at any visit or those who had previous 
treatment for diabetic eye disease. The study adhered to tenets of the Declaration of 
Helsinki for research involving human subjects and was approved by Kings College 
Hospital Ethics Committee (R&D 08/H0808/198, appendix 7). Each patient gave 
written consent before enrolment and for undergoing these tests as part of the clinical 
trial.  
All patients underwent visual function assessments including best-corrected visual 
acuity, achromatic and chromatic contrast sensitivity, retinal sensitivity measured by 
microperimetry at baseline, 3 and 6 months. All tests were carried out according to the 
standardized protocols and carried out by optometrists and photographers accredited for 
clinical trials. None of these patients had any previous experience of performing these 
tests. 
 
3.1.2.1 Visual acuity: 
Best-corrected visual acuity measurement was performed with Early Treatment of 
Diabetic Retinopathy Study (ETDRS) charts at 4 m. The ETDRS charts are modified 
versions of the logarithm of the minimum angle of resolution (logMAR) charts designed 
by Bailey and Lovie (Lighthouse International, New York, NY). Previous studies have 
tested the repeatability of scores on these charts.  Reported estimates of the 95% 
coefficient of repeatability of the ETDRS charts ranged from 3.5 to 8 letters in normal 
subjects (Elliott DB, 1988; Raasch TW, 1998) 
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3.1.2.2 Contrast sensitivity: 
Contrast sensitivity was assessed as total letters scored with the Pelli-Robson contrast 
sensitivity chart (Haag-Streit USA, Mason, Ohio, USA). The details of the procedure 
were as discussed in chapter 1 (section 1.5.3.3). Reported estimates of the 95% 
coefficient of repeatability of the Pelli-Robson charts ranged from 3-6 letters in normal 
subjects (Lovie-Kitchin JE, 2000; Elliott DB, 1990; Dougherty BE, 2005; Elliott DB, 
1993). 
 
3.1.2.3 Colour sensitivity:  
The colour vision thresholds were determined by the Chroma test. The colour contrast 
sensitivity was tested in each eye monocularly using the diabetic module of Chroma 
test, software programme analyzing the age-corrected tritan (TCCT) and protan colour 
contrast thresholds (PCCT) (Wong R, 2008). The computer finds the endpoint of the 
test by a Modified Binary Search method. The retinal sensitivity thresholds were noted.  
 
3.1.2.4 Retinal threshold by Microperimetry:  
The Nidek Microperimeter was used to quantify macular sensitivity. We used a fast 
threshold strategy to reduce the test time and influence of fatigability on the results. The 
test–retest variability of mean macular and point-wise retinal sensitivity has been 
investigated before in small samples of normal individuals (Hwang JC, 2005). They 
found that the averaged difference between tests for the 40 locations ranged between 0.1 
and 1.6 dB.  
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3.1.2.5 Optical Coherence Tomogram (OCT): 
Spectral-domain OCT was performed using the Macular Cube 512 x 128 scanning 
protocols (Cirrus, Carl Zeiss Meditec AG, Jena, Germany). The in-built software 
calculates average macular thickness (AMT) of all the 9 ETDRS-like zones, the central 
subfield thickness (CST) and the macular volume. Two observers graded the OCT and 
fundus photographic images for any morphological changes at the macula at all 3 visits. 
Only eyes with no morphological alteration and central subfield thickness of less than 
308 µm in all 3 visits were included in this study. Measurements of central subfield 
thickness are repeatable and reproducible in normal eyes with no macular pathology. 
The inter rater repeatability coefficients obtained measuring the central macular subfield 
was 10.2 µm for Cirrus HD-OCT in normal eyes (Giammaria  D, 2011). 
 
A blood sample was also obtained from each participant at baseline visit and at month 6 
to measure glycosylated haemoglobin (HbA1c) by the hospital clinical laboratory. 
 
3.1.3.Statistical Analysis: 
Med cal version 11.4 was used for the statistical calculations. The standard error of 
measurement (SEM) represents the extent to which a variable can vary in a 
measurement process. The Standard errors of measurement (Domholdt E, 2005) were 
calculated using the following equation: . In this equation, sd 
is the standard deviation of the measure, and r is the reliability coefficient (test-retest 
reliability in the form of intraclass correlation coefficient (ICC) for the subject group).  
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3.1.4 Results: 
Thirty-five eyes of 35 patients met the inclusion-exclusion criteria for this post-hoc 
analysis.  The mean age of the patients was 55.9 yr. The mean change of HbA1c for the 
time of follow-up was negligible (p=0.39). The OCT scans of all the eyes were assessed 
by two independent assessors and agreed in all cases that no clinically visible 
morphological progression was noted in 6 months of follow up and the central subfield 
thickness in all these cases in all visits were less than 308 µm.  Table 3.1 shows the 
mean values of the visual indices at baseline and 6 months.  
 
Table 3.1: Mean values of the visual indices at baseline and 6 months 
 Initial value Final value (6 months) Difference 95% CI p 
 Mean SD SE 
Mean 
Mean SD SE 
Mean 
Mean SD SE 
Mean 
  
BCVA 77.7         9 1.8 75          8.3    1.6 -3.3        10    2.1 -7.6 to 0.9 0.1 
Contrast 
sensitivity 
32.5         5.2 1.05 30.8       4.2 0.8 -1.8        5.0 1.0 -3.8 to 0.2 
 
0.08 
Protan 
threshold 
6.7            4.2 0.8 7             4.7 0.9 0.2   3 0.6 -0.9 to 1.5 0.6 
Tritan 
Threshold 
24.7  23.7 4.7 22.7  22 4.4 -2.1  11.3 2.3 -6.7 to 2.5 0.3 
Mean 
macular 
sensitivity 
14.5  3.5 0.7 15  4.1 0.8 -0.2  2.4 0.5 -1.4 to 1.0 0.7 
Mean 
foveal 
sensitivity  
14.3  4.2 0.8 14.6  4.4 0.9 0.4   4 0.8 -2.4 to 1.6 0.6 
SD: standard deviation, SE: standard error of mean, CI: confidence interval 
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None of the visual function tests showed any significant changes by 6 months. All the 
changes in visual functions were within the known range of measurement error for each 
test.  
 
3.2 Ability of the functional tests to distinguish eyes with and without cysts  
 
3.2.1 Introduction: This pilot study is carried out to elicit the ability of functional tests 
to differentiate the eyes with and without cysts. Recently in a retrospective analysis of 
ETDRS data, Gangnon and group (Gangnon RE, 2008) assessed ocular factors and 
systemic non-ocular factors, their regression to baseline visual acuities and found 
duration of DMO and extent of retinal thickening were correlated to the visual acuities. 
Here in this pilot study we tried to assess functional tests in eyes with and without cysts 
to see if there is any trend and whether these tests could be used as screening tools in 
detecting early progression of DMO. 
 
3.2.2 Material and Methods: 
A total of 65 eyes were eligible for this pilot study, of the total 70 eyes screened with 
diabetic maculopathy for the clinical trial as in chapter 2. All the eyes were grouped into 
2 categories based on their OCT findings at baseline: normal OCT (n = 30 eyes) and 
parafoveal intraretinal cyst (n = 35).  
Structural changes on macular cross-sections are best assessed with OCT. On OCT, 
DMO can also be classified based on the morphological appearance of the fluid 
accumulation into diffuse, cystoid, or subretinal macular detachment or a combination 
of these changes, which may coexist with vitreo-macular interface abnormalities.  
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3.2.2.1 Microperimetry: 
Quantification of retinal sensitivity using microperimetry, a fundus related retinal 
threshold test, allows for exact topographic correlation between fundus details and light 
sensitivity. The MP1 microperimeter provides a predetermined point-by-point 
quantification of the retinal threshold of the macula and allows automatic follow-up 
examination over the same retinal points. Retinal sensitivity is decreased over areas of 
macular thickening, hard exudates, and haemorrhage in DMO. The microperimeter has 
been used to evaluate the functional impact of the various subTypes of DMO on OCT 
and the effects of different treatment modalities for DMO.  
In this section we evaluated the ability of microperimetry and other functional tests to 
distinguish between eyes with no OCT evidence of DMO from those with a central 
inner retinal cyst due to diabetic maculopathy.  
 
3.2.2.2 Chroma test: 
Colour vision deterioration in patients with DMO precedes changes in other clinical 
measures (Hardy, 1992), is correlated with DR stage (Bresnick, 1985), and is increased 
in patients with diabetic maculopathy. By measuring visual function, the chroma test 
could be used to detect and monitor sight-threatening pathology (Wong, 2008) and to 
identify subjects at risk for severe retinal disease (Ong, 2003). It remains unknown 
whether colour vision is a sufficiently sensitive means of assessing early DMO, or 
whether the chroma test is capable of detecting DMO progression.  
 
3.2.3 Statistics: With an expected effect size of 0.2, the sample size required was 
estimated to be around 393 to obtain a power of 0.8, whilst sample of 65 would give 
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power of less than 0.25. So our study is expected to be a pilot study to look for the trend 
of functional test outcome in those eyes where there is a clinically significant amount of 
macular oedema. The median differences were depicted as Box and Whisker plots.  
 
3.2.4 Results: 
Demographic characteristics, mean VA, mean central retinal sensitivity on MP1, and 
OCT parameters at baseline are shown in Table 3.2.  
 
Table 3.2: Baseline characteristics in eyes with and without fluid on OCT 
VA, visual acuity; CST, central subfield thickness 
 
Paired sample t-tests of base line characteristics between eyes with cysts and without, 
using box-whisker plots (Tukey, 1977) are shown in figure 3.1-5. In the Box-and-
whisker plots, the central box represents the values from the lower to upper quartile (25 
to 75 percentile). The middle line represents the median. The horizontal line extends 
 Normal 
morphology 
Intraretinal 
cysts 
p-value 
Age (years), mean ± SD 55.77 ± 10.89 56.02 ± 11.26 0.92 
Gender (male/female) 18/12 25/10 0.61 
VA (mean ± SD) 79.93 ± 8.32 77.23 ± 7.61 0.18 
Central retinal sensitivity (MP1) (db ± SD) 15.27 ± 3.63 13.34 ± 3.5 0.03 
CST (µm ± SD) 238.48 ± 29.08 280.27 ± 52.73 0.0008 
Protan threshold 6.64 ± 4.04  7.38 ± 4.43 0.48 
Tritan threshold 23.27 ± 22.24 29.27 ± 25.63 0.32 
Contrast sensitivity 31.59 ± 5.37 30.85 ± 4.85 0.56 
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from the minimum to the maximum value, excluding outside and far out values, which 
are displayed as separate points. 
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Figure 3.1: Box-Whisker plot for baseline MP1 values. X-axis is retinal sensitivity 
thresholds in decibels (db). NC: no cysts; C: with cysts 
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Figure 3.2: Box-Whisker plot for baseline Visual acuity (VA). X-axis is vision in 
ETDRS letters. NC: no cysts; C: with cysts 
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Figure 3.3: Box-Whisker plot for baseline central sub-foveal thickness values. X-axis is 
retinal thickness in microns. NC: eyes with no cysts; C: eyes with cysts 
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Figure 3.4: Box-Whisker plot for baseline protan threshold values. X-axis is retinal 
sensitivity thresholds in decibels (db). NC: eyes with no cysts; C: eyes with cysts 
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Figure 3.5: Box-Whisker plot for baseline Tritan threshold values. X-axis is retinal 
sensitivity thresholds in decibels (db). NC: eyes with no cysts; C: eyes with cysts 
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3.3 Identifying progression of maculopathy  
3.3.1 Introduction: An interexaminer consensus was reached to establish progression 
of all the eligible eyes of the recruited patients as mentioned in section 3.1.2, based on 
OCT findings. This is a pilot study assessing agreeability between various functional 
tests. Gangnon and group from ETDRS (Gangnon RE, 2008) also found that in 
progressive DMO, final visual acuity depends on duration of DMO, location and 
thickeing of retinal fluid. In this pilot study we assessed whether functional tests could 
detect minute changes in DMO severity levels and agreeability between various tests, so 
that these tests could be used in screening early progressive changes. 
 
3.3.2 Material and Methods: 
All the eligible eyes from the study mentioned in 3.1.2 were examined by two assessors 
and a consensus was reached.  
 
3.3.3 Statistics: With an expected effect size of 0.2, the sample size required was 
estimated to be around 393 to obtain a power of 0.8, whilst a sample of 65 would give 
power of less than 0.25. So our study is expected to be a pilot study to look for the trend 
of functional test outcome in those eyes where there is a progression of diabetic macular 
oedema. 
 
3.3.4 Results: 
Of the 65 eyes assessed for structural and functional changes, interexaminer and 
intraexaminer consensus was as follows: 33 had no structural changes from which to 
establish progress; 19 had improved on the basis of the OCT appearance of cystic 
  123 
changes in the retina; and 13 had deteriorated. Table 3.3 compares the assessment of 
detection of progression by various functional tests at 6 months. There was high 
disagreement among the various structural and functional tests. Only 3 eyes (4.7%) 
showed total agreement with all of the functional parameters, whereas 12 eyes (20%) 
had good agreement with all of the parameters excepting any one functional test.  
Table 3.3: Progression from baseline to 6 months by various functional tests  
NA, not accessible; * Could not complete 
 
Results of the subjective assessment of OCT pictures agreed poorly with the results of 
the other functional tests. This observation has huge implications on the management of 
diabetic maculopathy, as it makes it difficult to determine whether maculopathy should 
be managed solely based on OCT changes, or use functional tests alone. This illustrates 
the importance of assessing progression by a combination of tests. It also highlights the 
need to understand the relationship between various structural and functional 
assessment tools. 
 No change Improvement Deterioration NA 
Objective OCT assessment 33 19 13 - 
Fundus photo assessment 23 18 15 9 
(NA) 
Chroma colour contrast-Protan 42 13 10 - 
Chroma colour contrast-Tritan 30 25 10 - 
Contrast vision test 30 18 17 - 
ETDRS vision test 36 12 17 - 
Mean Microperimetry threshold 40 10 6 9* 
Zone 1 Microperimetry threshold 37 13 6 9* 
OCT thickness in ETDRS zone 1 31 17 17 - 
OCT thickness, initial worst zone 39 21 5 - 
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3.4 Reliability of the outcome measures 
 
The general conclusion from this analysis is that in diabetic patients with normal 
thickness macula (defined as central subfield thickness of less than 308 µm on Cirrus 
OCT), change in any of the psychophysical tests was insignificant over 6 months This 
study shows that there are minimal changes in visual function over 6 months and 
variations are more likely to be due to measurement error. If there is an apparent change 
in test results over a 6 months period, these may be due to real biological changes, 
instrument or examiner related changes and/or patient related changes. Instrument 
related factors might include test stimulus variability: size, duration, luminance, 
background luminance, target size, test strategy, distance of target, intrinsic error in the 
measurement, lack of eye tracking. Patient related factors include understanding, pre-
test training, concentration for lengthier times, fatigue, pupil size, systemic co-
morbidities, extent of local damage, underlying retinal pathology, test point locus, under 
or over correction of the refractive error. In our series of patients all the tests were 
carried out just before midday. Patients were alerted before about the extended duration 
for these tests and to avoid hypoglycaemic episodes during their stay for the tests, but 
still influence of hypoglycaemia on these tests particularly which involve keen 
observance cannot be ruled out.  
Although the majority of our recruited patients are of type II diabetics, a proportion of 
them were on an Insulin regimen. As part of screening, only OCT analysis was done to 
rule out diabetic retinopathy related retinal structural changes, but no fundus fluoroscein 
angiogram (FFA) was carried out to estimate any evidence of ischaemia. This was done 
purposely to simulate real life scenario diabetic clinic patients, whom could be reviewed 
periodically without any interventional diagnostic and therapeutic measures. Also worth 
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noting is that these patients have OCT detectable changes in other eyes, less than 
CSMO, for the duration of follow-up. So underlying early hypoxic or neuronal 
functional changes may already be pre-existent in these patients.  
Given that none of these visual function changes showed significant variations over 6 
months, this suggests that changes in any of these tests can be used as an outcome 
measure of visual function in a clinical trial in very minimal or no retinopathy when no 
clinically visible vascular or macular thickness changes are noted. This study does not 
provide us information on the best outcome measure. However, in the evaluation of 
candidate visual components for multiple sclerosis clinical trials where the focus is on 
neuronal changes, ETDRS scores used to measure visual acuity did not change over 
time (Cutter GR, 1999). On the contrary, contrast sensitivity tested by Pelli-Robson 
charts in the Optic Neuritis Treatment Trial (ONTT) was shown to be a sensitive 
measure of afferent visual function, even among patient with Snellen acuities of 20/20 
or better (Keltner JL, 2010). Importantly, measures of low-contrast vision are predictive 
of ―real-world‖ visual tasks such as reading rate, facial recognition, and driving (Leat 
SJ, 1999).  
When the function tests were applied to baseline eyes with and without cysts there was 
a trend to show deteriorated visual function in eyes with cysts. But when the 
agreeability was tested to all the function tests based on progression determined by OCT 
changes, there was very minimal agreeability. 
Diabetic maculopathy is a progressive condition that resists even aggressive systemic 
treatment. Although early management and treatment of diabetic maculopathy are 
effective, they depend on the early detection of retinal changes. Assessment of 
progression can be made structurally or functionally; however, functional deterioration 
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far precedes any structural anatomic changes (Westall, 2005; Jacqueline Lopes de Faria, 
2001; Brinchmann-Hansen, 1993; Lieth, 2000.). Increased understanding of the 
pathogenesis of diabetic maculopathy has shifted the management paradigm towards 
early detection of changes by functional assessment.  
Assessing the retinal status by VA measurements alone does not provide sufficient 
information to detect early functional changes of the retina. Emerging techniques in 
OCT have permitted better understanding and quantification of the intricate structural 
changes that occur during retinopathy. Functional tests allow us to detect damage at 
earlier stages of the disease process. However, studies have shown varying correlation 
between structural and functional assessments (Chen, 2011; Kube, 2005; Okada, 2006; 
Rohrschneider, 2008; Vujosevic, 2006; Trick, 1988; Alkuraya, 1989; Brinchmann 
Hansen, 1993).  
Changes at the macula are responsible for the most common cause of visual impairment 
in people with diabetes. Visual acuity is the gold standard of assessment of visual 
function in clinical practice. Visual acuity estimates neuronal function at the fovea, but 
do not entirely reflect functional vision. Psychophysical tests assess the functional 
integrity of the entire visual pathway. In diabetic patients impaired night vision and 
difficulty in detecting the colour contrast and contours are more common complaints 
even with good visual acuity. Thus, structural changes observed in DMO do not 
correlate with VA. Functional vision is the impact of vision on the quality of life. This 
is better assessed by psychophysical tests. 
It is imperative that we assess outcomes with reliable psychophysical parameters. 
Assessments of VA with ETDRS charts (Ferris, 1996), colour vision with special 
computerized grating methods (Mulak, 2002; Ong, 2003), contrast sensitivity with Pelli-
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Robson charts (Elliott, 1990), and retinal sensitivity thresholds with microperimetry 
(Rohrschneider, 2008) are all well established.  
The results of psychophysical tests in patients with diabetes are unpredictable 
(Brinchmann-Hansen, 1993; Ewing, 1998) and sensitivity varies between tests. For 
example, contrast sensitivity and colour vision are decreased in diabetics with or 
without retinopathy (Dosso, 1996; Ewing, 1998). The variability of psychophysical 
tests, such as VA, in diseased states may be greater than that in normal subjects 
(Brinchmann-Hansen, 1993; Ang, 2006; Ismail, 1998; Patel, 2008).  
The repeatability of normal VA has been established (Raasch, 1998), and ETDRS charts 
are accepted as the gold standard for VA in clinical trials (Ferris, 1996). Under standard 
conditions, refraction and VAs are reproducible (Blackhurst, 1989). Previous studies 
have been conducted to test the repeatability of VA scores on ETDRS charts in normal 
elderly patients, macular degeneration patients, and patients with other advanced eye 
diseases (Lovie-Kitchin, 2000; Kiser; Blackhurst; Patel, 2008). Reported estimates of 
the 95% coefficient of repeatability (CR) of the ETDRS charts range from 3.5 to 8 
letters in normal subjects (Elliott, 1988; Raasch, 1998) and from 7.5 to approximately 
10 to 15 letters in patients with reduced vision (Camparini, 2001; Kiser, 2005).  
Contrast sensitivity (CS) can provide valuable information about visual function related 
to mobility and orientation in addition to visual acuity assessment (Arden, 1978). 
Therefore, it is important to establish the intersession repeatability of CS measurements. 
Studies have tested the repeatability of CS in normal population, using pelli-Robson 
charts: +/- 2 steps or 0.30 log units (Elliott, 1990), and in diseased eyes: CR of 0.35 log 
units in registered blind eyes (Kiser, 2005), and CR of 7 letters (0.35 log CS) in eyes 
with age related macular degeneration (Patel, 2009). Many other studies have also 
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assessed the repeatability and reproducibility of the Pelli-Robson CS chart in normal 
patients (Lovie-Kitchin, 2000; Elliott, 1990; Dougherty, 2005; Elliott, 1993) and in 
those with low vision (Haymes, 2004; Thayaparan, 2007).  
Fundus perimetry can be used to quantify macular sensitivity (Midena, 2010; 
Weingessel, 2009; Rohrschneider, 2008) and its repeatability in normal volunteers is 
well established: mean macular sensitivity of 19.6+/-0.5 dB in the 20 to 29 years of age 
group compared with 18.6+/-1.5 dB in the oldest age group of 70 to 75 years (Midena, 
2010). The test–retest variability of mean macular and point-wise retinal sensitivity has 
also been investigated in small samples of patients with early age-related macular 
degeneration (Weingessel, 2009) and in patients with nonspecific macular disease, co-
efficient of repeatability (CR) for mean sensitivity and central macular sensitivity were 
1.81, 2.13 respectively (Chen, 2009).  
The OCT test is repeatable and reproducible in normal eyes with no macular pathology 
(Baumann 1998; Garcia-Martin, 2011). 
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4: DISCUSSION 
Current and emerging treatments for diabetic retinopathy  
Long-term laser treatment outcome 
Laser photocoagulation remains the standard treatment for patients with CSMO. The 
main objective of laser treatment is to prevent visual loss, rather than to improve vision.  
Diabetic retinopathy is a leading cause of blindness in developing and developed 
countries. In current management, disease is diagnosed based on regular clinical 
examination. Retinopathy progression is determined according to clinical retinopathy 
changes assessed through OCT scan or FFA. The decision to treat is made based on 
macular thickening seen on OCT and on FFA, rather than on changes such as vision 
loss or functional vision deterioration. In most cases, treatment is by laser 
photocoagulation, a modality that is associated with significant disadvantages and poor 
clinical effectiveness compared to clinical trial results. Nevertheless, contemporary 
studies on laser photocoagulation for CSMO indicate that the visual outcomes with 
macular laser treatment are much better than those obtained with the ETDRS study with 
approximately 1 in 4 gaining ≥15 ETDRS letters by 3 years (Aiello LP, 2010; DRCRN, 
2009). Suggested reasons for this improvement include better glycaemic and blood 
pressure control and perhaps early detection and prompt treatment of cases compared to 
a decade ago. However, our study in a clinical setting catering to a multiracial inner city 
population shows that the long-term results (3–5 years) are inferior to those obtained in 
clinical trials, with approximately 12% showing improved vision and 26% suffering 
moderate vision loss at 5 years. 
To test the hypothesis that VA may continue to improve in eyes with laser-treated 
maculopathy (H1), the long-term (5-year) outcome of laser photocoagulation in a real-
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life, inner-city population was studied. We were successful in recruiting 100 subjects 
who were followed-up for 5 years after their initial laser treatment for diabetic 
maculopathy. The mean annual visual outcomes and systemic parameters were collected 
retrospectively and compared to outcomes of the laser arm of the DRCRN trial (section 
2.1.2). The mean change in VA at 5 years was found to be -5.23, with the 3-year 
outcome being inferior to the clinical trial results, with more people gaining vision (≥15 
letter gain) in the DRCRN group compared to this cohort (26% versus 9%)(section 2.1). 
Furthermore, 3 times more patients lost vision (>15 letter loss) in the real-life setting of 
this cohort compared to the clinical trial results of the DRCRN group (27% versus 8%, 
respectively). These results suggest that laser treatment is only effective at halting—and 
not reversing—retinal deterioration, which happens with no treatment (ETDRS report 1, 
1985). It can be argued that these patients are not trial patients and so not standardized 
with regard to age; race; sex; diabetic control; other associated systemic conditions, but 
the outcome suggests a real life scenario, where there is no standardization of the 
patients. The study has adequate power (sample size calculated for 95% confidence, ± 
5%), regular follow-up for 5 years, availability of visual acuities for all the visits, and 
other systemic functions including blood pressure, blood glucose levels for each visit. 
Visual acuities were tested by snellen charts according to clinic protocols and were later 
converted to logmar for data processing. Errors may therefore have occurred whilst 
assessing vision, because of inter examiner variability, intersession variability, and 
intrapersonal variability, lack of updated refraction, and to help compensate for these 
variations, we considered annual mean visual acuities. 
This long-term laser outcome study (chapter 2) assessed a number of factors that may 
determine the poorer outcome. These factors included demographic, ocular and 
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systemic factors, and issues associated with healthcare provision. Compared to the 
DRCRN study (baseline data comparing IVTA to laser for DMO), the mean age of the 
KCH cohort was 4 years younger. The KCH cohort also had more ethnic minority 
populations than the DRCRN group. The VA examiners were not certified, and VA 
measurements were recorded in busy clinic settings. Under these circumstances, it is 
possible that the examiner did not spend enough time encouraging the patient to read as 
far as possible. As a result, the best-corrected VA (BCVA) may have been 
underestimated at times. The meanHbA1C of our group was 8.5%, compared to 7.5% in 
the DRCRN group. HbA1C levels of ≥8 are associated with an increased risk of 
macular oedema, irrespective of the ethnic group (Chou TH, 2009). In a recent report, it 
was found that members of the African-Caribbean community are at increased risk of 
diabetic maculopathy because of genetic predisposition (Gulliford MC, 2010); 
furthermore, the risk of diabetic maculopathy independent of the ethnic group is 
significantly higher in subjects registered with family practices with the lowest quartile 
of HbA1C achievement (Gulliford MC, 2010). The present study results mirror those of 
the DRCRN group, indicating that the HbA1C levels do not influence the outcomes of 
macular laser treatment. Thus, decreasing HbA1C levels is more important with regard 
to the prevention of maculopathy than with regard to maculopathy treatment. This 
finding suggests that over time, other factors may dominate the course of the disease 
(Mahdy RA, 2010).  
Patients in the KCH cohort also had higher systolic and diastolic BP compared to the 
DRCRN group. Again, this difference may be explained in part by the differential 
susceptibility of the African-Caribbean group to high BP. However, unlike the ETDRS 
study, the DRCRN study reported that baseline systolic BP and mean arterial BP did not 
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influence VA outcomes. Despite the higher BP in the KCH cohort, univariate analyses 
did not reveal BP as a predictive factor. As discussed above with regard to HbA1C, 
epidemiological studies and clinical trials strongly support hypertension as an important 
modifiable risk factor for DR (Mohamed Q, 2007). In the UKPDS study, tight blood 
pressure control reduced the risk of retinopathy progression by about one-third, visual 
loss by one-half and the need for laser treatment by one-third in patients with type II 
diabetes. Similarly, the EUCLID study (Chaturvedi N, 1998), DIRECT study (Sjolie 
AK, 2008) and RASS study (Klein R, 2006) all showed positive outcomes for 
antihypertensives on DMO risk. However, these are risk reduction strategies for the 
development and progression of DR. Although both HbA1C and BP must be optimally 
controlled to decrease the rate of incident DR and DMO, they do not appear to influence 
laser treatment outcomes, as shown in the current study and based on the analysis of the 
DRCRN group (Aiello LP, 2010).   
Other factors that could have influenced the outcome were certain inclusion and 
exclusion criteria. DRCRN has completely excluded patients with chronic renal failure 
whilst KCH group had 15 patients with chronic renal failure requiring dialysis 
treatment. Also 13% of DRCRN cohort had additional treatments along with laser, 
whilst KCH cohort had none excepting laser treatment. Similar ceiling and floor effects 
were seen because of the amount of improvement that can occur when acuity is only 
mildly reduced and the amount of worsening that can occur when visual acuity is poor.   
Due to the large number of variables evaluated, we only considered associations with a 
P-value < 0.01 to be significant. Variables that met these criteria included: insulin users, 
number of laser applications, number of missed clinic appointments, baseline VA, and 
BMI ≥ 25. The possible explanation could be that patients who are already on insulin 
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have advanced macular oedema with poor visual acuity on presentation and so less 
influenced by ceiling effect. Similarly those who had more number of laser sessions and 
higher BMI have had poorer baseline visual acuities to present with and the 
improvement in number of letters with laser treatment is unaffected by ceiling and 
probably influenced by floor effects in minimising the deterioration. Nevertheless, a few 
of the variables met a P < 0.05 value threshold in multivariate analyses; they were the 
univariants (i.e., being on insulin medication and baseline VA). Similar to the analyses 
of the DRCRN group (Aiello LP, 2010), we found that visual improvement was better 
in eyes with poorer baseline VA (< 55 ETDRS letters). These types of ceiling and floor 
effects have been reported for treatment outcomes associated with both diabetic 
maculopathy and age-related macular degeneration (Aiello LP, 2010; Boyer DS, 2007).  
The duration of oedema may be an important determinant of final visual outcomes, but 
this factor was not analysed directly in the current study (Gangnon RE, 2012). 
Nevertheless, the poorer results in year 3-5 may serve as a surrogate marker of 
chronicity of disease.   
Despite the fact that all our patients were treatment naive at baseline, the mean number 
of laser applications was only 2.7 at 5 years compared to 2.9 at 3 years in the DRCRN 
group. Although it did not reach a significant level in the multivariate model, the 
number of laser applications is an important factor that may have influenced our 
outcomes. The high threshold among retinal specialists to perform more lasers when 2–
3 attempts have not shown a positive response should change, based on recent data 
reported by the DRCRN indicating that the probability of improvement of eyes treated 
previously with laser ≥ 3 times had a similar chance of VA improvement as eyes that 
had not had prior laser treatment (DRCRN, 2008). Taken together, these findings 
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suggest that it is useful to proceed with further laser treatment if there is sufficient space 
to apply more burns. Response to laser treatment is slow, and persistent oedema after 1–
2 laser treatments should not deter physicians from repeating the laser treatment. 
Another significant problem in the real-life setting of urban populations is lack of 
awareness of diabetic retinopathy and its associated complications. Twenty-two percent 
of the patients in a recent study of urban populations failed to attend screening 
appointments (Gulliford MC, 2010), with the highest nonattendance reported among 
18–34 year olds. In the current study, approximately 50% of the subjects were not 
followed-up regularly, and 16% were lost to follow-up. Therefore, these results may be 
worse than reported if the outcomes for the lost patients were known. The current 
screening and treatment guidelines ensure that patients with sight-threatening disease 
are promptly referred and treated. However, the major challenge of providing timely 
monitoring and treatment appointments for these patients remains unaddressed.  
The strength of the current study is that it included the largest number of patients with 
DMO who had macular laser treatments in real-life settings with long-term follow-up, 
thereby allowing the results to be compared with outcomes from contemporary clinical 
trial results. However, a limitation of this study is its retrospective nature. Despite the 
fact that consecutive patients with 5-year follow-up were recruited, approximately 50% 
of the patients did not complete the 5-year follow-up or did not have at least one annual 
follow-up visit during this time period. Therefore, it can only be postulated that the 
results may be inferior to the present data if all patients would have been followed. 
Finally, this study did not differentiate between focal and diffuse macular oedema, as 
angiograms were not available in all cases.  
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In summary, this study of long-term laser treatment outcome shows that retinal 
specialists should contemplate further laser treatments in patients with persistent 
oedema despite potential initial non-responsiveness to laser treatment. Rigorous 
measures should be initiated to ensure timely follow-up to avoid non-attendance and 
resultant loss of vision of these high- risk individuals. The theory behind the way laser 
works still remains elusive. Should the laser photocoagulation, which is permanent 
destruction of retinal pigment epithelium and the overlying photoreceptors, improve 
retinal oxygenation, the results should sustain in long term. But the results are contrary 
to this, and the mechanism of action of laser photocoagulation in diabetic maculopathy 
is inconclusive. So to evaluate if there is any effect of increased oxygenation, another 
trial was conducted where improved oxygenation of the retina was achieved by 
inhibiting the rod activity. 
Given that hypoxia contributes to the pathogenesis and aggravation of DR and DMO, 
and because photoreceptors utilize oxygen maximally during dark adaptation, the next 
part of the research aimed to test the hypothesis that decreasing the oxygen consumption 
by the photoreceptors via reducing dark adaptation may have a positive impact on 
diabetic maculopathy (H2). A phase II clinical trial was conducted to test whether 
inhibiting rod dark adaptation could reduce the oxygen load on the retina and halt 
progression of retinopathy (section 2.2).  
 
Outcome of the light mask trial: 
Thirty-five patients with treatment–naive DMO were assessed during and after a 6-
month period of wearing masks that illuminated the lid of one closed eye during their 
night time sleep. Patients included those who had DMO that was non–sight threatening 
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or too close to the fovea to laser. No adverse effects were encountered; and none 
reported any sleeping or visual disturbances. Further tests are required to see if there is 
any additional effect of heat generated, if any, as this could possibly cause production of 
heat shock proteins, which might have a protective effect against some types of cell 
injury. Morphologic changes in the illuminated eyes were monitored by OCT. 
Improvements were seen with intraretinal cysts, exudates, and retinal thickening, most 
of which disappeared or were substantially reduced with mask treatment. All these 
changes were noted in the first three months, and continued during the second 3 months. 
Tests of visual function in the study eyes improved (both achromatic and colour contrast 
sensitivity), whereas those in fellow eyes did not improve or worsened. Mean retinal 
sensitivity was improved and a slight increase in VA was observed in the study eyes. 
Because light therapy is inexpensive compared to the currently available interventions, 
and does not require medical supervision, its early adoption could possibly prevent or 
decrease progression of DMO. Further random control trials are required to consolidate 
the results. 
The probability that the improvement in the trial eyes in this study occurred by chance, 
or that such changes could be accounted for by regression to the mean, is extremely 
small. One possible explanation of this result could be that the OCT appearance 
fluctuated in time and, by chance, the first observation caught the condition at its worst, 
so that the later measurements would be nearer to the average and the apparent 
improvement would be fallacious (regression to the mean).  But the probability that the 
final measurement would be larger than the initial is exactly the same as the other 
condition, so the binomial probability would indicate the likelihood that regression to 
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the mean occurred. In general, diabetics with DMO get worse with time; therefore, the 
probability that the result could be obtained by chance is much lower.  
It is the common experience that untreated eyes with DMO worsen. In addition, in all 
the measures we used, retinal function improved in trial eyes. For most tests, this 
improvement was statistically significant. The sole exception was the VA, for which 
only a small increase in the number of ETDRS letters read was noted. However, in our 
patients the VA was normal or nearly normal prior to the trial; thus, the changes are 
subject to the ―ceiling effect‖. By contrast, there was deterioration of these other 
measures of function in the untreated eyes. Most of the improvement occurred within 
the first 3 months of the trial, although continued improvement was also observed in the 
latter half of the short trial.   
Trial design and failings   
One difficulty was the high failure rate of the masks, such that some patients did not 
have continuous periods of illumination at night.  We had no means of determining 
whether the light-emitting diodes were always positioned in front of the pupil, or if they 
could become displaced during the night. These failings in the mask are considered to 
reduce the efficiency of the treatment and increase the significance of any improvement 
detected. 
Comparison to Present-day treatments 
Although a series of treatments of DR are available, they are all invasive (except diet 
control) and some (e.g., pan-retinal photocoagulation) inevitably reduce visual 
performance (Massin P, 2010). In addition, considerable skill is required to carry out 
repeated intravitreal injections or laser treatments with safety. Delivering light therapy 
is a cheaper and non-invasive option to treat early diabetic maculopathy. Our trial 
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patients accepted this method of treatment very well and none reported any side effects. 
Although it is conceivable that present-day treatments might be given in areas with a 
shortage of basic medical facilities, the number of patients with diabetic eye disease is 
so great that employing the forms of treatment readily available puts great strain on 
most state-funded health services. In addition, none of the treatments is inexpensive.  
Comparison to other trials 
Most previous trials of treatment have been designed to test the efficacy of invasive 
methods; therefore, treatment has been given to patients with quite advanced disease. 
The patients in this trial do not meet ETDRS criteria for focal laser treatment. 
Therefore, direct comparison with other trials is difficult and our results cannot be 
directly used to estimate the value of the treatment for patients with more advanced 
disease.  
Implications of results for the causes of diabetic retinopathy 
The total power consumption of the electronics of masks was <2 mW. If this power 
were converted into photons with 100% efficiency (which is impossible) and all of 
those photons were distributed evenly on the retina, then the power would be ≈ 1 mW 
mm
2
.  Because of the attenuation of the light by the lids and the media (Harding S, 
2003; Robinson J, 1991), the actual maximal power incident on the retina must be 
approximately 1/100
th
 of this figure. Such a low light level cannot conceivably cause 
damage to the retinal structures, significant heating, or affect the mitochondrial 
function. However, alteration in the light/dark cycle can alter circadian rhythms, via 
activation of ganglion cells that contain melanopsin (Berson DM, 2002), and such 
alterations are associated with various disturbances, including an increase in the 
incidence of various cancers (Stevens RG, 2009). The action spectrum for modification 
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of the production of melatonin has been determined, and the retinal illumination of 480 
nm light required to cause a 50% reduction in the night-time increase of melatonin is 25 
uW cm
2
 (or 10
14
 photons cm
2
 s) (Brainard GC, 2001; Thapan K, 2001). Therefore, the 
trans-lid illumination caused by the masks would produce minimal changes in 
melatonin, and the effects on DMO must be mediated via absorptions in photoreceptors 
and activation of the transduction mechanism.  
The only known way for such weak light to reverse changes in early DMO is via the 
hypothesis already advanced (Arden GB, 2005): namely, that during dark adaptation, 
rod metabolic activity increases and the resulting hypoxia stimulates production of 
cytokines that cause retinal damage. Thus, the trial must be considered as a proof of 
principle. It naturally follows that many of the damaging biochemical changes in DMO, 
which have been analysed in detail, must be secondary to the insult caused by anoxia.   
Study limitations 
No adverse effects were encountered, but I have not investigated whether continuous 
light interrupts the synchronous shedding of rod tips that occurs each dawn (Schremser 
JL, 1995). Each RPE cell in the region of maximum rod density has to engulf 
approximately 20 mm
3
 of solid material each day, which is roughly its own cytosol 
volume; this material is presented in the course of a few minutes. If this shedding 
process did not occur, then the ability of RPE cells to phagocytise and digest rod discs 
might actually improve. Any adverse effect of low intensity continuous illumination is 
most unlikely: there must be a very large number of night workers who sleep in the day 
under mesopic conditions, and such employment has not been associated with any 
retinal damage. In rodents, which are very susceptible to light damage, increasing the 
average 24 h illumination within tolerable limits only results in a shortening of the rod 
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outer limb, which is auto regulatory, and results in the cell absorbing a constant 14,000 
photons/rod/s (Schremser JL, 1995; Williams TP, 1998, 1999). For this study, it was 
calculated that the illumination of the light masks provided only 50-500 photons 
absorbed/rod/s.  
Less than 50 patients have undergone trials with light-masks in this phase II trial, and 
much larger trials must be undertaken with longer periods of observation. The patients 
all had early stages of DMO, and it is not known whether light would be effective at 
advanced stages; therefore, additional trials, both of pre-proliferative DR and advanced 
DMO, would be desirable. Investigations of different populations (e.g., adolescents or 
people of different ethnic composition) to determine if they react in the same manner 
would be of interest.  
Significance for diabetic retinopathy 
Providing light during sleep is inexpensive, and methods of obtaining it are readily 
available in places where there is a constant electricity supply. However, the use of 
light-masks similar to those we have made has certain advantages: the intensity of light 
is known and is not subject to the patient covering the eyes. Furthermore, the cost of 
running the mask compares favourably with the cost of electrical room illumination. 
Provision of light at night, from whatever source, does not require tertiary medical 
supervision, or any supervision at all. It would be possible to make masks with 
mechanical chargers or solar-powered chargers in the absence of a reliable electrical 
supply. Therefore, even if the method only functions to reverse the earliest retinal 
diabetic changes, it might be widely adopted by people with diabetes of duration longer 
than a critical period, perhaps 10 years; this would reduce the global epidemic of DR 
and its complications to easily manageable proportions.  
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Current and emerging diagnostic approaches for diabetic neuropathy 
Short term fluctuations in functional tests 
Assessment of the reliability of various functional tests is crucial for patients with early 
diabetic macular oedema. Their systemic and ocular management could be influenced 
by the outcome of these tests. Because retinal neuropathic changes are thought to 
precede structural changes, it is imperative to assess the progress. Any psychophysical 
test is associated with an inherent measurement error.  
Factors that could affect reliability of the outcomes can be categorized as instrument-, 
examiner-, or patient-related. Instrument-related factors include test stimulus variability, 
size, duration, luminance, background luminance, target size, test strategy, distance of 
target, intrinsic error in the measurement, and lack of eye tracking. Patient-related 
factors include understanding, pre test training, concentration for lengthier times, 
fatigue, pupil size, co-morbidities, extent of local damage, underlying retinal pathology, 
test point locus, and under- or overcorrection of the refractive error (Heijl, 1989; 
Werner, 1990).  
In our series of patients, all tests were carried out just before midday. Patients were 
alerted before about the extended duration for these tests. They were told to avoid 
hypoglycaemic episodes during their stay for the tests, but the influence of 
hypoglycaemia on these tests cannot be ruled out. Although most of our recruited 
patients were Type II diabetics, some were on an insulin regimen. As part of the 
screening, only OCT analysis was done to rule out DR-related retinal structural 
changes; FFA was not performed to estimate evidence of ischaemia. This choice was 
made to simulate real-life scenario of diabetic patients in the clinic, whom we would 
review periodically without any interventional diagnostic or therapeutic measures. The 
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patients had OCT-detectable changes in the other eye (less than CSMO) for the duration 
of follow-up. Underlying early ischaemic and neuropathic changes cannot be ruled out 
that could influence the outcome of these psychophysical tests. 
Assessing the functional test outcomes in these eyes gives us better understanding of the 
variability expected in these compromised eyes, even if they are not showing any 
clinical signs of ongoing pathology. The functional outcome of these tests should give 
realistic expectations of the eyes assessed in DR clinics. Although no deterioration was 
noted on OCT in some of the eyes observed over a period of 6 months, neurologic 
deterioration cannot be ruled out. Various sources of variability were found, including 
those related to patient age, diabetic status, and ability to concentrate, as well as to 
instrumentation stimulus intensity, size, distance, and duration of tests. Although every 
measure was taken to ensure that the fatigability did not influence the outcome, 
nevertheless, errors could have crept into our results. 
The CR has been established in normal individuals, including early age related macular 
degeneration with no choroidal neovascular membrane (Patel, 2009; Patel, 2008) and 
other nonspecific macular conditions (Chen, 2009). We conclude that these tests haven‘t 
shown much progression in short term follow up periods, but taken with caution, 
because of the underlying ischaemic and neuropathic changes that happen before 
structural changes are evident clinically. 
The retinal thresholds by microperimetry in the sub-foveal region seemed to fluctuate 
more than the mean or peripheral sensitivity, due to the central subfoveal zone that is 
much more influenced by early macular ischaemic changes than the para- and peri-
foveal zones. This situation led us to assess only those eyes with no change in OCT-
based retinal thickness specific to the central subfoveal zone. 
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Despite these limitations, the implications are clear: no one test can be used to assess 
progression completely, and there is poor agreement between the tests in assessing 
progression. Therefore, combinations of tests are required to assess DMO progression 
and the influence of various new therapeutic interventions on macular oedema. 
 
Ability to differentiate eyes with cysts and without at baseline  
New diagnostic modalities are required to assess early functional visual loss and allow 
for early intervention. Vision assessment is a gross functional measure. With the onset 
of new therapeutic modalities in treating DMO, better assessment tools are required to 
improve functional outcome.  
Given that neuronal changes precede vascular changes, this study aimed to test the 
hypothesis that tests of visual function may be a better screening option than grades of 
DR. The objectives were to examine the relationship between structural changes in the 
macula and changes in visual function, in 70 eyes of 35 diabetic patients with treatment-
naïve diabetic maculopathy. The results of functional assessments, including VA, colour 
contrast sensitivity, and MP1, did not correlate to structural changes at the macula with 
OCT and colour fundus photographs. These findings may suggest that: 1) neuronal 
changes, as denoted by visual function tests, are independent of the visible structural 
changes on OCT of the macula denoted by intra retinal cysts; 2) other structural 
parameters on OCT that better estimate visual function should be explored; 3) OCT may 
not be sensitive enough to detect ultra structural changes within the retinal layers and so 
there is more scope for new technology to look more in depth into the structural 
changes; 4) a combination of tests could be considered when assessing these patients. 
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Detection of retinal macula progression by functional tests and OCT  
Various psychophysical tests could be used to identify early functional changes in the 
diabetic retina. For instance, the chroma test (Wong, 2008) can be used to determine 
colour vision thresholds, CS can provide valuable information about visual function 
related to mobility and orientation, in addition to VA assessment (Arden, 1978), and 
fundus perimetry can be used to quantify macular sensitivity (Rohrschneider, 2008). All 
of the functional tests used in this pilot study did show progression to variable extent in 
eyes with definite OCT-based deterioration.  
There was high disagreement among the various structural and functional tests. Only 3 
eyes (4.7%) showed total agreement with all of the functional parameters, whereas 12 
eyes (20%) had good agreement with all of the parameters excepting any one functional 
test.  
Results of the subjective assessment of OCT pictures agreed poorly with the results of 
the other functional tests. This observation has huge implications on the management of 
diabetic maculopathy, as it makes it difficult to determine whether maculopathy should 
be managed solely based on OCT changes, or use functional tests alone. This illustrates 
the importance of assessing progression by a combination of tests. It also highlights the 
need to understand the relationship between various structural and functional 
assessment tools.  
 
Structure-function disagreement  
As yet documentation of disease progression is one of the most challenging aspects in 
the management of diabetic maculopathy. Diabetes affects the neuronal functions of the 
retina and, hence, the psychophysical aspects of vision. Functional changes begin to 
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occur earlier than structural changes. With emerging techniques in assessing the 
structural morphology of the retina, we are able to better understand and quantify the 
intricate structural relations; meanwhile, functional tests assessing retinal sensitivity aid 
in the detection of very early retinal damage.  
Although OCT is considered to be the gold standard for assessing structural changes of 
the retina, OCT results do not always correlate with functional changes. Meanwhile, VA 
is considered to be the gold standard for assessing disease progression, but VA results 
do not correlate well with progressive structural changes. In this study, we tried to 
assess whether there is significant correlation between results by MP1 and OCT, and 
whether MP1 could better detect progressive changes than VA. 
 
Assessing the visual function by OCT, MP1, and VA 
Assessing retinal status only by VA measurements does not provide sufficient 
information to detect early functional changes of the retina. Macular function is not 
fully characterised by VA, and testing this functional aspect alone ignores central and 
para-central scotomas that could influence functional vision. Microperimetry mainly 
assesses the photoreceptor function, whereas OCT only assesses structural integrity 
within the layers in DMO. Whereas light sensitivity is reduced in areas of macular 
oedema, various studies have shown no correlation between the amount of oedema and 
visual function (Rohrschneider K, 2008); no correlation between macular oedema and 
light sensitivity threshold values (Kube T, 2005; Okada K, 2006; Rohrschneider K, 
2008; Vujosevic S, 2008; Trick GL, 1998, Alkuraya H, 1989; Brinchmann Hansen O, 
1993); and differing correlations between OCT thickness, MP1, and colour and contrast 
sensitivities in assessing DR (Okada K, 2006).  
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This study shows that not all OCT-related changes cause functional changes. Although 
previous studies have shown a strong correlation between CSMO changes, VA, and 
retinal sensitivity, no significant relation could be found while assessing progressive 
macular oedema. OCT-related cystic changes may fluctuate (Coefficient of repeatability 
(CR): 7.67) without actual functional deterioration, leading to high disagreement 
between structural and functional tests in assessing progression. This disagreement has 
huge implications on diabetic maculopathy management. Although the poor agreement 
could be partly due to measurement errors, there are undoubtedly other aspects, because 
the tests do not all measure the same retinal functions. Moreover, the association 
between structure and function of the retina would varyingly influence the outcome of 
these tests. These findings may suggest that neuronal changes, as denoted by visual 
function tests, are independent of the visible structural changes at the macula and should 
be used in conjunction with OCT parameters. This finding illustrates the importance of 
assessing progression by a combination of various tests, and of understanding the 
relationship between various structural and functional assessment tools.  
Although the tests were carried out under strict protocols, a few limitations should be 
noted, including short duration of the assessment period, lack of control over the 
glycaemic status of patients during the tests, and lack of control over the intensity and 
duration of the tests, which puts extra pressure on the diabetic patients. Although 
progressive cystic changes in the eyes were compared to eyes with no changes, 
neurologic deterioration over the 6-month period cannot be ruled out; this effect could 
have influenced the functional parameters. 
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Problems with MP-1 
MP1 documented individual areas where function was altered and correlated well with 
OCT changes; however, OCT changes did not statistically influence the mean MP1 
values or central MP1 thresholds. Therefore, although the point-based threshold values 
are good to follow, use of zonal summative thresholds similar to the zonal thickness 
given on OCT scans should be considered.  
This study shows that the measurement of macular sensitivity by microperimetry is a 
better tool for evaluating visual function than VA in eyes with early diabetic 
maculopathy. However, such measurements do not correlate with the CST, because the 
pathology could be anywhere in the macula in the early stages. Moreover, the mean and 
central MP1 thresholds are not an accurate tool to assess disease progression, unless the 
MP1 thresholds are subcategorised into subzone regions. This result is similar to the 
case with OCT, in which CST does not correlate well with other psychophysical 
functions, including VA. For microperimetry to be used as a screening tool to assess 
progression, the British Diabetic Association has indicated that the sensitivity and 
specificity must be as high as 80% and 95%, respectively. 
Although an exact correlation between fundus disease and functional defects can be 
achieved by integration of fundus imaging with computerized thresholds, it is not 
possible to follow-up the patients with zonal values. Therefore, obtaining central or 
mean values to correlate is of utmost importance; in this study, microperimetry failed in 
this regard. The current practice is to assess the functional impact of DMO by 
quantifying the best-corrected VA (BCVA), even if this parameter is just one aspect of 
macular function. However, MP1 has other drawbacks, including a sharp learning 
curve, time consumption, reliability, and cost effectiveness. 
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Chroma outcome 
Although VA is considered to be the gold standard for assessing progression of DR, it 
does not correlate well with progressive structural changes. In this study, we assessed 
whether tritan colour thresholds on the chroma test correlated better than VA with OCT 
subfoveal thickness. Seventy eyes with diabetic maculopathy were tested, including 
eyes with or without parafoveal intraretinal cysts according to OCT. No significant 
relationship was found between the 2 functional parameters and the structure-function 
correlation, in terms of the ability to differentiate OCT findings. Though both chroma 
tests and visual acuities failed to differentiate eyes with and without cysts at baseline, 
tritan thresholds were better at detecting progressive changes than VA, indicating a 
potential use for the chroma test in this application. But again colour vision and contrast 
visions are gross functional assessments like visual acuity, and doesn‘t provide details 
of localised changes as seen on microperimetry. Protan and in particular Tritan colour 
vision has been shown to be influenced by diabetic retinopathy (Treager, 1993). The 
most likely mechanism for this effect is thought to be reduced oxygen saturation levels 
in outer layers of retina. (Dean, 1997).  
The chroma test machine is a prototype and errors could have crept in which 
weremachine related; fatigability; and difficulty in controlling testing conditions. We 
tried to minimise these by doing the tests with the same observer, same time of the day 
each visit, since all these patients are diabetics and fluctuation in glucose levels 
anticipated. Though the colour vision thresholds weren‘t as sensitive as OCT changes, 
they were on par with visual acuities and better in detecting progressive changes. More 
refinement of the procedure is required. Future longitudinal studies with a larger sample 
population are needed to confirm these findings.  
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CHAPTER 5: CONCLUSION 
Current management of diabetic macular oedema involves diagnosis according to 
clinical structural changes (which appear much later than diabetes-associated functional 
vision changes), treatment decision according to macular thickening seen on OCT and 
on FFA (which are time-consuming and labour-intensive), and treatment by laser 
photocoagulation (which is associated with collateral damage and very poor clinical 
effectiveness in terms of its ability to reverse damage). With the development of new 
therapeutics in the management of diabetes, including VEGF inhibitors, newer 
antidiabetic agents that only indirectly affect insulin secretion, as well as incretin 
receptor agonists (i.e., exenatide) and enhancers (i.e., sitagliptin) that increase the 
activity of GLP-1, prevention of functional vision loss in DMO has become an 
achievable goal. Detection of early functional changes will require better diagnostic 
tools than are currently available. Continued research is needed into improved 
diagnostic and treatment modalities to halt the progression and improve the outcome of 
management of DMO. 
 
Possible future directions to this research are many:  
 Our findings that laser photocoagulation is far less effective in clinical practice 
than clinical trials and should be verified in long-term studies among larger 
populations. Steps should be taken to identify possible reasons for the 
discrepancy between trial and real-life findings. The various confounding factors 
could be age, race, ethnicity, diabetic control, blood pressure control, threshold 
for laser treatment, earlier detection and intervention, compliance of patients. 
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 Very optimistic results were obtained with a phase II clinical trial of rod dark 
adaptation by illuminated night-time masks. Given the cost-effective and non 
invasive qualities of this therapy, the results could have far-reaching applications 
for DMO management. However, this study was hampered in part by a high 
failure rate of the masks (approximately 30%). Additional trials, with improved 
electronics, larger sample size, in patients with varying degrees of severity of 
retinopathy, should be performed.  
 The results on the study of function-structure correlation for various visual 
functional assessment methods indicate that currently available diagnostic tools 
are inadequate for the early detection of functional changes related to DMO. 
Although these results may indicate that neuronal changes on visual function 
tests are independent of the visible structural changes on OCT, additional studies 
are needed to verify this claim. Moreover, additional research should be done 
into novel methods for detecting visual changes at the very early stages of 
retinopathy, when functional visual defects occur. 
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7. APPENDICES 
 
A) Instructions for our collaborators -How to use the light mask. 
 
When we give you the light mask, we will make the adjustments, which will bring 
the light onto your closed eyelid. You will be able to see the green light through 
your lid.  The light should seem to be over a wide area, and roughly “straight 
ahead”.   
Putting the mask on  
When you put the mask on yourself, you will have to learn to position it correctly. 
This may be a bit fiddly for a day or two. The most important thing is it should not 
be too tight, because then it will be uncomfortable to wear.  If your hat size is 7 ¼ 
or more, the elastic bands should be where the top of your neck joins your head, 
not over the bump at the back of your head. If your head is smaller then the bands 
should go higher. We could only make one size for this research and it has to do for 
everybody!   
 
Hold the mask a little way away from your face. Open your eyes and position the 
little lighted disc which so it is in front of your eye. Then close your eyelids and let 
the disc contact the lid.  You should see the dim green light through your lids. If you 
cannot the disc is not in position. Move the disc and try again. As we said, the mask 
may not be a good fit:  You can move the mask a little to make it more comfortable, 
and also, to make the light more central: try moving it from side to side, and up and 
down.  You should be able to see the green patch when the room lights are on. Do 
not try and make the light as bright as possible by pressing the mask against your 
eye- that is not needed.    
 
What to do when you take the mask off  
In the morning, when you take the mask off, place it face-side up on the charging 
plate.  Then move it around till the light goes off.  Then turn on the  switch on the 
side of the box, so  the charger is on: a little green light will appear on the top of the 
box.  In the evening  you can turn the charger off.  You should charge the mask 
every day, but if you forget, the battery will last several nights. If the battery in the 
mask goes completely flat, it may be difficult to get it to recharge properly.   
WHEN YOU COME UP TO THE HOSPITAL REMEMBER TO BRING YOUR 
MASK!!!! 
If you have any trouble  you can phone 02070408863   OR 0207 3599080…. 
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B) GP LETTER 
 
Project number [  08/H0808/198]  
Dear Dr. ….. 
Your patient …………………………………………………………………………. 
who is currently attending our Diabetic/ Eye clinic, has been approached by us,   as 
part of a research project  we are conducting  at   Kings College Hospital NHS Trust  
We are trying to obtain evidence to test the hypothesis that sleeping in complete 
darkness is a predisposing cause for  diabetic retinopathy, and we are asking 
patients to sleep in a “ light mask”  for 6 months. The mask is similar to ones on 
sale, but ours will illuminate only one retina (through the closed eyelid) during the 
hours of sleep. We believe that after 6 months we will be able to show a change in 
the progression of diabetic retinopathy in the patients’ illuminated eyes relative to 
the unilluminated. The light intensity is very modest, and cannot cause harm. The 
mask itself is inherently safe to wear, and well tolerated in a small preliminary 
trial.  If any participant found it uncomfortable or difficult to sleep in, we would 
end the individual’s participation in the trial. The trial is being conducted “ blind” 
and we therefore cannot inform your patients or you of their individual results 
during the trial, which l will last 1 year.  At the end of the trial, we will know if our 
work supports the hypothesis, and can give you more information.  
Yours sincerely  
Sohba Sivaprasad , Consultant  Ophthalmologist , Kings College Hospital NHS Trust , 
Hambledon Wing  Denmark Hill London SE5 9RS. 0203 299 9000 x 3542 senswathi 
@aol.com  
Professor G.B. Arden, City University, Northampton Square  London ECV1 0 HB, 
 0207 040 8863    g.arden@ city.ac.uk                                            
Project number [  08/H0808/198]  
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C) CONSENT FORM 
 
Title of Project: Dark adaptation and Diabetic Retinopathy 
Names of Researchers:    
Miss S. Sivaprasad       Professor G. Arden  
1. I confirm that I have read and understand the information sheet for the above 
study and have had the opportunity to ask questions.             
2. I understand that my participation is voluntary and that I am free to withdraw 
at any time without giving any reason, without my medical care or legal rights 
being affected.                                                                                             
3. I understand that sections of any of my medical notes may be looked at by 
responsible individuals from [City university] or from regulatory authorities 
where it is relevant to my taking part in research.  I give permission for these 
individuals to have access to my records. I explicitly agree that the information of 
the research project and my name, date of birth, and hospital number may be 
recorded on a computer, so that in the future comparison can be made with my 
clinical records                                                                                                 
4:   I agree that you can tell my GP,  I am participating  in the study                                              
5. I agree to take part in the above study.       
                                                  
Name of Patient or subject                                     Date             Signature 
  
Name of Person taking consent                     Date  Signature 
 
 
Project number [ 08/H0808/198] 
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D) PARTICIPANT INFORMATION LEAFLET 
 
1.          Study title: Diabetic Retinopathy and Dark Adaptation  
2. Invitation paragraph   
  You are being invited to take part in a research study.  Before you decide to join it is 
important for you to understand why the research is being done and what it will involve.  
Please take time to read the following information carefully. Talk to others about the 
study if you wish. Ask us if there is anything that is not clear or if you would like more 
information.  Take time to decide whether or not you wish to take part.  
3. What is the purpose of the study? 
Diabetes is a very common condition, and although it is treaTable, there may be 
serious complications. After many years, the eye may suffer, particularly the light 
sensitive retina. This is called Diabetic retinopathy (DR).  We believe we know the 
cause of this complication and are trying to test our ideas by a clinical trial.  If we 
are right, then it would be a considerable step in preventing this serious condition.   
4. Why have I been chosen? 
You have been chosen because you have diabetes, and there are early  signs in the 
back of your eye that  some changes associated with DR have begun and  that both 
eyes are similarly affected.  Also your general health is good.  
5. Do I have to take part? 
     It is up to you to decide whether or not to take part.  If you do decide to take part you 
will be given this information sheet to keep and be asked to sign a consent form. If you 
decide to take part you are still free to withdraw at any time and without giving a 
reason.  A decision to withdraw at any time, or a decision not to take part, will not 
affect the standard of care you receive. 
6. What will happen to me if I take part? 
 If you are interested in taking part in this project, we want you to go to sleep every 
night, wearing a “light mask” (which we will show you), that will shine light onto 
your eyelid while you are asleep.  We think that this light will improve your retina 
relative to the other (which will remain in darkness). We will only treat one eye, 
chosen at random, because that will give us a rapid way of assessing whether we 
are right or wrong. We do not want to treat only “worse eyes” because this would 
influence our result.  
7:     What do I have to do? 
We will fit you with a light mask, and ask you to take it home and try it out.  We ask 
you to return after a week. If you feel you can use it without discomfort and loss of 
sleep we will then ask you to volunteer for our trial, and ask you to sign a consent 
form.  We will give you detailed eye examinations of the sort you have already had 
after 3 and 6 months. This means you will have to come to the Hospital once or 
twice more often than if you were not in the trial.   We will contact you at home in-
between, to check on how you are getting on.    We are not asking you to make any 
other change whatsoever in your life.  If you are already having treatment of any 
sort it will continue.  
8:     What is the procedure that is being tested? 
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In complete darkness, the retina becomes more sensitive, and it does this by using 
much more oxygen than in light.  We believe this extra oxygen cannot be 
completely supplied in people with diabetes, and this is the cause of the DR.  You 
only dark-adapt when you sleep in the dark. We are trying to prevent this in one 
eye.  At the end of the trial, of course, if we are right we could treat both, but the 
comparison between your right and left eyes is important.    
9:     What are the possible disadvantages and risks of taking part? 
We cannot think of any disadvantage except that you may not be able to sleep 
undisturbed when wearing our mask.   If so, we want you to stop and return it.  
The mask is designed not to cause any damage or irritation.  
10.    What are the possible benefits of taking part? 
 It is not likely that you will get any personal benefit from taking part in our trial , 
but if we are right, you will be among the first to benefit from the later 
developments. 
11.    What happens when the research study stops? 
We will analyze all the data, and publish it.  If our ideas are correct they will be 
taken up everywhere in the world.  We will keep you informed of the results when 
the trial is over. There are various ways in which you could continue to sleep in 
light, if you wanted to, and we could advise you about them and help you.  
12. What if something goes wrong? 
We believe that our test cannot possibly do you or anyone any harm.  If you have 
complaints, you should address them to the investigators, (names addresses and 
telephone numbers given below). If you want to complain about the way the study 
has been conducted you can use the normal complaints mechanism available to 
anyone receiving care in the National Health Service. Your right to use this service 
is not compromised in any way because you have taken part in a clinical research 
study.  You can additionally complain to a Research Administrator at City 
University – for names see below. These people will deal with any complaint 
whether it is related to the trial itself, or any other experience you have while 
attending the outpatients department. We are legally bound to tell you the 
following: 
 ‗If you are harmed by taking part in this research project, there are no special 
compensation arrangements.  If you are harmed due to someone‘s negligence, then 
you may have grounds for a legal action but you may have to pay for it.  Regardless 
of this, if you wish to complain, or have any concerns about any aspect of the way 
you have been approached or treated during the course of this study, the normal 
National Health Service complaints mechanisms should be available to you.‘ 
13. Will my taking part in this study be kept confidential? 
For purposes of analyzing the data, some information about the state of your eyes 
will have to be recorded, and of course we will have to have details so we can have 
access to records in the future. Therefore we will need to record your name, date 
of birth and hospital number, and also we want to contact you at home so we 
would like your address and telephone number We plan to keep this data on a 
computer at City University. London.   The computer will be password protected, 
and kept secure. The data will also be encrypted.  Data such as this is always 
transferred to discs, in case the computer breaks down. Such discs will also be kept 
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securely.  The data-analysis will remove any piece of information that could be 
used to identify you and all the data will be kept strictly confidential. If you agree 
we will write to your GP about our work and explain you have volunteered. You 
might also like to consult him before agreeing.   
14. What will happen to the results of the research study? 
When the research has been analyzed we expect to publish in major journals 
related to eye disease and to diabetes.  We cannot tell you exactly when such a 
publication would occur or where.   If it appears that the results might be of 
general use, you are likely to hear about it from the press, and we would produce a 
leaflet to be distributed in this clinic.  
15.  Who is organizing and funding the research? 
This research has not been paid for in whole or part by any public body or 
commercial firm.  
16.  Who has reviewed the study?   The Research & Ethics and the  #research and 
Development Committee of the King’s College Hospital NHS Trust  
17: Contact for Further Information   Professor G.B. Arden, City University.   
Northampton Square  EC1 V 0HB Tel 0207 040 8863 or out of working hours  0207 
359 9080 g.arden@city.ac.uk  
Dr. P  Bunting, Research Administrator, School of Community and Health Sciences  
City University Northampton Square London EC1V 0HB   
Miss S  Siviprasad  Consultant Ophthalmologist, Kings College Hospital NHS Trust 
Denmark Hill London SE 5 9 RS 0203299 9000x 3542  senswathi@aol.com 
 
Thank you for taking part in this study. This information sheet and a copy of any 
consent form you sign should be kept by you.  
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E1) EXCELL SHEETS comparing King’s study patients to ETDRS and DRCRN patients 
 
DRCRN 
BASELIN
E 
(330EYE
S) 
DRCR
N 1YR 
(286) 
DRCRN 
2YR 
(272) 
DRCR
N 3YR 
STUDY 
BASELIN
E 
STUDY 
1YR 
STUDY 
2YR 
STUDY 
3YR 
STUDY 4 
YR 
STUDY 
5YR 
ETDRS 
1YR 
ETDRS 
2YR 
ETDRS 
3YR 
TOTAL 
COMPLETED 330 286 272 115   150 140 135 123 122 
614(80
%) 
416(55
%) 
268(35
%) 
AGE 63   63 59         
WHITE 
243(74%
)    55(36%)         
BLACK 31(9%)    70(46%)         
ASIAN 7(2%)    
25(16.6
%)         
AMERICAN 
INDIAN 2(1%)             
HAWAIN 1(<1%)             
MULTI RACIAL 1(1%)             
UNKNOWN 6(2%)             
TYPE 1 14(4%)    15(10%)         
TYPE 2 
316(96%
)    
135(90%
)         
DURATION OF DM 15    13         
HBA1c median 7.5    9.52 9.16 9.22 8.81 8.88 8.11    
prior 
photocoagulation 
for DMO 
198(60%
)    NONE         
PHAKIC 
262(79%
)    
138(92%
)         
BASELINE VA 62    66         
MILD-MOD 
186(58%
)    123         
SEVERE 43(14%)    15         
PDR 88(28%)    9         
PRPC 53(16%)    3         
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Mean(SD) change 
in VA 62 1+-16 2+-17 5+-17 66+-14 0+-14 -1+-15 -4+-16 -4+-16 -4+-17    
Median change in 
VA(IQR)25TH, 
75TH percentile 62 
3(-
5,10) 
5(-
5,12) 
8(-2 
TO 
15) 70 0 0 -5 -5 -5    
>=15 letter gain (15%) 14% 20% 
30(26
)  
17(11.3
%) 
15(10.7
%) 
14(10.4
%) 17(13.8%) 15(12.3%)   
10-14 letter gain  14% 14% 
21(18
)  13(8.6%) 
11(7.86
%) 10(7.4%) 3(2.43%) 5(4.1)    
5-9 letter gain  17% 17% 
21(18
)  
19(12.6
%) 
20(14.3
%) 
16(11.9
%) 
13(10.56
%) 8(6.56)    
no chage +- 4 
letters  29% 22% 
24(21
)  
58(38.6
%) 
38(27.2
%) 
26(19.3
%) 
24(19.51
%) 30(24.6)   
5-9 letter loss  9% 9% 5(4)  13(8.6%) 
16(11.4
%) 
17(12.6
%) 
18(14.63
%) 17(13.94)   
10-14 letter loss  3% 6% 5(4)  11(7.3%) 
16(11.4
%) 13(9.6%) 12(9.75%) 16(13.12)   
>15 letter loss  14% 13% 9(8)  
19(12.6
%) 
22(15.7
%) 
38(28.2
%) 
36(29.26
%) 
31(25.4
2) 5% 6% 0.1 
ENDOPHTHALMI
TIS   0           
RETINAL DETACHEMENT  2           
RVO   3           
RAO   1           
AION   0           
VIT   31           
INCREASED IOP   25           
POAG   0           
GLAUCOMA SURGERY  0           
CATARACT 
SURGERY              
NO: LASERS ONCE   
52(19
%)       38(25%)   
2 TIMES   
65(24
%)       42(28%)   
3 TIMES   
67(25
%)       32(21%)   
4 TIMES   49(18       16(10%)   
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%) 
5 TIMES   
28(10
%)       11(7%)    
6 TIMES OR 
MORE   11(4%)       9(6%)    
MEAN (SD)   
2.9+-
1.4       2.66    
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E2) DATA SHEETS FOR KING’S LASER TREATED PATIENTS 
Ethni
city 
E
y
e 
PRE 
LASER 
PROCE
DURE 
AG
E 
AT 
FIR
ST 
LAS
ER 
Stage 
of DR: 
Mild/ 
moder
ate/ 
severe
/ PDR 
time 
gap 
betw
een 
mac
ular 
and 
PRP 
No: 
of 
mac
ular 
laser
s in 
5 
year
s 
VA 
base
line 
V
A 
at 
1s
t 
ye
ar 
V
A 
at 
2n
d 
ye
ar 
V
A 
at 
3r
d 
ye
ar 
V
A 
at 
4t
h 
ye
ar 
V
A 
at 
5t
h 
ye
ar 
cha
nge 
in 
VA 
cen
sor 
ti
m
e 
stat
us 
No
: of 
ey
e 
ap
pt 
in 
5 
ye
ars  
No: 
of 
fail
ed 
to 
atte
nd 
app
ts 
in 5 
yea
rs 
VR 
surg
ery 
in 5 
year
s 
Cata
ract 
surg
ery 
in 
the 5 
year
s:  
3 L 2 32 2 6 2 85 75 60 60 75 75 -10 1 12 1 1 8 2 0 0 
2 L 2 75 1   2 62 55 LOST     -7 0 12 1  
9 
LOS
T 
4 
LOS
T 0 0 
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1 L 2 
7
8 1  1 
7
5 
7
5 60 60 45 
DECEASE
D 
-
3
0 0 
2
4 1  9+DECEASED 1+DECEASED 0 0 
1 L 2 
5
0 1 96 2 
8
3 
8
5 85 88 85 87 4 1 
1
2 0  13 0 0 0 
2 R 2 
7
0 1  5 
6
5 
7
0 75 60 55 45 
-
2
0 1 
1
2 1  20 8 0 0 
1 L 2 
6
0 1  1 
8
5 
8
3 88 70 70 82 -3 1 
1
2 1 1 12 3 0 0 
1 L 2 
6
0 1  1 
8
5 
8
3 88 70 70 82 -3 1 
1
2 1 1 12 3 0 0 
1 L 2 
6
5 1  3 
4
5  35 35 40 40 -5 1 
2
4 1 1 13 2 0 0 
1 R 2 
4
7 3 0 3 
7
0 
3
5 10 45 25 25 
-
4
5 1 
1
2 1  20 1 1 1 
1 L 2 
4
7 1 0 1 
7
5 
7
5 70 70 73 73 -2 1 
2
4 1 1 16 2 0 0 
2 R 2 
6
5 1  6 
7
0 
8
2 75 75 73 71 1 1 
1
2 0  20 3 0 0 
3 L 1 
6
3 1  5 
5
5 
6
0 60 70 60 45 
-
1
0 1 
6
0 1 1 16 2 0 1 
1 R 2 
4
9 2 9 3 
7
5 
7
5 75 60 60 75 0 1 
3
6 0  23 4 1 0 
1 R 2 
4
9 2 30 3 
7
5 
7
5 75 60 60 75 0 1 
3
6 0  23 4 1 0 
2 L 2 
5
5 3 0 3 
3
5  35 55 53 33 -2 1 
6
0 1 1 22 4 0 0 
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1 R 1 
6
5 3 -24 1 
7
0 
5
5 60 60 60 60 
-
1
0 1 
1
2 1 1 9  0 0 
1 R 2 
5
6 1  3 
6
0 
6
5 65 65  
DECEASE
D 5 0 
1
2 0  NA N 0 0 
3 L 2 
5
0 1  2 
7
5 
7
5 70 70 70 75 0 1 
6
0 0  16 4 0 0 
3 R 2 
7
3 1  3 
4
5 
4
5 40 40 40 40 -5 1 
1
2 1 1   0 1 
2 R 2 
4
8 2 0 2 
6
0 
6
0 70 
LOS
T 
LOS
T LOST 
1
0 0 
2
4 0   LOST LOST   
3 R 1 
6
1 1  2 
6
0 
7
0 35 35 35 35 
-
2
5 1 
2
4 1  18 6 0 0 
2 R 2 
7
3 1  3 
6
0 
3
5 65 60 60 70 
1
0 1 
6
0 0 0 21 0 0 0 
2 L 2 
6
1 1  3 
4
5 
7
0 75 70 60 60 
1
5 1 
1
2 0 0 14 2 0 0 
2 L 2 
5
7 2 42 6 
7
5 
7
5 60 55 55 65 
-
1
0 1 
2
4 1 1 26 5 0 0 
2 L 1 
5
8 1 62 2 
6
0 
7
0 70 65 75 55 -5 1 
6
0 1  6 2 0 0 
1 R 2 
6
5 3 0 2 
7
0 
7
5 70 60 60 60 
-
1
0 1 
3
6 1 1 30 3 0 0 
2 R 2 
4
6 3 0 1 
8
0 
8
5 82 84 LOST LOST 4 1 
1
2 0  11,LOST 2 0 0 
2 R 2 
6
2 1  6 
6
0 
6
0 60 45 65 60 0 1 
6
0 0  20 5 1 0 
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1 L 2 
5
7 1  3 
7
0 
8
5 85 85 85 85 
1
5 1 
1
2 0 0 15 2 0 0 
1 L 2 
5
8 1 36 2 
7
0 
7
5 75 70 60 70 0 1 
1
2 0  19 3 0 0 
2 R 2 
5
4 1  6 
7
5 
7
5 70 75 70 60 
-
1
5 1 
6
0 1  16 1 0 0 
2 L 2 
4
1 1  2 
7
0 
8
0 75 75 70 35 
-
3
5 1 
6
0 1  20 8 0 0 
2 R 2 
7
7 1  5 
8
0 
7
0 69 75 70 85 5 1 
6
0 0  30 10 0 0 
2 L 2 
6
2 1  2 
8
5 
8
2 70 77 
LOS
T LOST 
-
1
5 0 
2
4 1  12 LOST 
LOST 
AFTER 3 YR 0 0 
2 L 2 
5
7 3 -48 1 
7
5 
8
0 70 85 85 55 
-
2
0 1 
6
0 1  14 4 0 0 
2 L 1 
8
0 1 35 3 
6
5 
4
5 50 50 50 50 
-
1
5 1 
1
2 1  7 1 0 0 
2 R 2 
7
5 1 19 5 
6
0 
2
0 35 20 35 35 
-
2
5 1 
1
2 1  35 3 1 1 
1 R 2 
6
7 1  4 
8
0 
7
5 85 75 75 62 
-
1
8 1 
1
2 1  20 3 0 0 
2 L 2 
5
9 2 96 3 
4
5 
4
5 45 45 45 55 
1
0 1 
6
0 0 0 19 4 0 0 
2 L 2 6 1  2 3 4 40 35 35 35 0 1 6 0  10 2 0 0 
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1 5 5 0 
2 R 2 
6
5 1  5 
7
0 
6
0 75 75 75 75 5 1 
6
0 0  18 2 0 0 
2 R 2 
7
0 1  3 
7
0 
6
0 55 60 
LOS
T LOST 
-
1
0 0 
1
2 1  10,LOST LOST  
1 R 2 
7
1 1 24 4 
7
0 
6
0 60 55 55 50 
-
2
0 1 
1
2 1  30 2 0 0 
2 L 2 
5
8 1 48 7 
6
0 
5
5 55 60 60 70 
1
0 1 
6
0 0 0 17 6 0 0 
2 R 2 
5
0 1 84 6 
7
0 
7
0 70 35 35 25 
-
4
5 1 
6
0 1  15 3 0 0 
1 R 2 
7
1 1 24 4 
7
0 
6
0 60 55 55 50 
-
2
0 1 
6
0 1  30 2 0 0 
2 R 2 
5
5 1 96 3 
7
5 
7
5 80 65 75 75 0 1 
6
0 0  11 
4 LOST FOR 
FOLLOW UP 0 0 
2 L 2 
6
4 1  5 
7
5 
7
0 60 60 70 55 
-
2
0 1 
6
0 1  5 0 0 0 
2 L 2 
6
8 1 70 1 
6
0 
5
5 47 45 45 45 
-
1
5 1 
6
0 1  11 2 0 0 
2 R 2 
6
0 3 -48 1 
5
5 
3
5 35 35 35 35 
-
2
0 1 
6
0 1  12 5 0 0 
3 R 2 
5
9 1  3 
9
0 
8
7 55 84 83 73 
-
1 1 
6
0 1  20 3 0 0 
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7 
3 L 2 
4
7 1 85 2 
7
0 
6
2 84 77 65 70 0 1 
6
0 0  10 2 0 0 
2 R 2 
4
4 2 70 1 
7
0 
7
0 70 60 55 35 
-
3
5 1 
6
0 1  10 4 0 0 
1 R 2 
5
6 1 60 2 
4
5 
6
0 75 70 75 75 
3
0 1 
6
0 0 0 
12, LOST TO 
FU 4 0 0 
1 R 2 
5
2 1 50 9 
8
5 
7
5 75 85 80 80 -5 1 
6
0 1  31 7 0 0 
1 R 2 
5
2 1 50 9 
8
5 
7
5 75 85 80 80 -5 1 
6
0 1  31 7 0 0 
3 R 2 
4
7 1 
11
6 4 
7
5 
8
5 75 75 75 72 -3 1 
6
0 1  17 3 0 0 
1 L 2 
5
7 2  1 
5
5 
5
5 60 55 
LOS
T LOST 0 0 
3
6 0  
7 UNTIL 
07/2004 N 1 0 
1 L 2 
5
7 2  1 
5
5 
5
5 60 55 
LOS
T LOST 0 0    
7 UNTIL 
07/2004 N 1 0 
2 R 2 
6
0 1  2 
7
5 
7
0 60 85 90 90 
1
5 1 
6
0 0 0 11 1 0 0 
2 L 1 
6
8 1  3 
4
5 
6
0 60 75 45 75 
3
0 1 
6
0 0 0 16 2 0 0 
2 R 2 
6
3 1  2 
7
0 
7
0 45 45 45 65 -5 1 
6
0 1  5 1 0 0 
2 R 2 
5
8 1  1 
7
5 
7
5 75 75 60 70 -5 1 
6
0 1  12 2 0 0 
2 L 2 
5
4 1  1 
6
1 
7
0 75 75 65 70 9 1 
6
0 0  14 2 0 1 
3 L 2 
6
1 1 48 2 
7
0 
8
5 85 75 75 75 5 1 
6
0 0  21 2 0 0 
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2 L 2 
6
7 1  5 
7
5 
7
5 75 75 70 60 
-
1
5 1 
6
0 1  28 5 0 0 
2 L 2 
6
7 1  6 
6
0 
4
5 35 25 35 45 
-
1
5 1 
6
0 1  29 4 0 1 
1 R 2 
5
8 1  3 
8
5 
8
5 88 88 87 88 3 1 
6
0 0  18 2 0 0 
3 L 2 
5
6 1  2 
7
0 
8
5 75  85 85 
1
5 1 
6
0 0  18 4 0 0 
2 R 2 
5
7 1  3 
7
5 
8
5 85 85 83 72 -3 1 
6
0 1  23 4 0 0 
1 R 2 
4
8 1  5 
7
5 
7
3 70 70 70 70 -5 1 
6
0 1  20 2 0 0 
1 R 2 
4
8 1  5 
7
5 
7
3 70 70 70 70 -5 1 
6
0 1  20 2 0 0 
2 R 2 
7
0 1  1 
6
0 
6
5 65 60 70 70 
1
0 1 
6
0 0 0 12 4 0 1 
1 R 2 
7
2 3 8 1 
4
5 
5
5 45 25 20 20 
-
2
5 1 
6
0 1  35 3 1 1 
1 R 2 
7
6 1   1 
7
7 
6
2 93 LOST   
-
1
5 0 
2
4 1   
17 IN 3YR,  
LOST FOR FU 5 AND LOST 0 0 
2 R 2 
6
4 1   1 
7
7 
7
5 LOST     -2 0 
1
2 1   4LOST 4 LOST 0 0 
2 R 1 
6
1 1  2 
4
5 
4
5 55 55 
LOS
T LOST 
1
0 0 
6
0 0  LOST LOST 0 0 
2 R 2 
6
6 1  2 
7
5 
7
5 75 70 70 70 -5 1 
6
0 1  10 0 0 0 
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1 R 2 
7
1 1 24 4 
7
0 
6
0 60 55 55 50 
-
2
0 1 
6
0 1  30 2 0 0 
1 L 2 
5
4 1  1 
7
5 
8
0 75 75 75 75 0 1 
6
0 0  7 2 0 0 
2 R 2 
3
8 1 20 3 
7
5 
7
4 55 50 75 75 0 1 
6
0 0  17 0 0 0 
1 L 2 
4
0 1   3 
9
0 
9
0 86 DNA DNA DNA 4 0 
2
4 0   5, DNA 
ONLY 2YR 
FU, DNA 0 0 
1 R 2 
2
5 1 52 3 
8
5 
7
0 70 63 63 63 
-
2
2 1 
6
0 1  25 12 0 0 
1 L 2 
4
7 1  2 
7
5 
8
5 78 75 80 80 5 1 
6
0 0  15 4 0 0 
1 L 2 
5
7 1  3 
4
9 
5
5 35 35 40 40 -9 1 
6
0 1  10 0 0 0 
2 R 2 
5
4 1  1 
8
5 
8
5 75 70 70 75 
-
1
0 1 
6
0 1  16 5 0 0 
3 R 2 
5
9 1   2 
4
5 
5
0 DNA   DNA 5 0 
1
2 0  5 THEN DNA 2 THEN DNA 
1 R 2 
4
6 1 30 3 
5
5 
5
5 65 55 35 35 
-
2
0 1 
6
0 1  34 5 0 0 
1 R 2 
4
6 1 30 3 
5
5 
5
5 65 55 35 35 
-
2
0     34 5 0 0 
1 R 2 
6
4 1  2 
5
5   60 55 47 -8 1 
6
0 1  10 4 0 0 
2 L 2 4 3 0 1 7 7 75 70 70 73 -2 1 6 1  16 2 1 0 
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7 5 5 0 
1 R 2 
5
0 1 27 3 
4
5 
4
5 70 75 75 65 
2
0 1 
6
0 0 0 25 1 0 0 
2 R 2 
6
5 1 12 1 
5
0 
5
5 46 55 70 40 
-
1
0 1 
6
0 1  31 4 0 1 
1 R 2 
4
1 1 36 4 
7
0 
5
5 70 65 75 70 0 1 
6
0 1  37 2 0 1 
2 L 2 
5
3 1  5 
8
5 
7
0 75 60 75 70 
-
1
5 1 
6
0 1  18 3 0 0 
3 L 2 
6
0 1 36 4 
2
9 
4
0 60 47 55 55 
2
6 1 
6
0 0 0 25 4 0 0 
3 R 2 
6
8 1 36 3 
7
5 
6
0 65 68 70 70 -5 1 
6
0 1  24 4 0 0 
2 R 2 
6
4 1   1 
5
0 
5
5 DNA     5 0 
1
2 1   10 5 0   
2 L 2 
6
2 1 10 2 
3
5 
7
0 75 50 65 65 
3
0 1 
6
0 0 0 18 1 0 0 
3 L 2 
6
3 1  2 
5
6 
6
0 60 55 60 50 -6 1 
6
0 1  16 4 0 0 
3 L 2 
5
7 1  1 
6
0 
7
0 80 70 75 70 
1
0 1 
6
0 0 0 12 4 0 0 
2 R 2 
5
3 1  1 
3
5 
5
5 70 80 80 80 
4
5 1 
6
0 0 0 15 5 0 1 
2 R 2 
6
0 1  6 
5
0 
5
5 55 40 35 35 
-
1
5 1 
6
0 1  14 2 0 0 
1 L 2 
5
3 3 0 2 
8
5 
7
0 35 20 20 20 
-
6 1 
6
0 1  31 4 0 0 
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5 
1 R 2 
7
0 1  2 
7
0 
7
5 75 77 70 75 5 1 
6
0 1  9 3 0 0 
1 L 2 
5
9 2 13 1 
5
5 
7
0 60 35 45 45 
-
1
0 1 
6
0 1  6 2 0 0 
1 L 2 
4
9 1   3 
5
5 
6
5 DNA   DNA 
1
0 0 
1
2 0   5 THEN DNA 
3 THEN 
DNA 0 0 
2 R 2 
6
4 1  2 
7
0 
7
0 75 60 60 60 
-
1
0 1 
6
0 1  10 1 0 0 
2 L 2 
6
2 1 
10
3 2 
5
5 
7
5 70 70 
LOS
T LOST 
1
5 0 
3
6 0  2, LOST 
DNA FOR 
3YR 0 0 
2 R 2 
6
2 1 40 1 
3
5 
3
5 35 35 LOST LOST 0 0 
3
6 0  13, LOST 2 0 0 
2 L 2 
5
4 1 84 3 
7
5 
7
5 75 60 70 60 
-
1
5 1 
6
0 1  28 2 0 0 
1 L 2 
8
3 1  2 
3
5 
5
5 25 20 LOST 
-
1
5 0 
3
6 1  7 LOST TO FU 3 0 1 
3 L 2 
6
9 1  1 
7
0 
7
6 75 77 60 65 -5 1 
6
0 1  14 3 0 0 
1 R 2 
5
3 1  2 
7
0 
7
0           LOST  
2 L 2 
5
0 2 7 4 
7
5 
6
0 60 45 55 45 
-
3
0 1 
6
0 1  31 0 0 1 
1 L 2 
5
2 1  1 
8
5 
7
0 70 90 90 85 0 1 
6
0 0  12 5 0 0 
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2 L 2 
8
3 1  1 
6
5 
7
5 70 70 70 70 5 1 
6
0 0  11 4 0 0 
3 L 1 
7
2 1  1 
7
0 
5
0 70 70 70 70 0 1 
6
0 0  18 6 0 0 
1 R 2 
5
8 1 36 4 
8
0 
8
5 80 80 60 60 
-
2
0 1 
6
0 1  18 5 0 0 
2 L 2 
5
7 1 58 4 
7
5 
7
5 60 70 70 70 -5 1 
6
0 1  12 3 0 0 
2 R 2 
6
4 1  2 
6
0 
8
5 85 85 85 90 
3
0 1 
6
0 0 0 14 N 0 0 
1 L 1 
6
5 1  2 
7
7 
7
7 80 75 75 70 -7 1 
6
0 1  17 3 0 0 
2 R 1 
5
0 2  2 
3
5 
7
0 75 75 75 65 
3
0 1 
6
0 0  25 4 0 0 
1 L 2 
5
6 1  1 
9
0 
8
5 85 83 75 77 
-
1
3 1 
6
0 1  15 2 0 0 
1 L 2 
4
4 2 8 2 
7
0 
9
0 80 75 LOST LOST 5 0 
3
6 0  19/ 3yr 2 0 0 
2 R 2 
5
5 1   2 
5
5 
5
5 LOST     0 0 
1
2 0   7 LOST 
LOST 
AFTER 2YR 0 0 
2 L 2 
6
9 1  2 
6
2 
4
5 35 25 
LOS
T LOST 
-
2
0 0 
3
6 1  13 LOST 
2, LOST 
AFTER 3YR 0 0 
1 R 2 
5
6 1  4 
6
0 
6
0 60 45 45 50 
-
1
0 1 
6
0 1  14 2 0 1 
1 R 2 
5
6 1  4 
6
0 
6
0 60 45 45 50 
-
1 1 
6
0 1  14 2 0 1 
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0 
2 R 2 
6
1 1  3 
7
5 
7
5 70 75 75 75 0 1 
6
0 0  9 N 0 0 
3 R 2 
5
4 1 14 1 
6
0 
3
5 60 70 65 60 0 1 
6
0 0  29 4 1 0 
3 R 2 
5
5 1  1 
6
0 
3
5 60 70 65 60 0 1 
6
0 0  29 4 1 0 
2 L 1 
6
5 1  1 
5
5 
7
0 70 75 75 75 
2
0 1 
6
0 0 0 12 2 0 0 
2 R 2 
7
4 3 6 1 
7
0 0 0 0 0 0      22 2 1 1 
1 R 2 
6
1 1   2 
6
0 
6
0 70 LOST   
1
0 0 
2
4 0   
11 IN 3YR, 
LOST FOR FU 
2, AND 
LOST 0 0 
2 L 2 
7
1 1 17 4 
7
5 
7
5 LOST   LOST 0 0 
1
2 0   3 AND LOST 2 AND LOST 
3 
Righ
t 2 
7
4 1  1 
8
5 
8
0 80 70 70 85 0 1 
6
0 0  10 N 0 1 
3 R 2 
7
5 1  1 
8
5 
8
0 80 70 70 85 0 1 
6
0 0  10 N 0 1 
3 R 2 
7
5 1  1 
8
5 
8
0 80 70 70 85 0 1 
6
0 0  10 N 0 1 
3 R 2 
5
0 1 
12
6 3 
8
5 
7
5 
LOS
T 75 
LOS
T 75 
-
1
0 0 
6
0 1  LOST   
2 L 2 
7
1 3 1 3 
3
5 
2
5 45 35 35 30 -5 1 
6
0 1  20 3 0 0 
2 L 2 
5
1 1  1 
6
0 
6
0 60 70 65 65 5 1 
6
0 0  9 2 0 0 
1 R 2 
5
6 1  4 
6
0 
6
0 60 45 45 50 
-
1 1 
6
0 1  19 2 0 1 
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0 
1 R 2 
5
6 1  4 
6
0 
6
0 60 45 45 50 
-
1
0 1 
6
0 1  19 2 0 1 
1 L 1 
6
6 1 54 3 
7
5 
7
0 65 65 30 30 
-
4
5 1 
6
0 1      
1 R 2 
6
9 1 58 2 
7
5 
7
5 75 75 75 75 0 1 
6
0 0      
3 R 2 
6
2 2 24 4                               
2 L 2 
5
9 1 27 4 
6
0 
6
0 55 60 64 60 0 1 
6
0 0  13    
2 R 2 
6
8 1 34 4                               
1 R 2 
7
6 1 20 5 
4
0 
5
5 55 50 50 55 
1
5 1 
6
0 0 0 16    
3 R 2 
5
2 2  2 
6
0 
6
0 55 5 76 76 
1
6 1 
6
0 0 0 16    
2 R 2 
4
6 1 17 2 
6
0 
6
5 LOST LOST LOST LOST 5 0 
1
2 0  LOST     
2 R 2 
6
2 1 36 3 
7
0 
8
5 65 65 
LOS
T LOST 5 0 
3
6 0  LOST   
2 L 2 
6
6 1 40 3                               
3 R 2 
4
6 1 50 3                               
3 R 2 
5
5 1   3                               
3 L 2 4 1 41 4                
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E3) LIGHT ADAPTATION PATIENT DEMOGRAPHICS 
 
patien
t ID,                             
CODE 
   HbA1c 
       
TOTAL 42 
PATIENTS 
CONSENTED  AGE TYPE DM pre 
3rd 
month 
6th 
month 
       
 AK LE 59 2 7.3 7.1 6.4 
 MM LE 50 2 9.2 9.1 7.9 
OTHER 
EYE 
AVASTIN 
TREATED 
PD                                              
RT 40 1 7 7.6 8.1 
 BK LE 71 2 6.1 6.1 6 
 AM LE 57 2       
 JC LE 61 2 11.6 10.9 10.2 
 PH RT 61 2 8.1 8.2 7.7 
 RB RT 50 2 7.5 9.7 9.8 
 BT RT 55 2 6.4 7.7 7.4 
 JN LE 68 2 6.9 6.9 6.9 
 OO LE 42 2       
 WP RT 41 2 10.8 10.8 10.8 
 FI RT 58 2 7.2 8 9.4 
 JJ LE 55 2 9.1 9.1 10.5 
OTHER 
EYE PRPC 
DS                                                              
RT 66 2 10.2 10.2 10.2 
 BA RT 52 2 10.3 10.4 10.4 
 RS RT 72 2 6.7 6.4 7.2 
 HSK RT 48 2 8.9 10.4 10.4 
 AG LE 49 2 7 7.7 7.7 
 BP LE 45 2 10.2 10.3 10.3 
 CD LE 75 2 8.2 7.3 8 
 KM LE 46 2 7.1 6.2 6.4 
RE has 
undergone 
laser in 
1st month 
AM                                                                     
LE 43 2 10 9.5 10.4 
 SS LE 45 2 8.6 8.3 8.3 
 GU LE 63 2 7.3 7.3 7.1 
 Left eye 
has 
undergone 
laser in 
1st 
month/ ill 
health 
BP                                                                                           
RT 51 2 9.3 9.3 9.5 
 EB RT 62 2 7.1 7.1 7.1 
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 MA RT 44 2 10.1 10.1 10.1 
 LD RT 70 2 7.9 7.9 8.6 
no 3rd m 
review OP RT 60 2 7.7 8.8 8.8 
ill health TC LE 53 1       
 FN LE 72 2       
non 
complianc
e first 3m JR LE 70  7.5 7.5 7.1 
no 3rd m 
review DM  RT 33 1       
stroke, 
hosp 
admission 
at 
3m(laser 
control 
eye after 
3rd m) JS RT 70 2 6.3 6.3 6.3 
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E4) CATEGORICAL CLASSIFICATION OF PROGRESSION 
Progression 
in OCT SS 
analysis 
progression 
in protan 
vision 6m 
progression 
in tritan 
vision 6m 
progression 
in contrast 
vision 6m 
progression 
in mean 
MP1 6m 
progression 
in vision 
6m 
progression 
in ZONE 1, 
MP1 6m 
progression 
in ZONE 1 
thickness 
6m 
progression 
in ZONE 
worst 
thickness 
6m 
Fundus 
photo 
progression 
month 6 
1 0 0 1 0 0 0 0 0 1 
1 0 0 0 0 0 0 0 0 0 
1 1 1 0 0 0 0 1 1 1 
1 1 1 0 0 0 0 0 0 0 
1 0 1 0 0 0 0 1 1 1 
0 0 0 0 0 0 0 0 0 1 
0 0 0 0 0 0 0 0 0 1 
0 0 0 0 0 0 1 0 0 1 
0 0 2 0 0 0 0 0 0 0 
0 0 0 2 1 0 1 0 0 0 
0 1 1 1 1 0 1 0 0 1 
1 0 0 0 0 0 0 1 1 1 
1 2 1 0 1 0 1 0 0  
1 0 2 1 0 0 0   1 
1 0 0 0 0 0 0   1 
2 0 0 1 0 0 0 0 0 0 
1 0 1 0 0 0 0 0 1 0 
1 0 1 0 0 0 0 0 1 1 
1 0 0 0 0 0 0 1 0 1 
1   0 0 0 0 0 0 2 
0 0 1 0 0 0 1 1 0 0 
2 0 0 0 0 0 0 2 2 2 
1 0 2 0 0 1 0 0 1 1 
1 1 0 2 0 0 0 0 0 2 
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0 1 0 0 0 0 0 2 0 2 
2 0 1 0 0 1 0 2 0 0 
0 0 0 0 0 0 0     0 
0 0 0 1 0 0 0 0 0 2 
1 0 0 0 0 1 0   0 
1 0 0 0 0 0 0   2 
0 2 0 0  2     
1 1 1 0 0 1 0 0 0  
1 0 0 0 0 0 0 0 1 2 
1 0 1 0 1 1 0    
1 1 1 1 0 1 0 1 1 1 
0 0 0 0 0 1 0 2 0 0 
0 0 0 0   0   0 0 0 
x                   
0 0 1 0   0   0 0 0 
1 0 0 0   0   0 0 1 
0 1 1 0 0 1 0 0 0 2 
0 0 0 0   2   0 0 2 
0 0 0 0 0 0 0 0 0 2 
0 0 0 2 0 2 0 0 0 1 
0 1 1 0 0 0 1 0 0 0 
0 0 0 2 0 0 1 0 0 0 
1 0 0 0 0 0 1 0 0 1 
0 2 1 0 0 0 0 0 0   
2 0 1 0 0 0 0 0 0 0 
x                   
0 0 0 0 0 1 0 0 0 1 
0 2 0 0 0 0 0 2 0 0 
0 0 0 2 0 0 0 0 0 2 
0 0 0 2 0 0 2 0 0 2 
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2             0 0 2 
0 0 0 0 0 0 0 0 0 0 
0 0 0 0 0 0 0 0 0 2 
x                   
1 0 0 2 0 0 0 0 0 2 
0 2 2 0 2 2 0 1 1 0 
x                   
2 0 0 2 0 0 0 2 0 0 
0 0 0 0   2 0 0 0 0 
0 2 0 0 0 0   0 0 0 
0   1 0   2   0 0 0 
0 0 0 0   2   0 0   
0 0 0 0 2 0 0 0 0   
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F) KING’S RESEARCH & DEVELOPMENT APPROVAL LETTER 
 
 
  221 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  222 
G) PUBLICATIONS, POSTERS, PRESENTATIONS  
 
Presentations (oral, international) 
 Light adaptation improves diabetic maculopathy. ARVO, May 2010 
 
Posters (international) 
 Intersession Repeatability of Visual Acuity, Colour Vision, Contrast 
Sensitivity, Retinal Sensitivity Thresholds and Retinal Thickness in Mild 
Diabetic Retinopathy. Sreedhar B. Jyothi, R Leung, Mathew Richardson, 
Elizabeth Pearce, Sobha Sivaprasad. ARVO 2011 
 
 Effects of retinal neuronal thickness on contrast sensitivity in eyes with 
minimal diabetic retinopathy. Yi Fang Lee, Sreedhar Jyothi, Sobha 
Sivaprasad, Asia ARVO, Jan 2011 
 
 Light adaptation delays diabetic maculopathy. Sobha Sivaprasad, Sreedhar 
Jyothi, Geoffrey Arden. EURETINA 2010 
 
 Qualitative, Quantitative OCT Changes Following Laser Photocoagulation for 
Diabetic Macular Edema. R.V. Vemala, S. Koshy, S. Jyothi. ARVO 2010 
 
 Visual Function Is Not Related To The Number And Location Of 
Microanuerysms In The Macula In Diabetic Retinopathy. Yi Fang Lee, 
Sreedhar Jyothi, Richard Leung, Elizabeth Pearce, Sobha Sivaprasad. ARVO 
2010 
 
 Long-term outcome following laser photocoagulation for diabetic macular 
oedema in Afro-Caribbean's. S B Jyothi, A Yandra, F Mubashar, T Adewoyin, S 
Sivaprasad. ARVO 2009 
 
 Systemic factors in patients treated with macular laser for diabetic macular 
oedema in Type II diabetes. A Yandra, S Jyothi, F Mubashar, T Adewoyin, S 
Sivaprasad. ARVO 2009 
 
 
 A Comparison of Functional and Structural Measures in identifying 
Progression of Diabetic Maculopathy. S Jyothi, S Sivaprasad. RCO 2011 
 
 Microaneurysms count and distribution do not correlate with neuronal 
changes in early diabetic retinopathy, Yi Lee, Sreedhar Jyothi, Richard 
Leung, Elizabeth Pearce, Sobha Sivaprasad. RCO 2010 
 
 The effects of laser photocoagulation on colour vision in patients with 
diabetic maculopathy. S Jyothi, Roger Wong, Geoffrey Arden, Sobha 
Sivaprasad. RCO 2010 
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Publications  
 
 
 Five-year visual outcome following laser photocoagulation of diabetic 
macular oedema.  
S Jyothi, S Sivaprasad. Eye, EYE-10-960R, Aug 2011 
 
 Prevention of dark adaptation causes regression of diabetic macular oedema.  
G Arden, S Jyothi, C Hogg, Y Li, S Sivaprasad. Eye, Oct 2011 
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